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1. Background and aims 
Osteopontin (OPN) is a multifunctional protein that is expressed in different cell types and 
in a variety of tissues including liver. It is a key regulator of many metabolic and inflammatory 
diseases. OPN has been associated with different liver disorders; in fact, its expression is increased 
in different stages of non-alcoholic fatty liver disease (NAFLD). Regarding the progression of the 
disease, several mice and human studies show a role for OPN in the pathogenesis and progression 
of NAFLD and liver fibrosis. 
OPN is a modulator of liver lipid metabolism. It modulates the fate of acetyl-CoA in liver and it 
regulates the cross-talk between phosphatidylcholine (PC) and cholesterol metabolism. OPN is also 
involved in the regulation of the expression of some nuclear factors related to biliary metabolism, 
which are altered in NAFLD progression. Hence, we propose that OPN might modulate the cross-talk 
between cholesterol and PC metabolism via CYP7A1 regulation in hepatocytes, consequently 
modulating the conversion of free cholesterol (FC) into bile acids (BA). Thus, the altered conversion 
of FC into bile acids will also induce changes in biliary PC secretion. Regarding liver regeneration, 
deficiency of OPN leads to a remodeling in lipid metabolism that allows the correct regeneration 
after partial hepatectomy (PH). The liver has the capacity for regeneration after cellular damage or 
surgery resection. During regeneration, liver cells need to acquire sufficient energy and metabolic 
precursors. PC, cholesterol and bile acids play an important role in liver regeneration, and since OPN 
can modulate these lipids, we suggest that OPN might have an important role orchestrating lipid 
metabolism in liver regeneration. 
OPN is involved in diseases in which metabolic dysregulation is key, and taking into account 
that the prevalence of metabolic diseases increases with age, we considered the fact that OPN could 
be involved in the aging of the liver. Indeed, OPN expression is increased in many diseases in which 
aging in the primary risk factor and it has also been described as a senescence-associated secretory 
phenotype (SASP) factor. There are several studies linking OPN and aging but the available data does 
not give conclusive results about the role of OPN in the aging process. 
Aging of the liver is associated with several hepatic alterations; these changes can negatively 
affect the morphology, physiology and oxidative capacity of the liver. During aging there is a loss of 
hepatic volume of 1/3 approximately, a reduction of the blood perfusion as well as a decrease in the 
capacity to metabolize certain compounds. There are also changes in the expression of a variety of 
proteins and diminished hepatobiliary functions. In addition, it has been reported a loss of capacity 




lipids can accumulate in non-adipose tissues like skeletal muscle, heart and liver. Thus, aging is 
associated with an increase in the lipid accumulation within the liver that may compromise the 
normal function due to lipotoxicity. These changes in liver during aging can reduce hepatic function 
and promote liver injury. Aging is associated with high morbidity and a poor prognosis in patients 
with various liver diseases, including NAFLD, hepatitis C and liver cancer, as well as with surgeries 
such as liver transplantation. In addition, epidemiological studies have demonstrated that NAFDL and 
non-alcoholic steatohepatitis (NASH) are common among the elderly. 
The number of senescent hepatocytes in the liver increases with age. Indeed, a significant 
fraction of hepatocytes develops a senescent phenotype during the life course. Several studies have 
shown that cellular senescence drives age-dependent hepatic steatosis and that elimination of 
senescent cells may be a novel therapeutic strategy to reduce steatosis. Interestingly, senescent cells 
have been found in the livers of NAFLD, cirrhotic patients and in the liver of high fat diet fed and 
genetically obese mice. Thus, based on the evidence that OPN is linked with liver disorders, which 
prevalence increases with age; and that OPN plays a role in liver lipid metabolism, which is 
dysregulated in aging, we propose that OPN could have a role in the susceptibility of the liver to 
aging-associated NAFLD progression. 
In this context, we proposed the following specific aims: 
Aim 1. To investigate whether OPN regulates PC and cholesterol metabolism via CYP7A1 in 
hepatocytes, and, if so, to analyze the pathways involved. 
Aim 2. To elucidate which metabolic pathways are involved in OPN-KO mice liver lipid 
remodeling during regeneration after PH. 
Aim 3. To investigate the role of OPN in the metabolic disorders of aging: 
Aim 3.1 To investigate whether OPN is involved in the aging of the liver, and in that case, to 
identify the mechanisms involved. 
Aim 3.2 To find out whether during aging OPN modifies the vulnerability of the liver to the 
development of NAFLD; and if so, to identify the mechanisms involved. 









To investigate the changes that OPN induces in liver lipid metabolism in quiescent and 
regenerating livers 10-12-week-old female OPN deficient (OPN-KO) mice and their WT (C57BL/6J) 
littermates were used. To study regeneration, 2/3 PH was performed, and mice were sacrificed 24 
and 48 hours (h) after PH. 
For the aging studies, a cohort of individuals with normal liver (NL)(n=34) and another with 
NAFLD (n=123) was analyzed. For the animal model studies male and female WT mice of 3, 6, 10, 14 
and 20 months-old (m) were used. In addition, for the study of the effect of OPN in the liver lipid 
metabolism and hepatosteatosis development during aging, 3, 10 and 20 m WT and OPN-KO female 
mice were analyzed. Besides, a group of 16 m mice was fed a high fat diet (HFD) prior to their sacrifice 
at 20 m. For the in-vitro studies HepG2 and Hep3B hepatic cell lines were used.  
To identify the disruption of lipid metabolism, body parameters, serum and liver lipid 
concentration and metabolic fluxes were analyzed. Among the metabolic fluxes analyzed, de novo 
lipogenesis, oleate esterification, fatty acid beta oxidation and several enzyme activities involved in 
synthesis and hydrolysis processes were evaluated. In addition, for the study of signaling pathways 
western blot analysis were performed. Additionally, to evaluate the state of the liver, different 
histochemical analysis were performed. For the in-vitro studies, in order to induce senescence to 
HepG2 and Hep3B cells palbociclib or H2O2 were used after knockdown of OPN.  
3. Results 
Osteopontin controls bile acid metabolism by regulating CYP7A1 levels in liver and hepatocytes 
Regarding the role of OPN regulating PC and cholesterol metabolism via CYP7A1, we found that 
treating hepatocytes with recombinant OPN (rOPN) reduced CYP7A1 levels together with a trend 
toward decreased 7a-hydroxi-4-cholesteren-3-one (C4) levels, an indirect biomarker of CYP7A1 
activity, while it was increased in OPN-KO mice livers. To determine the mechanism by which OPN 
downregulates CYP7A1, we took into account that several reports have involved AKT and/or ERK and 
JNK, in CYP7A1 transcription. In WT mice treated with rOPN, phosphorylation and activation of FAK 
was increased, while in OPN-KO animals FAK phosphorylation was reduced. In rOPN treated WT mice, 
together with the increased FAK phosphorylation there was an increased free cholesterol (FC) 
concentration. This supports the fact that rOPN downregulates CYP7A1 levels, which in turn 
decreases the conversion of cholesterol into BA, increasing the cholesterol levels in liver. In order 
to assure the involvement of this pathway in CYP7A1 regulation we used the PI3K and FAK inhibitors 
LY294002 and Y15, respectively. When inhibiting the FAK-AKT signaling pathway, CYP7A1 levels 
increased in rOPN treated hepatocytes. Thus, demonstrating a mechanism by which rOPN decreases 




signaling activation, the upregulation of CYP7A1 protein levels, and thus the conversion of 
cholesterol into BA. OPN will decrease the synthesis and secretion of BA. This decreased secretion 
will also reduce PC secretion, which will contribute to higher liver levels of PC. 
Rewiring of lipid metabolism modulates liver regeneration after partial hepatectomy in 
OPN-KO mice 
In regeneration, we analyzed the lipid metabolic pathways that are controlled by OPN. While 
OPN-KO mice are capable of regenerating correctly, they undergo a lipid remodeling. Since OPN-KO 
hepatocytes show decreased de novo lipogenesis, and assuring that the prevision of sufficient 
metabolites is key for an adequate regeneration, we analyzed the contribution of dietary fatty acids 
in the OPN-KO mice liver. For this, we evaluated if TG and PC species containing the essential linoleic 
acid (18:2) were altered, and we observed that most of the TG species that were increased in OPN-
KO quiescent livers were enriched in linoleic acid. We also observed that PC species containing the 
linoleic acid were reduced in the quiescent OPN-KO liver compared to the WT. This suggests that the 
decreased de novo TG synthesis observed in the OPN-KO mice liver is compensated by increased 
dietary FA uptake. Thus, there is a shift of linoleic towards TG. However, this compensation does not 
occur with PC loss. Given that the big changes in liver lipid content during regeneration occur mainly 
24 h after PH, we investigated whether the increased TG storage was associated with the increase in 
linoleic acid. The results showed that 24 h after PH the TG species containing linoleic acid were 
increased in WT compared with OPN-KO mice liver. The decrease in TG containing linoleic acid can 
be explained by the increased FA oxidation in OPN-KO mice livers 24 h after PH. Regarding FA 
oxidation, 24 h post PH, lipid oxidation was increased in OPN-KO mice when compared to WT mice.  
Moreover, despite the increased fatty acid oxidation and increased levels of ROS production, lipid 
peroxidation levels remained unaltered in OPN deficient mice along liver regeneration. Taken 
together, these results show that, the decrease in the PC liver concentration and the de novo 
synthesis is not compensated with the dietary essential FA linoleic, unlike what happens with TGs. 
The increased dietary-lipid uptake in OPN-KO mice provides the metabolic precursors required for 
regeneration 24 h and 48 h after PH.  
Atorvastatin treatment did not induce changes in the accumulation of lipid droplets or in the 
liver TG content 24 h after PH in the OPN-KO or WT mice. In addition, atorvastatin recovered PC 
levels just in OPN-KO. In addition, the results showed that differences between WT and OPN-KO in 
DHE disappeared after atorvastatin treatment. Thus, atorvastatin induces changes in the liver 
lipidome during regeneration only in OPN-KO mice. In which, as shown in previous work, atorvastatin 





Osteopontin plays a role in the age-associated NAFLD progression 
Regarding OPN involvement in liver aging, the results showed that in individuals with NL there 
was a positive correlation between serum OPN levels and age while this correlation was lost in 
patients with NAFLD, in which serum levels of OPN were higher than in NL subjects. In WT mice, this 
positive correlation was also observed. In addition, liver levels of OPN were increased at 10 m and 
remained elevated at 20 m. Senescence is one of the key features of aging, and when senescence 
was induced to HepG2 cells, intra and extracellular OPN levels increased. Besides, when treating cells 
with recombinant OPN, the effect of the senescence inducing agent palbociclib was reduced, 
suggesting that OPN is involved in aging and senescence.  
The lost age-OPN correlation in NAFLD patients, suggests that OPN might play a role in the age-
associated liver vulnerability to NAFLD progression. Here, we wanted to analyze if the increased OPN 
expression during aging is protective or detrimental for the age-associated hepatosteatosis 
development. Liver β-Galactosidase and p21 levels together with hepatic concentration of 
triglycerides (TG) and cholesterol esters and their de novo synthesis were increased in 10 m OPN-KO 
mice when compared to their WTs. This phenotype was associated with the decrease of the 
chaperone GRP78, the activation of ER stress and the increase in fatty acid synthase (FAS) levels. The 
generation of senescence in OPN-knockdown HepG2 cells led to a decrease in GRP78. Although 20 
m OPN-KO mice did not show ER stress symptoms, the activation of caspase 12 together with 
gamma-H2AX reinforces the existence of further tissue damage. In addition, in 20 m OPN-KO mice, 
evaluation of the liver fibrosis and inflammation showed a worse progression of the disease, 
especially in the HFD fed mice.  
p53 controls several metabolic and cellular functions and modulates cellular adaptations to 
stress. It is one of the most important tumor suppressor genes, and some studies have linked p53 to 
OPN regulation in fibroblasts. Here, we wanted to evaluate whether p53 could modulate OPN levels. 
Knockdown of p53 in HepG2 cells reduced OPN levels in cells and media. Moreover, Hep3B cells, in 
which p53 is absent were unable to generate OPN when senescence was induced with palbociclib or 
H2O2. In vivo, p53 is involved in hepatosteatosis since p53-KO mice develop steatosis and its 
overexpression improves steatosis and ER stress . It is known that feeding a HFD increases OPN levels; 
however, p53-KO mice did not show increased liver OPN levels when fed a HFD. Thus, p53 might 
regulate OPN levels when inducing senescence and when feeding a HFD. 
Taken together, these results show that OPN deficiency leads to an early age-associated 
hepatosteatosis, accompanied by an ER stress and increased senescence. This phenotype leads in 
old age to a worse progression of the disease as reflected by increased fibrosis, inflammation, 
damage and apoptosis markers. In addition, p53 might be necessary for OPN induction in response 





1. Osteopontin (OPN) regulates the cross-talk between cholesterol and PC metabolism through 
modulation of CYP7A1 levels in hepatocytes. The FAK-AKT signaling pathway is involved in 
the regulation of CYP7A1 by OPN in liver.  
 
2. OPN modulates metabolic pathways involved in TG and cholesterol metabolism during liver 
regeneration. 
2.1. OPN deficient (OPN-KO) mice show increased fatty acid catabolism when facing 
regeneration. The increased metabolic demands and the decreased de novo synthesis of TG 
are compensated with dietary fatty acids.  
2.2. Inhibition of cholesterogenesis using atorvastatin provides a new metabolic scenario 
linked to improvement of early regeneration in OPN-KO mice. 
 
3. OPN is required to maintain the whole body metabolic homeostasis during aging. 
3.1 OPN is involved in liver aging. Serum OPN positively correlates with age in individuals 
and animal models with normal liver. In the animal model, the increased OPN levels in 
serum are linked to increased levels in liver. The induction of senescence in HepG2 cells, 
through modulation of p53, increases cellular OPN levels and its secretion. 
3.2  OPN is regulated to maintain the liver lipid metabolism balance during aging. OPN 
deficiency in mice makes the liver more vulnerable to age-associated hepatosteatosis, 
being the underlying mechanism the increased de novo lipogenesis linked with induced 
senescence and an impaired ER stress response due to the GRP78 decreased levels.  
3.3 In old HFD-fed mice, deficiency in OPN does not induce body weight changes. However, 












1. Antecedentes y objetivos 
La osteopontina (OPN) es una proteína multifuncional que se expresa en diferentes tipos 
celulares y tejidos, incluido el hígado, y es también un regulador clave de muchas enfermedades 
metabólicas e inflamatorias. OPN se ha asociado a diferentes trastornos hepáticos, de hecho, su 
expresión se encuentra incrementada en diferentes etapas de la enfermedad del hígado graso no 
alcohólico (EHGNA). En cuanto a la progresión de la enfermedad, varios estudios en modelos de ratón 
y humanos muestran que la OPN tiene un papel en la patogénesis y progresión de la EHGNA y en la 
fibrosis hepática. 
La OPN modula el metabolismo de lípidos hepáticos, ya que modula el destino del acetil-CoA en 
el hígado y regula la interacción entre el metabolismo de la fosfatidilcolina (PC) y del colesterol. La 
OPN está involucrada en la modulación de la expresión algunos factores nucleares relacionados con 
el metabolismo biliar, que se encuentran alterados en la progresión de la EHGNA. Por lo tanto, 
proponemos que OPN modula el metabolismo del colesterol y la PC a través de CYP7A1 en 
hepatocitos, controlando así la conversión de colesterol libre (FC) en ácidos biliares. En cuanto a la 
regeneración hepática, la deficiencia de OPN conduce a una remodelación del metabolismo lipídico 
que permite la correcta regeneración tras una hepatectomía parcial (PH). El hígado posee capacidad 
de regeneración tras un daño celular o resección quirúrgica. Durante la regeneración, las células 
hepáticas necesitan adquirir suficiente energía y precursores metabólicos para una regeneración 
adecuada. La PC, el colesterol y los ácidos biliares juegan un papel importante en la regeneración del 
hígado. Dado que OPN puede modular estos lípidos sugerimos que podría desempeñar un papel 
importante orquestando el metabolismo lipídico durante regeneración hepática. 
La OPN está implicada en enfermedades en las que la desregulación metabólica es clave, y 
teniendo en cuenta que la prevalencia de las enfermedades metabólicas aumenta con la edad, 
consideramos que OPN podría estar implicada en el envejecimiento hepático. La expresión de OPN 
aumenta en muchas enfermedades en las que el envejecimiento es el principal factor de riesgo, 
además también se ha descrito a OPN como un factor de fenotipo secretor asociado a senescencia 
(SASP). Existen varios estudios que vinculan OPN con el envejecimiento, pero los datos disponibles 
no ofrecen resultados concluyentes sobre el papel de OPN en el proceso de envejecimiento. 
El envejecimiento del hígado está asociado a una serie de alteraciones; estos cambios pueden 
afectar negativamente la morfología, la fisiología y la capacidad oxidativa del hígado. Durante el 
envejecimiento hay una pérdida de volumen hepático de 1/3 aproximadamente, una reducción de 
la perfusión sanguínea, así como una disminución de la capacidad para metabolizar ciertos 
compuestos. También hay cambios en la expresión de una variedad de proteínas y disminución de 
las funciones hepatobiliares. Además, de la disminución de la capacidad para luchar contra el estrés 




habituales, y los lípidos pueden acumularse en tejidos no adiposos como el músculo esquelético, el 
corazón y el hígado. Por lo tanto, el envejecimiento se asocia con un aumento de la acumulación de 
lípidos hepática que puede comprometer la función normal debido a la lipotoxicidad. Por tanto, estos 
cambios en el hígado durante el envejecimiento pueden reducir la función y promover daño 
hepático. El envejecimiento está asociado con una alta morbilidad y un mal pronóstico en pacientes 
con enfermedades hepáticas, incluyendo EHGNA, hepatitis C y cáncer de hígado, así como en cirugías 
como el trasplante de hígado. Estudios epidemiológicos han demostrado que la EHGNA y la 
esteatohepatitis no alcohólica son comunes entre la población anciana. 
El número de hepatocitos senescentes en el hígado aumenta con la edad. Una fracción 
significativa de hepatocitos desarrolla un fenotipo senescente a medida que se envejece. Varios 
estudios han demostrado que la senescencia promueve la esteatosis hepática asociada a la edad y 
que la eliminación de las células senescentes puede ser una nueva estrategia terapéutica para reducir 
la esteatosis. Relacionado con esto, se han encontrado células senescentes en los hígados de 
pacientes cirróticos y en el hígado de ratones alimentados con una dieta rica grasa y en ratones 
genéticamente obesos. Por lo tanto, en base a la evidencia de que OPN está relacionada con 
trastornos hepáticos, cuya prevalencia aumenta con la edad; y que OPN desempeña un papel en el 
metabolismo de lípidos hepáticos, que se encuentra desregulado en el envejecimiento, proponemos 
que OPN podría tener un papel en la susceptibilidad del hígado a la progresión del EHGNA asociada 
al envejecimiento. 
En este contexto, proponemos los siguientes objetivos concretos: 
Objetivo 1. Investigar si OPN regula el metabolismo de la PC y del colesterol a través del CYP7A1 en 
hepatocitos y, en caso afirmativo, analizar las vías implicadas. 
Objetivo 2. Definir qué vías metabólicas están involucradas en la remodelación lipídica del hígado 
durante la regeneración tras hepatectomía parcial en ratones OPN-KO  
Objetivo 3. Investigar el papel de OPN en los trastornos metabólicos del envejecimiento: 
Objetivo 3.1 Investigar si la OPN está implicada en el envejecimiento del hígado y, en tal caso, 
identificar los mecanismos implicados. 
Objetivo 3.2 Averiguar si durante el envejecimiento OPN modifica la vulnerabilidad del hígado 
al desarrollo de EHGNA y, en caso afirmativo, identificar los mecanismos implicados. 







Para investigar los cambios que induce OPN en el metabolismo de lípidos hepáticos en hígados 
quiescentes y regenerantes se utilizaron ratones de entre 10-12 semanas de edad deficientes en OPN 
(OPN-KO) y sus controles WT (C57BL/6J). Para estudiar la regeneración, se realizó el procedimiento 
de hepatectomía parcial (PH) 2/3, y los animales se sacrificaron 24 y 48 horas post PH. 
Para los estudios de envejecimiento se analizó una cohorte de individuos con hígado normal 
(NL)(n=34) y otra con EHGNA (n=123). Para el estudio en el modelo animal se utilizaron ratones WT 
de 3, 6, 10, 14 y 20 meses de edad. Además, para el estudio del papel de OPN en el metabolismo de 
los lípidos hepáticos y el desarrollo de EHGNA durante el envejecimiento, se utilizaron ratones 
hembra de 3, 10 y 20 meses de edad WT y OPN-KO. Un grupo de cada genotipo fue alimentado con 
dieta rica en grasa desde los 16 meses hasta los 20, cuando se sacrificaron. Para los estudios in vitro 
se utilizaron las líneas celulares hepáticas HepG2 y Hep3B.  
Para identificar la desregulación del metabolismo lipídico se analizaron los parámetros 
corporales, la concentración de lípidos en el suero y el hígado y los principales flujos metabólicos. 
Entre los flujos metabólicos estudiados se evaluaron la lipogénesis de novo, la esterificación de 
oleato, la beta oxidación de ácidos grasos y actividades enzimáticas implicadas en la síntesis e 
hidrólisis de los principales lípidos. Además, para el estudio de las vías de señalización se realizaron 
análisis mediante western blot. Asimismo, para evaluar el estado del hígado, se realizaron diferentes 
análisis histoquímicos. En los estudios in vitro, para inducir senescencia se utilizó palbociclib o H2O2 
tras el silenciamiento de OPN.  
3. Resultados 
La osteopontina controla el metabolismo de ácidos biliares regulando los niveles de CYP7A1 
en el hígado y en hepatocitos 
En cuanto a los resultados sobre el papel de OPN en la regulación del metabolismo de PC y del 
colesterol, observamos que el tratamiento de los hepatocitos con OPN recombinante (rOPN) redujo 
los niveles de CYP7A1 junto con una tendencia hacia la disminución de los niveles de 7a-hydroxi-4-
cholesteren-3-one (C4), que es un marcador indirecto de la actividad de CYP7A1. Para determinar el 
mecanismo mediante el cual OPN reduce CYP7A1, tuvimos en cuenta que en varios estudios han 
descrito que AKT y/o ERK y JNK participan en la transcripción de CYP7A1. En los ratones WT tratados 
con rOPN la fosforilación de FAK se incrementó, y por tanto su actividad, mientras que en los 
animales OPN-KO se redujo la fosforilación de FAK. Además, en ratones WT tratados con rOPN, junto 
con el aumento de la fosforilación FAK, se produjo un aumento de la concentración de colesterol 
libre (FC). Esto muestra que la rOPN disminuye los niveles de CYP7A1, lo que a su vez disminuye la 




asegurar la participación de esta vía en la regulación CYP7A1 se utilizaron los inhibidores de PI3K y 
FAK LY294002 e Y15, respectivamente. Cuando se inhibió la vía de señalización FAK-AKT, los niveles 
de CYP7A1 aumentaron en hepatocitos tratados con rOPN. Demostrando así, un mecanismo por el 
cual la rOPN disminuye los niveles de CYP7A1 en hepatocitos. Por lo tanto, proponemos que OPN 
inducirá, a través de la activación de la señalización FAK-AKT, el descenso de los niveles proteicos 
CYP7A1, y por lo tanto la conversión de colesterol en ácidos biliares. El efecto de OPN disminuirá la 
síntesis y secreción de ácidos biliares. Este descenso de la secreción también fomentará la menor 
secreción de PC, lo que contribuirá a una mayor concentración hepática de PC. 
La reorganización del metabolismo lipídico modula la regeneración hepática tras una 
hepatectomía parcial en ratones OPN-KO. 
En la regeneración hepática, analizamos las vías metabólicas de lípidos que controla OPN. 
Aunque los ratones OPN-KO son capaces de regenerar correctamente, sufren una remodelación 
lipídica. Dado que los hepatocitos OPN-KO muestran una disminución de la lipogénesis de novo, y 
dado que asegurar la previsión de suficientes metabolitos es clave para una adecuada regeneración, 
analizamos la contribución de los ácidos grasos provenientes de la dieta en el hígado de los ratones 
OPN-KO. Para ello, se evaluó si las especies de TG y PC que contienen el ácido graso esencial linoleico 
(18:2) estaban alteradas, y se observó que la mayoría de las especies de TG que estaban aumentadas 
en los hígados OPN-KO quiescentes estaban enriquecidas en ácido linoleico. También observamos 
que las especies de PC que contenían ácido linoleico estaban reducidas en el hígado quiescente de 
los animales OPN-KO en comparación con los WT. Esto sugiere que la disminución de la síntesis de 
novo de TG observada en el hígado de los ratones OPN-KO se compensa con una mayor absorción 
de FA en la dieta. Por lo tanto, el linoleico de la dieta se direcciona hacia TG. Sin embargo, esta 
compensación no se produce en caso de la PC. Dado que los grandes cambios en el contenido de 
lípidos hepáticos durante la regeneración ocurren principalmente 24 horas después de la HP, se 
investigó si el aumento del almacén de TG estaba asociado con el aumento del ácido linoleico. Los 
resultados mostraron que 24 horas tras la PH, las especies de TG que contenían ácido linoleico 
estaban incrementadas en el WT en comparación con los OPN-KO. Esta disminución de los TG que 
contienen ácido linoleico puede explicarse por el aumento de la oxidación de FA en los animales 
OPN-KO 24 horas post PH. En cuanto a la oxidación de los FA 24 horas post PH, la beta oxidación 
aumentó en los ratones OPN-KO en comparación con los ratones WT.  Además, a pesar del aumento 
de la oxidación de los ácidos grasos y de los niveles de producción de ROS, los niveles de peroxidación 
lipídica permanecieron inalterados en ratones con deficiencia de OPN durante la regeneración 
hepática. En conjunto, estos resultados muestran que la disminución de la concentración de PC en 
el hígado y la síntesis de novo no se compensan con el ácido esencial de la dieta linoleico, a diferencia 




KO proporciona los precursores metabólicos necesarios para la regeneración 24 h y 48 h después de 
la PH.  
El tratamiento con atorvastatina no indujo cambios en la acumulación de gotas lipídicas o en el 
contenido de TG hepático 24 horas post PH en los ratones OPN-KO o WT. Además, la atorvastatina 
recuperó los niveles de PC sólo en OPN-KO. Asimismo, los resultados mostraron que las diferencias 
entre el WT y el OPN-KO en DHE desaparecieron tras el tratamiento con atorvastatina. Por tanto, la 
atorvastatina induce cambios en el lipidoma hepático durante la regeneración sólo en ratones OPN-
KO. En los que, como se ha demostrado en trabajos anteriores, la atorvastatina mejora la 
regeneración temprana.  
La osteopontina juega un papel en la EHGNA asociada a la edad 
En cuanto al papel de la OPN en el envejecimiento, los resultados mostraron que en personas 
con NL había una correlación positiva entre los niveles séricos de OPN y la edad, mientras que esta 
correlación se perdía en los pacientes con EHGNA, en los cuales los niveles de OPN son más altos que 
en sujetos con NL. Además, en ratones WT también se observó esta correlación positiva. 
Conjuntamente, los niveles hepáticos de OPN aumentaron a los 10 meses y permanecieron elevados 
a los 20 meses. La senescencia es una de las características clave del envejecimiento, cuando se 
indujo senescencia en células HepG2, los niveles intra y extracelulares de OPN aumentaron. Además, 
al tratar las células con OPN recombinante, el efecto del agente inductor de la senescencia palbociclib 
se redujo.  
Los resultados anteriores sugieren que la OPN está involucrada en el envejecimiento, y podría 
jugar un papel en la vulnerabilidad al desarrollo de EHGNA asociado al envejecimiento. Quisimos 
analizar si el aumento de la expresión de OPN durante el envejecimiento es protector o perjudicial 
para el desarrollo de la hepatoteatosis asociada a la edad. Los niveles hepáticos de β-galactosidasa y 
p21 junto con la concentración hepática de TG y ésteres de colesterol y su síntesis de novo se 
encontraban incrementados en ratones OPN-KO de 10 meses en comparación con sus WTs. Este 
fenotipo estaba asociado con la disminución de la chaperona GRP78, la activación del estrés de 
retículo y el aumento de los niveles de FAS. La generación de senescencia en las células con OPN 
silenciada llevó a una disminución del GRP78. En ratones OPN-KO de 20 meses, la evaluación de la 
fibrosis hepática y la inflamación mostraron una peor progresión de la enfermedad y aunque los 
ratones OPN-KO de 20 meses no mostraron síntomas de estrés de retículo, la activación de la 
caspasa-12 junto con la gamma-H2AX refuerza la existencia daño hepático mayor en los animales 
OPN-KO. 
p53 controla varias funciones metabólicas y celulares y modula las adaptaciones celulares al 




relacionado p53 con la regulación del OPN en fibroblastos. Quisimos evaluar si p53 podía modular 
los niveles de OPN. El silenciamiento de p53 en células HepG2 redujo los niveles de OPN intracelular 
y en el medio. Además, las células Hep3B, en las que no hay p53, no eran capaces de generar OPN 
cuando se indujo senescencia con palbociclib o H2O2. In vivo, p53 está implicado en la hepatoteatosis, 
ya que los ratones p53-KO desarrollan esteatosis. Se sabe que al alimentar con HFD aumentan los 
niveles de OPN; sin embargo, los ratones p53-KO no mostraron un aumento en los niveles de OPN 
en el hígado cuando fueron alimentados con una HFD. Por lo tanto, p53 podría regular los niveles de 
OPN al inducir senescencia y en respuesta a una HFD. 
En conjunto, estos resultados muestran que la deficiencia de OPN conduce a una hepatoteatosis 
temprana asociada a la edad, acompañada de un estrés de retículo y un aumento de la senescencia. 
Este fenotipo conduce a una peor progresión de la enfermedad en la vejez, reflejado por el aumento 
de la fibrosis, la inflamación y los marcadores de apoptosis. Además, p53 podría ser necesario para 
la inducción del OPN en respuesta a senescencia o HFD. Por lo tanto, durante el envejecimiento, OPN 
podría estar regulada para mantener la salud hepática. 
4. Conclusiones 
1. La osteopontina (OPN) regula la interacción entre el colesterol y el metabolismo de la PC 
modulando de los niveles de CYP7A1 en hepatocitos. La vía de señalización FAK-AKT está 
implicada en la regulación de CYP7A1 por parte de OPN en el hígado.  
2. La OPN modula las vías metabólicas que intervienen en el metabolismo del TG y del colesterol 
durante la regeneración hepática. 
2.1. Los ratones deficientes en OPN muestran un aumento del catabolismo de ácidos grasos 
cuando hacen frente a la regeneración. El aumento de las demandas metabólicas y la 
disminución de la síntesis de novo de TG se compensan con los ácidos grasos de la dieta.  
2.2. La inhibición de la colesterogénesis mediante atorvastatina proporciona un nuevo 
escenario metabólico relacionado con la mejora de la regeneración temprana en ratones 
OPN-KO. 
3. La OPN es necesaria para mantener la homeostasis metabólica del organismo durante el 
envejecimiento. 
3.1 La OPN está implicada en el envejecimiento del hígado. En suero OPN se correlaciona 
positivamente con la edad en individuos y modelos animales con hígado normal. En los 
modelos animales, el aumento de los niveles de OPN en suero está relacionado con el 
aumento de los niveles en el hígado. La inducción de senescencia en células HepG2, 




3.2 OPN está regulada para mantener el equilibrio del metabolismo lipídico del hígado 
durante el envejecimiento. La deficiencia de OPN en ratones hace que el hígado sea más 
vulnerable a la hepatoteatosis asociada a la edad, siendo el mecanismo subyacente el 
aumento de la lipogénesis de novo asociada a la senescencia y a una alteración de la 
respuesta al estrés de retículo debido a la disminución de los niveles de GRP78.  
3.3 En ratones viejos alimentados con HFD, la deficiencia de OPN no provoca cambios en el 


































































































































1.1 Definition and features 
Aging is a multidimensional process characterized by a progressive loss of physiological integrity 
that leads to impaired function of the organism. At a biological level, aging is associated with the 
gradual accumulation of a wide variety of molecular and cellular damage. Over time, this damage 
leads to a decrease in physiological function, an increased risk of many diseases, and a general 
decline in the capacity of the individual to maintain homeostasis, which ultimately results in death. 
The deterioration of the organism function is the primary risk factor for major human diseases (World 
Health Organization, 2015).  
There are many theories about what causes aging, and the debate is still ongoing. Despite the 
variety of theories, most of them can be classified into two categories; programmed or damage 
theories. Those that assume that aging would be predetermined are commonly known as program 
theories; and those that claim that the aging process would be the result of the sum of alterations 
and damage that occur randomly and accumulate over time, damage theories (da Costa et al., 2016).  
Programmed aging theories, which are also referred to as active or adaptive aging theories, 
suggest that there is a deliberate deterioration with age because a limited life span results in 
evolutionary benefits. Moreover, this plan could be the result of aging genes. Genes undoubtedly 
contribute to longevity, although the extent of genetic versus non-genetic factor contributions to 
aging remains uncertain. If aging is indeed programmed, the purposes of such program remain 
unclear. Some have suggested that aging may constitute an altruistic plan (Longo, Mitteldorf, & 
Skulachev, 2005), by eliminating post-reproductive age individuals, who would compete for 
resources, by avoiding overpopulation and by promoting adaptation through a succession of 
generations. 
Regarding damage theories, evolutionary biologists argue that aging occurs due to the absence 
of natural selection at the post-reproductive stage of life. Hence, aging is not programmed; instead, 
it is the absence of selection for maintenance. The accumulation of damage is a spontaneous 
entropy-driven process. It can be genetically and environmentally modulated, resulting in the wide 
range of life spans we observe. In damage theories, one of the fundamental contributors for the 
causing aging is genome instability (López-Otín, Blasco, Partridge, Serrano, & Kroemer, 2013). Both 
stability and integrity of DNA and other macromolecules are challenged on a continuous basis by 
numerous endogenous and exogenous factors, including DNA replication errors and physical, 





Lopez-Otín et al., divided the hallmarks that represent the aging process into 3 groups 
(López-Otín et al., 2013); primary hallmarks, antagonistic hallmarks and integrative hallmarks (Fig. 
B.1). 
 
1.1.1 Primary hallmarks of aging 
Genomic instability, telomere attrition, epigenetic alterations and loss of proteostasis are 
considered the primary hallmarks of aging. These are considered the cause of cellular damage. One 
of the most common and accepted denominators of aging is the accumulation of genetic damage.  
Genomic instability: The genetic lesions caused by extrinsic or intrinsic damages are very diverse and 
include point mutations, translocations, chromosomal gains and losses, telomere shortening, and 
gene disruption caused by the integration of viruses or transposons. All the organisms have evolved 
a complex network of DNA repair mechanisms that are collectively capable of dealing with most of 
the damages inflicted to nuclear DNA. This machinery for genomic stability also include specific 
mechanisms for maintaining the appropriate length and functionality of telomeres.  
Telomere attrition: The telomeres are a region of repetitive nucleotide sequences at each end of a 
chromosome, which protects the end of the chromosome from deterioration and from fusion with 
Figure B.1 Interconnections between the Hallmarks of Aging. The nine hallmarks of aging are grouped into three 
categories. Primary Hallmarks, those hallmarks considered the primary causes of cellular damage. Antagonistic 
Hallmarks, those considered part of compensatory or antagonistic responses to the damage. These responses 
initially mitigate the damage, but eventually, if chronic or exacerbated, they become deleterious. Finally, 
integrative hallmarks that are the result of the previous two groups of hallmarks and are ultimately responsible 




neighboring chromosomes. Telomeres are particularly susceptible to age-related deterioration, 
where the general chromosomal DNA replication machinery cannot completely copy the DNA out to 
the extreme ends of the linear chromosomes. Over the course of cell divisions, this leads to attrition 
of chromosome ends. This deficiency can be resolved in eukaryotes by the cellular ribonucleoprotein 
enzyme telomerase, which can add telomeric repeat sequences to the ends of chromosomes, hence 
elongating them to compensate for their attrition (Blackburn, Greider, & Szostak, 2006). On the other 
hand, even mildly over-activating telomere maintenance promotes risks of subsets of cancers 
(Blackburn, Epel, & Lin, 2015).   
Epigenetic alterations involve alterations in DNA methylation patterns, posttranslational 
modification of histones, and chromatin remodeling. Studies of chromatin changes suggests that 
there is a global upregulation of activating marks and downregulation of repressive marks and that 
there are gene-specific changes in chromatin states regulating expression of key longevity genes 
Histone demethylases, for example, modulate lifespan by targeting components of key longevity 
routes such as the insulin/ insulin and insulin-like growth factor-1 (IGF-1) signaling pathway. In 
addition, inhibitors of histone deacetylases (HDACs) have been proposed, among other drugs, as a 
promising anti-aging therapy (López-Otín et al., 2013; Sen, Shah, Nativio, & Berger, 2016). 
Proteostasis is the concept that refers to the competing and integrated biological pathways within 
cells that control the biogenesis, folding, trafficking and degradation of proteins present within and 
outside the cell (Balch, Morimoto, Dillin, & Kelly, 2008). Not just the damaged genetic material 
contributes to aging, but also damage in other macromolecules such as proteins. The proteostasis 
network can be divided into several processes: protein synthesis, folding and conformational 
maintenance, protein degradation and posttranslational modifications (PTM) (Klaips, Jayaraj, & 
Hartl, 2018).  
Protein synthesis: Although the production of individual proteins is regulated by specific factors and 
pathways, the levels of bulk protein synthesis must be adjusted to the protein folding capacity of the 
cell to avoid the accumulation of misfolded proteins. Translation attenuation is also critical in 
relieving proteostasis network overload in conditions of stress. This is typically mediated by inhibition 
of translation initiation factor 2α (eIF2α). For example, on activation of the unfolded protein 
response (UPR) to the accumulation of misfolded proteins in the endoplasmic reticulum (ER), protein 
kinase RNA-like ER kinase (PERK) in the ER membrane, phosphorylates eIF2α attenuating its function 
in translation (Harding et al., 2001).  
Protein folding: Proteins often face significant challenges during folding, because partially folded 
states with exposed hydrophobic amino acids residues are in danger of misfolding and aggregating. 
Aberrant folding may occur during de novo synthesis or in conditions of conformational stress, where 
preexisting proteins may fail to maintain their folded states. To be able to deal with protein folding, 




maintenance and regulation of another protein without becoming part of its final structure. 
Accumulation of protein aggregates and loss of the balance is often observed in aging. One feature 
affecting protein damage in cellular senescence is the downregulation of cellular chaperones mainly 
Hsp90 and Hsp70 (Ogrodnik et al., 2018). Thus, a healthy chaperone network is required to maintain 
a stable proteome and to prevent the accumulation of toxic aggregate proteins. 
Degradation: When proteins are not able to properly fold, they must be disposed to avoid the 
formation of toxic aggregates. Like other proteostasis pathways, the ability of the cell to maintain 
spatial quality control also declines with age (Klaips et al., 2018). Misfolded proteins usually undergo 
disposal by the ubiquitin-proteasome system or by chaperone mediated lysosomal degradation (C. 
Zhang & Cuervo, 2008). If these degradation systems do not work properly, misfolded and 
aggregated proteins can accumulate. Chronic expression of unfolded, misfolded, or aggregated 
proteins contributes to the development of some age-related pathologies, such as Alzheimer’s 
disease, Parkinson’s disease, and cataracts. 
The protein network ensures that most proteins fold to a stable native state. When these proteins 
are no longer needed or errors in folding occur, they are efficiently targeted for degradation, 
primarily via the ubiquitin-proteasome system (UPS). If cells undergo transient stress, healthy cells 
activate a stress response. Chaperone bind to misfolded species and trigger the appropriate 
transcriptional program leading to a general increase in protein-folding capacity, increase in protein 
turnover, and decrease in the production of additional substrates via attenuation of general protein 
translation. In cases of chronic stress, such as during aging or disease, sequestration of key protein 
network components by aggregates can lead to aberrant transcriptional programs, a deficit in folding 
capacity due to a lack of functionally available chaperones, and a buildup of misfolded species due 
to a decline in proteasome capacity. This can lead to an inability to restore the balance and further 
accumulation of misfolded species (Fig B.2)(Klaips et al., 2018). 
Protein posttranslational modifications (PTMs) occur as a consequence of either modifying 
enzymes related to posttranslational processing or signaling pathway activation. In this context, both 
enzymatic and nonenzymatic PTMs can undergo age-related alterations. Alteration in the pattern of 
nonenzymatic PTMs depends mainly on the nature of the modifying substances, such as metabolites 
and free radicals. In contrast, changes in the nature of enzymatic PTMs rely primarily on the activities 
of modifying enzymes. Associated to the aging process, phosphorylation, N-Acetylation, 
glycosylation, sumoylation, nitrosylation, methylation and oxidation are some of the changes that 







1.1.2 Antagonistic hallmarks of aging 
 The antagonistic hallmarks are those considered part of compensatory or antagonistic 
responses to the damage. The antagonistic hallmarks are the deregulated nutrient-sensing, the 
mitochondrial dysfunctions and cellular senescence. These responses initially mitigate the damage, 
but eventually, if chronic or exacerbated, they become deleterious themselves.  
Altered nutrient sensing: The correct regulation of the nutrient sensing is key for the 
maintenance of the cell. It has been observed that many manipulations that attenuate signaling of 
insulin and IGF-1 pathway at different levels are able to expand lifespan. Other nutrient sensing 
regulators like mTOR and AMP-activated protein kinase (AMPK) have influence on lifespan.  A 
growing list of evidence suggests that mTOR signaling influences longevity and aging. Indeed, 
inhibition of the mTOR complex 1 (mTORC1) with rapamycin is currently one of the known 
pharmacological treatments that increases lifespan in many model organisms studied (Weichhart, 
2018). AMPK is a fundamental regulator of energy metabolism and stress resistance. AMPK signaling 
controls an integrated signaling network that is involved in the regulation of lifespan and its 
activation mediates lifespan extension. AMPK can inhibit mTOR, IGF-1 signaling (Salminen, 
Kaarniranta, & Kauppinen, 2016). Evidence suggests that the anabolic signaling accelerates aging and 
that the decreased nutrient signaling (i.e. dietary restriction) extends longevity (Fontana, Partridge, 
& Longo, 2010; López-Otín et al., 2013).  
Mitochondrial dysfunction is other antagonistic hallmark of aging. On one hand, the aging-
associated mitochondrial dysfunction is thought to cause an increased production of radical oxygen 




species (ROS), which causes further mitochondria deterioration and cellular damage. This is the basis 
for the mitochondrial free radical theory of aging (Harman, 1965). Apart from generating ROS, the 
dysfunctional mitochondria can also affect the apoptotic signaling and reduces the bioenergetics 
efficiency. During aging, cells present defective mitophagy (a form of macroautophagy that targets 
defective mitochondria for degradation), and lower mitochondrial biogenesis. These two 
phenomena leads to a decreased turnover of “healthy” mitochondria, which may contribute to the 
aging process.  Thus, mitochondrial dynamics can also be important for delaying aging and extend 
longevity by improved mitochondrial quality control (Bratic & Larsson, 2013; R. Shi, Guberman, & 
Kirshenbaum, 2018). 
Cellular senescence is considered one of the key hallmarks of aging. One of the main features of 
aged organisms is the accumulation of senescent cells. However, senescence and aging should not 
be considered as the same concept, although many times aging and senescence words are used 
indistinctly. Indeed, aging is a much broader and complex process. Senescence is the irreversible cell 
cycle arrest that constitutes a stress response triggered by insults such as genomic instability and 
telomere attrition, radiation, oncogenic stress, oxidative stress, tumor suppressor loss, oxidative 
stress and certain cytokines among other factors (Bolden & Lowe, 2015; López-Otín et al., 2013; 
McHugh & Gil, 2018). Thus, it is a mechanism to restrict the propagation of cells under stress. A cell 
can enter cellular senescence either by gradual accumulation of damage in replicative aging or by a 
sudden outburst of damage, like the damage induced by radiation or chemotherapeutics. Therefore, 
senescent cells often show high levels of various forms of damage and resemble chronologically aged 
cells observed in an old organism. While the cell stops dividing when entering senescence, it remains 
metabolically active and keeps accumulating damage in the process that can last months or even 
years ending in cell death (Ogrodnik et al., 2018). Senescence is characterized for several features 
like flat enlarged cytomorphology, extracellular matrix reorganization, reorganization of chromatin, 
p53/Rb pathway activation, senescence-associated β-Galactosidase (SA β-Galactosidase) activity, the 
formation of senescence-associated heterochromatic foci (SAHF), epigenetic changes and secretion 
of a diverse collection of soluble and insoluble factors: the senescence-associated secretory 
phenotype (SASP) (Bolden & Lowe, 2015). 
The main outputs of senescence are beneficial as senescence imposes a potent barrier to 
tumorigenesis and contributes to tissue repair and embryonic development, together with a role in 
wound healing, tissue regeneration and immune surveillance. However, senescence can also have 
detrimental consequences as the SASP can enhance proliferation of neighboring tumor cells, 
chemoresistance, and aging (Lujambio, 2018; Malaquin, Martinez, & Rodier, 2016). The SASP is one 
of the key features of the senescent cells, and it can affect intercellular communication. This 




(Malaquin et al., 2016). However, the SASP can vary depending on cell type and senescent stimuli. 
These secreted factors function physiologically in the tissue microenvironment, in which they can 
propagate the stress response and communicate with neighboring cells, having thus, paracrine but 
also autocrine effects. Some SASP factors have important roles in the onset of stable cell‐cycle arrest 
in senescent cells, which contributes to the tumor‐suppressive function of cellular senescence. 
Paradoxically, many SASP factors have the potential to cause chronic inflammation and 
tumorigenesis, depending on the biological context (Lau & David, 2019; Rao & Jackson, 2016). 
Despite the deleterious effects of SASP, it is important to keep in mind, that, primarily its effects 
are beneficial, since it also contributes to embryonic development, wound healing and inhibits 
tumorigenesis (Fig B.3). These beneficial effects of SASP happens when the presence of senescent 
cells in the tissue is transient (Malaquin et al., 2016). The SASP plays a critical role by removing these 
transient senescent cells via immune-mediated clearance, by recruiting immune cells. It is when 
senescent cells remain in the tissue because of defective clearance when the detrimental effects 
appear. Thus, depending on the biological context senescence will have a beneficial or deleterious 
effect. Senescence in the aging context has negative effect, since accumulation of senescent cells 
contributes to tissue dysfunction. 




The mechanisms by which senescence is induced can be diverse, many of which involve p53 
activation. Most senescence inducers activate the tumor suppressor pathways TP53/CDKN1A and/or 
pRb/CDKN2A. All the mechanism meet in the activation of the cyclin-dependent kinase (CDK) 
inhibitors such as p16, p15, p21 and p27. The inhibition of CDK-cyclin complexes results in 
proliferative arrest. Being its feature the hypo-phosphorylation of Rb. The senescence-inducing 
pathways may vary from a cell type to others (Munoz-Espin & Serrano, 2014).  
1.1.3 Integrative hallmarks of aging 
Finally, the integrative hallmarks are the consequence of the primary and antagonistic hallmarks, 
and are ultimately responsible for the functional decline associated with aging. These hallmarks are 
stem cell exhaustion and altered intracellular communication (López-Otín et al., 2013). 
Stem cell exhaustion: the decline in the regenerative potential of tissues is one of the most 
obvious characteristics of aging. The life-long persistence of stem cells in the body makes them 
particularly susceptible to the accumulation of cellular damage. Interestingly, recent promising 
studies suggest that stem cell rejuvenation may reverse the aging phenotype at the organismal level 
(Rando & Chang, 2012). Stem cells in many tissues have been found to undergo profound changes 
with age, exhibiting reduced responsiveness to tissue injury, dysregulation of proliferative activities 
and declining functional capacities. Exhaustion of the stem cell pool with age can occur because these 
cells lose self-renewal activity and terminally differentiate, thereby exiting the stem cell pool, or 
because they undergo apoptosis or senescence induced by exposure to cellular stress. These changes 
translate into reduced effectiveness of cell replacement and tissue regeneration in aged organisms 
(Oh, Lee, & Wagers, 2014).  
Intercellular communication is another integrative hallmark of aging. Intercellular 
communication is key for cells to grow and work normally. Cells signal each other by direct contact 
with each other or by the release of a substance from one cell that is taken up by another cell. 
Intercellular communication is fundamental to the immune response. Several studies have 
highlighted that aging is characterized by a state of low-grade persistent inflammation that leads to 
a global loss of efficiency, being the biological background for many aging-related diseases and may 
be the underlying mechanism responsible for the decline in physical function with age. The so-called 
“Inflammaging”, which may result from multiple causes. Various data suggest that besides persistent 
viral and bacterial infections, cell debris, misplaced self-molecules and misfolded and oxidized 
proteins are major contributors to inflammaging (Franceschi, Garagnani, Parini, Giuliani, & Santoro, 
2018). Linked to this, a major characteristic of inflammaging is the chronic activation of the innate 




response in the elderly (Bruunsgaard, Pedersen, Schroll, Skinhøj, & Pedersen, 2000; Fagiolo et al., 
1993).  
Senescent cells secrete proteins, such as inflammatory cytokines, chemokines, extracellular 
matrix remodeling factors, and growth factors. These secreted proteins function physiologically in 
the tissue microenvironment, in which they could propagate the stress response and communicate 
with neighboring cells. As previously mentioned, this is known as the SASP. Interestingly, 
inflammaging and metaflammation (a specific situation of chronic inflammation caused by nutrient 
excess) largely share the same molecular mechanisms (Franceschi et al., 2018).  
1.1.4 Perspectives and consequences 
Aging is emerging as a key policy issue because both the proportion and absolute number of 
older people in populations around the world are increasing dramatically (Fig. B.4). There are two 
key drivers of population aging, increased life expectancy and decreased fertility rates. Regarding the 
increasing life expectancy, on average, people around the world are living longer. Part of this global 
increase is due to the improved survival of people at older ages, the other part is explained by 
improved survival at younger ages. The second reason is that populations are aging because of falling 
fertility rates (World Health Organization, 2015).  
The aging of the population is expected to have a severe socio-economic impact especially in the 
developing countries, which account for over 60% of the older population (World Health 
Organization, 2015). Because the health dynamics of older age are related to increased needs for 
health care, it might be expected that increasing age would be associated with increased health-care 
utilization. This predicted increase in the life expectancy over the next years demands better 
healthcare services and disease prevention measures. Research in the aging field has gained a great 
relevance lately because age-related issues involve a large part of the population, not only the 
elderly, but also the mayor part of society because of the medical and economic impact. Therefore, 
it is essential to have a better understanding of the mechanisms of the progression of organ 
dysfunction with aging, to be able to find markers, targets and treatments to help to reduce or avoid 
the severity of diseases associated or aggravated with age and improve as much as possible the 





1.2 Aging and disease 
The aging of a large part of the population, especially in Western societies, is a quite recent 
phenomenon that is consequence of the rise in the human life expectancy and low fertility. However, 
longer lifespan does not mean the maintenance of the health span, usually the number of chronic 
diseases in the elderly population is very high, especially of metabolic and cardiovascular diseases 
(Ferrucci, Giallauria, & Guralnik, 2008). Several underlying changes tend to occur to some degree in 
all humans as they age. Although there is marked diversity in how these changes are experienced at 
an individual level, general trends are seen when the population as a whole is considered. All the 
following features are considered a manifestation of the aging process: sarcopenia, decline in vision 
and hearing, decrease of cognitive function, decreased immune function and frailty (World Health 
Organization, 2015) 





The deterioration that accompanies aging is the primary risk factor for major human pathologies, 
including cancer, diabetes, cardiovascular disorders, and neurodegenerative disorders. An important 
aspect of disease status that distinguishes the older population from the younger population is the 
high rate of co-occurrence of multiple chronic conditions, termed comorbidity. The concept of 
comorbidity is useful in considering the burden of disease in older people. The reason for the 
increased prevalence of diseases in the elderly is, as mentioned above, the accumulation of damage 
that leads to the tissue malfunction and deterioration, and the inability to repair this damage leads 
to disease, often, chronic disease. Among them, the prevalence of metabolic diseases is high as 
shown in the table (Table B.1).  
 
 
The most common metabolic disorders associated with aging are: 
Hypertension: Hypertension, a major contributor to atherosclerosis, is the most common chronic 
disease of older adults. Atherosclerosis and hypertension are the major factors responsible for the 
myocardial infarction and stroke. Isolated systolic hypertension is particularly common among older 
adults and is associated with mortality at advanced ages (Belikov, 2018; Jaul & Barron, 2017).  
 Cardiovascular Disease: Cardiovascular disease remains the most common cause of death of 
older adults, although death rates have dropped in the last 20 years. This category includes chronic 
ischemic heart disease, congestive heart failure, and arrhythmia. Normal aging includes vascular 
remodeling and vascular stiffness (J. C. Wang & Bennett, 2012). Atherosclerosis causes inflammation 
and further vascular changes increasing risk for cardiac events, stroke, peripheral vascular disease, 
cognitive impairment, and other organ damage (Collerton et al., 2009; Jaul & Barron, 2017). 
 
Table B.1. Prevalence of the main health problems in the population over 64 years, rate for every 1,000 people 
assigned to the primary care of the National Health System, sorted by gender. Spain, 2012 
Health problem Both genders Males Females
Hypertension 503,3 473,6 525
Lipid metabolism disorders 341,6 310,6 365
Athrosis (except back bone) 220 146,6 275,6
Diabetes mellitus 197 218 181
Acute  infection of the respiratory apparatus 165,7 160,9 169,4
Backbone syndromes 127,3 105 144,2
Other locomotor system problems 106,9 69,5 135,2
Cataracts 101,5 89,9 110,3
Arrithmia 95,2 105,1 87,7
Obesity and overweight 95,2 79,2 107,2
Teeth / gums diseases 94,2 100,1 89,8
Other cardiovascular diseases 89,1 61 93,6
Skin disorders 88,4 81,7 53,7




Diabetes Mellitus: Diabetes rates have been increasing as populations age and become more 
overweight. The prevalence of diabetes among American older adults may increase more than 400% 
by 2050. Diabetes mellitus is the group of metabolic diseases characterized by increased blood 
glucose levels. Diabetes is considered a strong risk factor for cardiovascular disease; it is also 
associated with peripheral arterial disease and peripheral neuropathy, contributing to diabetic foot 
ulcers and amputation. There many other complications associated to diabetes. These would include 
skin conditions, fatty liver disease, infections, polycystic ovarian syndromes, Alzheimer’s disease and 
cancer (Jaul & Barron, 2017).  
Cancer: Cancer is the second leading cause of death in older adults. However, by age 85, the 
death rate from cancer begins to fall (Gorina, Goulding, Hoyert, & Lentzner, 2005). Slow-growing 
tumors seem to be common in old population. Usually, response to cancer treatment depends on 
functional status rather than age. At any age, life expectancy when suffering from cancer is quite 
variable in older adults, based on comorbidities and other factors (Jaul & Barron, 2017).  
1.3 Aging and metabolic changes in whole body metabolism 
The prevalence of metabolic syndrome (MS) is increasing worldwide, especially among the 
elderly. Indeed, the prevalence of MS is increased with aging (Bertolotti et al., 2014a). Due to 
multiple age-related physiologic mechanisms, MS is a term that describes a cluster of independent 
risk factors that increase the likelihood of cardiovascular disease and type 2 diabetes. These factors 
include central obesity, insulin resistance, dyslipidemia (elevated levels of triglycerides and low 
density lipoproteins (LDL) and decreased levels of high density lipoprotein (HDL)), and high blood 
pressure. In addition, there are other factors such as proinflammatory and prothrombotic states that 
have been associated with MS (Hutcheson & Rocic, 2012).  
Aging complicates the maintenance of cellular and organic metabolic homeostasis, hence 
favoring an imbalance in metabolism that self-amplifies and eventually becomes clinically manifest. 
Several metabolic alterations accumulate over time along with a reduction in biological fitness, 
suggesting the existence of a “metabolic clock” that controls aging. It has been demonstrated that 
some metabolic interventions can increase longevity, such as caloric restriction, selective limitations 
of specific nutrients and physical exercise (López-Otín, Galluzzi, Freije, Madeo, & Kroemer, 2016). 
Multiple defects in metabolism accelerate aging, whereas genetic loci linked to exceptional longevity 
influence metabolism. Lipids are crucial for a variety of biological processes, including aging and 
longevity. Interestingly, it has been demonstrated that lipid metabolism can regulate chromatin 
modifications. Signaling pathways that regulate longevity, such as the insulin pathway and the mTOR 




activity of transcription factors that in turn modulate enzymes involved in lipid metabolism (Papsdorf 
& Brunet, 2018).  
Major metabolic impairments associated to aging include unrestrained hepatic gluconeogenesis, 
adipose lipogenesis, defective glycogen synthesis and defective glucose uptake in skeletal muscle 
(Barzilai, Huffman, Muzumdar, & Bartke, 2012). Energy expenditure regulation is key for the 
maintenance of the metabolic state. Dysregulation of energy intake occurs in old age even in 
apparently healthy individuals and increase the risk of energy imbalance. Interestingly, when 
examined relative to the energy needs of the metabolically active tissues, the release of free fatty 
acids is actually greater in older compared to younger individuals (Toth & Tchernof, 2000). Thus, 
there is data suggesting the existing dysregulation of body energy expenditure and substrate 
oxidation in old age. The extent to which body weight and fat increases or decreases in response to 
age-related energy dysregulation will depend on the prevailing environmental circumstances and 




















2. Liver disease  
2.1 Liver 
2.1.1 Liver features and function 
The liver is the largest organ of the human body, it represents between 2 to 5% of the body 
weight in adults. It is located in the abdominal cavity inferior to the diaphragm. It is the organ that 
most irrigation receives, accounting the 27% of the cardiac output in rest. The human liver structure 
is composed of four lobes: right, left, squared and caudate lobe. Its basic structure is the liver lobule, 
which is hexagonal in shape. The lobule consists of many cellular plates that radiate from the central 
vein, and each plate consists of liver specialized cells, the hepatocytes. The liver functional unit is the 
hepatic acinus, a mass of liver parenchyma that is supplied by terminal branches of the portal vein 
and hepatic artery, and drained by branches that form the hepatic vein (Fig B.5). 
The liver is composed of several cell populations (Fig B.6). These cells are classified into two principal 
groups: parenchymal cells or hepatocytes and non-parenchymal or sinusoidal cells such as 
endothelial cells, Kupffer cells, stellate cells, lymphoid cells or Pit cells and the biliary epithelium.  





Hepatocytes represent about 60% of the liver population, and roughly, 80% of the mass of the 
liver is contributed by hepatocytes. The cells are polygonal in shape, and can have a single nucleus 
or more nuclei. Hepatocytes present acidic cytoplasm with basophil bodies and have abundant 
organelles. They can store intracellular lipids and glycogen. The hepatocytes are polarized with a 
basolateral membrane facing the blood and an apical membrane facing the bile canaliculus. The 
canaliculus is defined by two adjoining cells, which are connected by junctional complexes.  In the 
liver, endothelial cells lack basement membranes, and this facilitates transfer of materials into the 
space of Disse between endothelial cells and hepatocytes and allows the hepatocytes to contribute 
to blood proteins and lipoproteins.  
Liver sinusoidal endothelial cells (LSECs) line the low shear, sinusoidal capillary channels of the 
liver and are the most abundant non-parenchymal hepatic cell population. LSECs do not simply form 
a barrier within the hepatic sinusoids but have vital physiological and immunological functions, 
including filtration, endocytosis, antigen presentation and leukocyte recruitment. Reflecting these 
multifunctional properties, LSECs display unique structural and phenotypic features that 
differentiate them from the capillary endothelium present within other organs. It is now clear that 
LSECs have a critical role in maintaining immune homeostasis within the liver and in mediating the 
immune response during acute and chronic liver injury (Shetty, Lalor, & Adams, 2018). 
Kupffer cells, the resident macrophage in the liver, comprise the largest population of resident 
tissue macrophages in the body. Kupffer cells play a critical role in the innate immune response; their 
localization in the hepatic sinusoid allows them to efficiently phagocytize pathogens entering from 
the portal or arterial circulation. Kupffer cells also serve as a first line of defence against particulates 
and immunoreactive material. Dysregulation in the precise control of inflammatory responses in 
Kupffer cells can contribute to chronic inflammation in the liver.  





Hepatic stellate cells (also known as perisinusoidal cells or Ito cells) are located between the 
hepatocytes and small blood vessels in the liver, also known as the space of Disse. They are 
characterized by the presence of lipid droplets and thin protrusions extending around the blood 
vessels. Their activation in damaged liver leads to secretion of collagen and formation of scar tissue, 
leading to chronic fibrosis or cirrhosis.  
Pit cells are one type of hepatic sinusoidal cells, defined morphologically as large granular 
lymphocytes (LGLs) and functionally as liver-associated natural killer (NK) cells. They are situated 
inside the sinusoidal lumen, adhering to the endothelial cells and Kupffer cells.  
Cholangiocytes are the epithelial cells of the bile duct. They are a heterogeneous, highly dynamic 
population of epithelial cells that line a three-dimensional network of bile ducts known as the biliary 
tree. Their major physiologic function lies in modification of hepatic canalicular bile as it is 
transported along the biliary tree. 
The liver has a central role regulating whole body metabolic homeostasis. It processes 
aminoacids, carbohydrates, lipids and vitamins coming from the digestive system for its storage, 
processing and/or secretion to the blood or bile. It also synthetizes essential proteins, secretes 
lipoproteins and takes part in defensive processes of the organism, such as the defensive humoral 
response as detoxifying of substances like drugs and alcohol. Most of the metabolic functions are 
carried out by hepatocytes.  
2.1.2 Liver lipid metabolism 
Lipid metabolism in hepatocytes includes processes of acquisition of lipids, including uptake 
from diet and from circulating lipoproteins, and fatty acids derived from white adipose tissue 
(WAT) lipolysis, as well as lipid de novo synthesis (de novo lipogenesis); lipid storage and formation 
of lipid droplets and lipid disposal in consumption processes and the secretion of lipids into 
lipoproteins (Fig B.7). Many liver diseases are accompanied by disorders in lipid metabolism. 
TG and FA metabolism: Hepatocyte uptake of fatty acids (FA) can occur through passive diffusion 
because of the hydrophobicity of FAs. However, facilitated transport of particularly long-chain FAs 
is regulated by translocases and transporters. In the fasting state, a reduction in insulin levels 
stimulates triglycerides (TG) hydrolysis in adipose tissue releasing FAs, which will be transported 
to the liver.  
Dietary fats are packed into chylomicrons in enterocytes. Once in circulation the 
endothelial lipoprotein lipase of adipose tissue and muscle will hydrolyze the chylomicrons and 




chylomicron remnants, which are imported into hepatocytes by remnant receptors through apoE 
on the surface of the remnants. 
As previously mentioned FAs can also be synthesized in the hepatocyte. De novo 
lipogenesis (DNL) of FAs occurs in the cytosol. Under physiological conditions, excess glucose 
stimulates FA and TG synthesis in hepatocytes. SREBP1c is a key transcription factor regulating FA 
synthesis, which upregulates several lipogenic genes, including those encoding acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (FAS). FAs can be used for the synthesis of TG via 
esterification, which will be stored into lipid droplets, or secreted into VLDL in which 
apolipoprotein B (apoB) is required. Regulation of VLDL assembly and secretion is a complex 
process. VLDLs transport FAs from the liver to adipose tissue and other peripheral tissues. TGs are 
synthesized primarily in the liver, adipose tissue and small intestine as a major nontoxic energy 
storage form. In the liver, the acyl-CoA diacylglycerol acyltransferases (DGAT) membrane-bound 
enzymes that catalyze the final step of TG synthesis from diacylglycerol (DAG) and fatty acyl-CoA, 
play a crucial role. 
Figure B.7 Schematic representation of the main processes involved in lipid output and input in the liver. 
Orange arrows represent the main lipid input processes and blue arrows the main lipid output processes. 
Ac.Coa (Acetyl-CoA), ASM (Acid soluble metabolites), BA (bile acids), CE (cholesteryl ester), DG (diglycerides), 
DNL (de novo lipogenesis), FA (Fatty acid), FC (Free cholesterol), HDL (high density lipoprotein), LD (lipid 


































In the liver, FAs derived from peripheral tissue or diet can be used for energy production 
via mitochondrial β-oxidation. The β-oxidation of FAs occurs within the mitochondria and 
peroxisomes. In general, short-, medium-, and long-chain FAs are oxidized within mitochondria, 
while very long-chain FAs are oxidized within peroxisomes. β-oxidation is a major metabolic pathway 
that is responsible for the mitochondrial breakdown of long-chain acyl-CoA to acetyl-CoA for energy 
production. This process involves many steps that are regulated at the transcriptional and post-
transcriptional level.  
Cholesterol metabolism: The liver plays an important role in the metabolism and regulation of 
cholesterol. There are two hepatic forms of cholesterol: free cholesterol (FC) and cholesteryl ester 
(CE). CE can either be stored, hydrolyzed or secreted. There are two sources of cholesterol, the diet 
and de novo synthesis. Both dietary cholesterol and de novo synthesized cholesterol are transported 
through the circulation into lipoprotein particles. The cholesterol biosynthesis pathway involves 
enzymes that are in the cytoplasm, endoplasmic reticulum (ER) and peroxisomes. Synthesis of 
cholesterol, like most biological lipids, begins from the two-carbon acetate group of acetyl-CoA. The 
initial steps in the pathway of cholesterol biosynthesis are collectively called the mevalonate 
pathway. The cholesterol synthesis is a long process with high demands of energy. Excess of FC can 
be converted into CE, a more inert lipid, and stored. High cholesterol concentrations can be toxic for 
the cells. Thus, the cholesterol output pathways include bile acid formation, bile secretion and 
secretion into lipoproteins. Cholesterol can be oxidized in bile acids (BA). This conversion represents 
the major pathway for its elimination; representing half of the daily excretion. The liver excretes FC 
via bile, into the digestive tract.  
Phospholipid (PL) metabolism: The PLs found in most of the cell membranes are 
glycerophospholipids. The most abundant glycerophospholipid types are phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI). The structure 
of the phospholipid molecule generally consists of two hydrophobic fatty acid and a hydrophilic part 
consisting of a phosphate group. These two components are joined together by a glycerol molecule. 
The phosphate groups can be modified with simple organic molecules such as choline, ethanolamine 
or serine. The nature of the acyl groups and the type of the alcohol group decide the classification, 
properties, and biological functions of the PL.  
PC is the most abundant PL in the liver and can be synthesized by two different pathways: 
the Kennedy pathway and the phosphatidylethanolamine methyltransferase (PEMT) pathway. The 
de novo or the CDP-choline pathway, known as the Kennedy pathway, is in charge of 70% of the PC 
synthesis in liver. The phosphatidylethanolamine methyltransferase (PEMT) pathway, which is 




2.1.3 Hepatic changes with aging 
In general, the liver function under normal physiological conditions is not intensely impaired with 
aging. However, when is stressed the aged liver will respond differently (Sheedfar, Biase, Koonen, & 
Vinciguerra, 2013). Changes in liver during aging can reduce hepatic function and promote liver 
injury. The aging liver is associated with higher morbidity, enhanced vulnerability and a poor 
prognosis in patients with various liver diseases, including NAFLD, hepatitis C and liver cancer. In 
addition, liver regeneration capacity is decreased with aging (Schmucker & Sanchez, 2011).  There 
are hepatic changes associated with the aging process; these changes can negatively affect the 
morphology, physiology and oxidative capacity of the liver. During aging there is a loss of hepatic 
volume of 1/3 approximately, a reduction of the blood perfusion and a decrease in the capacity to 
metabolize certain compounds (Wynne et al., 1989). There are changes in the expression of a variety 
of proteins and diminished hepatobiliary functions. Aging is also accompanied by significant liver 
sinusoidal deregulation (Maeso‐Díaz et al., 2018) and a loss of capacity to fight against oxidative 
stress (Schmucker, 2005). In addition, apoptosis increases with liver aging (Zhong et al., 2017).    
In old age, fat is redistributed outside the usual fat deposits, and lipids can accumulate in non-
adipose tissues like skeletal muscle, heart and liver. Aging is associated with an increase in the lipid 
accumulation within the liver that may compromise the normal function due to lipotoxicity (Slawik 
& Vidal-Puig, 2006). Fat may accumulate in the liver as a result of many alterations in lipid 
metabolism (Cohen, Horton, & Hobbs, 2011). Although there are many possible mechanisms to 
explain the increase of age-related liver steatosis, the mechanisms that underlie this accumulation 
are not clearly defined. Increased fatty acid uptake, increased de novo lipogenesis (DNL) (Kuhla, Blei, 
Jaster, & Vollmar, 2011), decreased FA oxidation, and/ or disrupted synthesis or secretion of VLDL 
(Toth & Tchernof, 2000) could be involved in the aging-associated liver lipid accumulation.  Finally, 
the rate of liver regeneration is decreased in old animals and humans and this may enhance the 
progression of hepatic diseases and compromise liver transplantation in the elderly (Schmucker, 
2005). 
The number of senescent hepatocytes in the liver increases with age. Hepatocyte senescence is 
characterized by expression of SA-β-gal activity, blockage of cell proliferation, accumulation of foci 
of DNA damage and increased levels of cell cycle inhibitors p16, p21 and p53 (M. Wang et al., 2014). 
Senescence of hepatocytes can also be induced by metabolic stress, oncogene over-expression or 
deletion of tumor suppressing genes, either in vivo or in vitro.  
Hepatocyte senescence is also involved in development and progression of other chronic liver 
diseases such as NAFLD (A. Aravinthan et al., 2013). It was found that the fibrosis stage of patients 




such senescence occurs highly selectively in hepatocytes rather in hepatic stellate cells or 
lymphocytes, and this process is associated with progression of liver cirrhosis (Wiemann et al., 2002). 
 2.1.4 Liver regeneration and aging 
Liver regeneration has been investigated in detail in rodents using the partial hepatectomy (PH) 
model, a surgical resection that removes two-thirds of the liver. The remaining liver expands in mass 
to compensate for the lost tissue. Therefore, the liver regeneration is, actually, a compensatory 
growth. Liver regeneration is a complex process regulated in young animals by the cooperation of 
several signal-transduction pathways. However, as mentioned above, one of the main features of 
the aging liver is the decreased rate of regeneration. It is well established that adult hepatocytes are 
characterized by a very low replicative rate; however, they can rapidly re-entry into the cell cycle 
following tissue loss/death (Fausto, Campbell, & Riehle, 2006; Fausto, FAU, & Riehle, 2006; 
Timchenko, 2009). Since aging affects the regenerative response of the liver after chronic tissue 
injury or following surgical resection, it represents a critical problem in aged patients with liver 
disease (Zhu et al., 2014). 
Figure B.8 Prolonged senescence may restrict tissue regeneration (Lasry & Ben-Neriah, 




The age-dependent decline of the liver regeneration capacity is the consequence of multiple 
factors that cooperate to affect liver mass recovery after tissue damage. The induction of hepatocyte 
proliferation factors and the expression of cell cycle genes is inhibited in the elderly. In addition, the 
repression of cell proliferation and cell cycle gene inhibitors is compromised in the elderly (Pibiri, 
2018; Schmucker & Sanchez, 2011).  
Regarding hepatocyte senescence, it has been observed that chronic hepatocyte damage and 
concomitant hepatocyte regeneration accelerate telomere shortening in hepatocytes. When 
hepatocytes reach the senescent stage, liver regeneration decreases but the chronic liver damage 
continues. At advanced stages of liver disease, other cell types, like hepatic stellate cells, which 
usually do not participate in the regenerative process, become activated and form fibrotic scar tissue 
in areas of hepatocyte loss (Wiemann et al., 2002). Senescence and SASP have an important role in 
tissue regeneration. As previously mentioned, SASP provides signals that induce cell plasticity and 
stemness, which are beneficial for tissue regeneration. However, an aberrant or prolonged exposure 
to the SASP can generate a cell-intrinsic senescence that blocks and obstructs the growth promoting 
signals (Fig. B.8). This results in a decreased regenerative capacity. In benign senescence, SASP 
activates the immune system to promote its own clearance and also induces plasticity in neighboring 
cells. This facilitates the replacement of the cleared cells and promotes tissue regeneration. 
However, this mechanism is defective in old livers (Fig B.8)(Ritschka et al., 2017).   
2.2 Non-alcoholic fatty liver disease (NAFLD) 
NAFLD is considered one of the most common cause of chronic liver disease in the Western 
world, and it is commonly associated with insulin resistance and obesity, which are the most 
prevalent risk factors for NAFLD. This disease includes a spectrum of disorders (Fig B.9). Hepatic 
steatosis is the earliest stage of NAFLD, and it is caused by the accumulation of fat in the hepatocytes. 
The aberrant accumulation of lipids in the liver can lead in some individuals to an inflammatory 
response that can progress to pathologies like hepatitis, cirrhosis and liver cancer. The NAFLD 
pathogenesis is complex, and involves a state of lipotoxicity in which insulin resistance, ER stress 
along with other processes related with altered lipid metabolism, may play an important role in the 
progression to nonalcoholic steatohepatitis (NASH). The altered processes involved in this onset are  
increased free FA release from the adipose tissue to the liver, an unbalance between mechanisms of 
lipid input (uptake and synthesis) and output (lipid secretion as lipoproteins and disposal through 
bile acid synthesis) (Friedman, Neuschwander-Tetri, Rinella, & Sanyal, 2018; Slawik & Vidal-Puig, 
2006). NASH is characterized by steatosis with necroinflamation and eventual fibrosis, which can lead 
to further progression of liver disease (Cohen et al., 2011; Lomonaco, Sunny, Bril, & Cusi, 2013). Any 




form within the liver, and if the scarring continues the liver can develop a state called cirrhosis. The 
pathogenic mechanisms for NASH are being unraveled, but metabolic stress, inflammation and 
fibrosis are considered key processes (Fig B.10) (Diehl & Day, 2017). It is considered that 20-30% of 
NASH patients will develop fibrosis, which may progress to fibrosis. Cirrhosis is a condition where 
normal liver tissue is replaced by fibrotic tissue, and the function and structure of the liver are 
disrupted. Severe cases of cirrhosis can provoke liver failure, and cirrhosis patients are at high risk of 
developing hepatocellular carcinoma (HCC). However, HCC can also develop in the absence of liver 
cirrhosis.  Indeed, NAFLD is also fueling the increasing incidence and prevalence of primary liver 
cancer in many countries. The incidence of HCC is at least 1 to 2% per year among patients with 
cirrhosis related to NASH; primary liver cancers can also develop in patients with non-cirrhotic NASH 
and NAFLD (Fig B.10)(Issa & Alkhouri, 2017)(Diehl & Day, 2017). Interestingly, NAFLD has become the 
most common liver disease associated with HCC development. In fact, metabolic risk factors are 
common among patients with HCC. Besides, HCC related mortality is increasing, with typical patients 
being elderly with metabolic risk factors (Fig B.11) (Dyson et al., 2014).  
The disease is reversible in the early stages; simple steatosis has the best prognosis within the 
spectrum of NAFLD, but the treatment becomes more complicated with progression, and if not 
treated, it may progress to more severe stages such as cirrhosis and HCC (Angulo, 2002). NAFLD is 
often considered the hepatic manifestation of the MS. Presence of MS in an individual is the 
strongest risk factor for NAFLD and NASH. The association between NAFLD and features of MS may 
be bidirectional, particularly with respect to diabetes and hypertension, meaning that not only MS 
increases the risk of NAFLD, but also NAFLD may enhance several features and comorbidities of MS. 
Thus, effective treatment of NASH could have the additional benefit of improving the features of MS 
(Friedman et al., 2018) 
Figure B.9 The disease spectrum of nonalcoholic fatty liver disease. Schematic progression of NAFLD with 
histological sections illustrating the different stages. Collagen fibers are stained blue with Masson's trichrome 











2.2.1 NAFLD and aging 
NAFLD is more prevalent in older populations (Fig B.12). In fact, aging is the most common cause 
for the progression of NAFDL. It is a disease that progresses slowly with age. However, not in all 
patients in the same way.  Continued high rates of adult obesity and diabetes mellitus (DM) along 
with an aging population will increase NAFLD‐related liver disease and mortality in the western 
countries (Estes, Razavi, Loomba, Younossi, & Sanyal, 2018).  
Figure B.10 Histologic features and prevalence of NAFLD. (A) NASH is a progressive type of nonalcoholic 
fatty liver disease (NAFLD). Histologic features of NASH in liver-biopsy specimens: ballooned hepatocytes 
(arrows), inflammatory infiltrate (arrowheads) and (B) fibrosis. (C) Relative distribution of NAFLD, NASH, 






The earliest stage of NAFLD, hepatic steatosis, is characterized by an accumulation of TGs in the 
cytoplasm of hepatocytes. The spontaneous steatosis observed in aging has been observed in mice 
from 12 months of age and in aging rhesus monkeys, in which the prevalence was increased when 
monkeys suffered from MS (Zheng et al., 2018). Older patients show more severe biochemical, 
hematological and histological changes, and the female sex is no longer protective with increasing 
age. In fact, estrogens have a protective role, during female fertile period; women tend to be 
protected from NAFLD compared to men. However, although they tend to develop the disease 
approximately 10 years later than men do, post-menopausal women are no longer protected from 
NAFLD. Elderly people have a high risk for strongly age-dependent hepatic and extra-hepatic 
complications. NAFLD in the elderly is expected to carry a substantial burden of NASH, cirrhosis and 
HCC (Bertolotti et al., 2014b; Dyson et al., 2014). 
Figure B.12 Incidence of NAFLD by age group and sex.(Younossi, 2018) 
 
 
Figure B.11 Etiologies of chronic liver disease associated with HCC and prevalence of metabolic risk factors in 
patients with HCC. (A) Alcoholic liver disease (ALD), NAFLD and cases without chronic liver disease (CLD) account 
for the majority of cases. NAFLD-associated HCC increased from an unknown entity at the start of the decade to 
the commonest CLD associated with HCC. (B) Metabolic risk factors, defined as 1 major (obesity or type 2 diabetes), 
or two minor (hypertension, hypertriglyceridemia, reduced HDL cholesterol, previous cardiovascular event) were 





The mechanisms underlying NAFLD are not completely understood nor is why its prevalence 
increases with aging. It has been speculated that aging process may promote NAFLD via different 
mechanisms, many of which are related to metabolic alteration (Fig B.13). Some of  these 
mechanisms include altered metabolic fluxes and signaling pathways, which are explained below. 
Regarding metabolic fluxes fat absorption and uptake, most of the studies demonstrate that 
the contribution of changes in dietary fat absorption to the development of hepatic steatosis is 
probably minimal in healthy aging (Ferramosca & Zara, 2014). However, regarding fat uptake by the 
liver, the reduction in FABP1 with aging and in NAFLD can have several consequences, such as 
impairment in β-oxidation through changes in PPARα thereby exacerbating the potential lipotoxicity 
of FAs, contributing to the pathogenesis and progression of NAFLD (Gong, Tas, Yakar, & Muzumdar, 
2017).  
Regarding TG export, aging is associated with higher levels of apoB in both men and women 
(Schaefer et al., 1994) which could be explained by the presence of age associated hepatic insulin 
resistance (Gong et al., 2017). Indeed, insulin resistance is associated with increased secretion and 
decreased clearance of apoB. This increase in lipoproteins increases the risk of cardiovascular 
disease. Besides, the age-related insulin resistance causes alterations in the post-prandial 
distribution of carbohydrate away from muscle to the liver, producing an increased DNL and thereby, 
hepatic steatosis (Gong et al., 2017). Increased hepatic lipid content may partially be attributed to 
the enhanced hepatic lipid uptake in the absence of growth hormone (GH) signaling.  
DNL contributes to no more than 5-10% of the hepatic TG content under physiological 
conditions, whereas the contribution increases to more than 25% in NAFLD patients, showing that 
DNL may be a major determinant for NAFLD development in humans. Age- associated changes in 
DNL appear to be primarily modulated through changes in systemic mediators such as insulin 
resistance and changes in growth hormone/ insulin-like growth factor (GH/IGF) axis. 
The process of FA oxidation in the liver is influenced by many factors including aging and 
circulating adipokines such as adiponectin and leptin. In fact, expression of genes involved in the FA 
oxidation in liver are decreased with aging (Houtkooper et al., 2011). Mitochondrial dysfunction can 
also contribute to a defective FA oxidation. Mitochondrial dysfunction and oxidative damage 
inevitably occur in normal aging and can lead to further progression or initiation of disease 
(Kudryavtseva et al., 2016). 
There are some mediators of metabolism that can be altered in aging. For instance, aging is 
associated with decline in GH levels. This affects FA uptake in the liver and could be a contributor to 
increased hepatic lipid accumulation in aging (Gong et al., 2017). GH/IGF-1 have a key role in 
development and progression of NAFLD. Decrease of these two hormones is closely associated with 
the progression of NAFLD, while its replacement has shown to improve this disease (Takahashi, 




decade of adult life; and changes in GH/IGF-1 axis have been linked to longevity across species 
(Berryman, Christiansen, Johannsson, Thorner, & Kopchick, 2008). 
Leptin is a protein produced by the adipocytes that significantly affects hepatic lipid metabolism. 
Secreted leptin acts primarily at the level of the hypothalamus to decrease appetite. The amount of 
leptin secreted by the adipocytes is proportional to fat mass. Receptors for leptin have been 
identified in multiple other tissues including liver, indicating direct action on target tissues. Leptin 
has a role in modulating liver fat levels. In fact, increased FA oxidation, increase in ketogenesis and 
decrease in DNL are mechanisms through which leptin decreases hepatic lipid accumulation. Thus, 
leptin resistance has a role in the development of hepatic steatosis. The age-associated increase in 
hepatic fat accumulation is a leptin-resistant state. Serum leptin levels are increased, along with a 
lack of effects on body intake and energy expenditure to infused leptin. Age-associated leptin 
resistance, along with age-related changes in body composition and insulin resistance contribute to 
increased hepatic lipid accumulation with age. In addition to its role in hepatic lipid metabolism, 
leptin plays a role in hepatic inflammation and fibrosis (Gong et al., 2017). 
Insulin is the master regulator of glucose utilization by liver and extrahepatic tissues. Through 
suppression of lipolysis, insulin decreases the circulating FA levels, thereby reducing the availability 
of FA to the liver. In liver, insulin inhibits gluconeogenesis, and promotes glycogen synthesis and DNL. 
In addition, insulin, through the phosphoinositide-3-kinase (PI3K) pathway, controls DNL via 
Figure B.13 NAFLD incidence and age, inflammaging, growth factors and other elements involved in the disease 







activating nuclear transcription factor SREBP-1c, which induces ACC and FAS expression, two key 
enzymes in fatty acid synthesis. As mentioned above, insulin also controls TG export by decreasing 
post-prandial VLDL secretion via restricting apoB synthesis and increasing its degradation. Aging is 
often considered an insulin resistant state. Many factors contribute to insulin resistance in aging  
including changes in body adiposity, increase in visceral fat, alterations in biology of fat including 
increased adipose tissue inflammation, age associated increase in circulating cytokines, decrease in 
activity, sedentary life style and changes in the GH-IGF axis. Indeed, caloric restriction has been 
shown to decrease body weight, visceral fat, thereby improving insulin resistance as well as improve 
NAFLD.  
Apart from the mechanism explained above, there are other processes that are important for 
the pathogenesis of NAFLD progression related to aging such as adipose tissue dysfunction (Duval 
et al., 2010), impaired autophagy (González-Rodríguez et al., 2014) and oxidative stress (Kumar 
et al., 2013).  
Regarding the role of senescent cells in NAFLD progression, a significant fraction of 
hepatocytes develops a senescent phenotype during the life course (C. Wang et al., 2009). Several 
studies have shown that cellular senescence drives age-dependent hepatic steatosis and that 
elimination of senescent cells may be a novel therapeutic strategy to reduce steatosis (Ogrodnik 
et al., 2017). Interestingly, senescent cells have been found in the livers of NAFLD, cirrhotic 
patients and in the liver of high fat diet (HFD) fed mice (A. D. Aravinthan & Alexander, 2016; 
Ogrodnik et al., 2017).  
There is a relationship between NAFLD and the typical clinical features associated with aging, 
but this relationship is not well defined yet. For example, sarcopenia and NAFLD share a number of 
pathophysiological mechanisms, such as insulin resistance, decreased vitamin D concentrations and 
chronic low-grade inflammation. Several studies have shown an increased risk of NAFLD among 
patients with sarcopenia (Bertolotti et al., 2014; Tovo, Fernandes, Buss, & de Mattos, 2017). The 
association between fat accumulation in the liver and in the muscle has recently been established. 
The fat content in the paravertebral muscles may be correlated with aging and steatosis, and a 
reduction in muscle fat may be associated with a decrease of the liver fat content. Interestingly, 
insulin resistance and MS has been consistently associated with sarcopenia and NAFLD. However, 
the association between sarcopenia and NAFLD seems to be independent of IR, raising the possibility 
that the loss of muscle mass may contribute to the development of NAFLD. Other feature related to 
aging is dementia; NAFLD has recently been postulated to be an additional risk factor for dementia 
(Yilmaz & Ozdogan, 2009).  
In general, there is a marked increase in mortality due to liver disease in elderly subjects in 
comparison to younger populations. It has been reported a 3–5-fold increases in deaths due to liver 





3.1 Molecule and characteristics 
Osteopontin (OPN) is a multifunctional protein that is expressed in different cellular types and 
in a variety of tissues: brain, liver, gastrointestinal tract, lung, bone, cardiac tissues, joints, and 
kidney; and it also appears in a variety of biologic fluids: milk, urine, blood... This protein is involved 
in many physiological and pathological processes.  OPN is classified as a cytokine involved in bone 
mineralization, in kidney, cell survival, inflammation and tumoral processes. Several studies have 
identified that OPN expression is increased in tumorogenesis, angiogenesis and in response to 
inflammation, cellular stress and injury (Urtasun et al., 2012). OPN induces the expression of a wide 
variety of proinflammatory cytokines, such as IL-12, IL-6 and inhibits IL-10 and IL-27 (Castello et al., 
2017). In addition, it plays an important role in different pathologies as arthrosclerosis and hepatic 
inflammation (Kiefer et al., 2011a). In addition, OPN has a role in metabolic disorders such as diabetes 
and obesity. OPN was primarily described as a secreted protein, but it has also been found 
intracellularly, thus OPN is a soluble cytokine and a matrix-bound protein that can stay intracellular 
or be secreted; and therefore allowing autocrine or paracrine signaling.  
 
OPN is encoded by the gene SPP1 in human, (Spp1 in mice). In humans this gene is localized in 
the long arm of chromosome 4, its localization is 4q13. Its gene (SPP1) contains 7 exons. The protein 
is composed of approximately 300 aminoacids with a molecular mass ranging 40-80 kDa due to the 
Figure B.14 Structural features of osteopontin molecule. Domains of the osteopontin molecule 
are represented: aspartate domain, arginine-glycine-aspartate domain (RGD), Ser-Val-Val-Tyr-Gly-
Leu-Arg (SVVYGLR) domain, thrombin cleavage domain, calcium binding domain and heparin 








alternative splicing and the variety of post transcriptional modifications. To date three splice variants 
have been identified: OPNa, the full-length isoform, OPNb that lacks exon 5, and OPNc that lacks 
exon 4. OPN has an arginine‐glycine‐aspartic acid (RGD) cell binding sequence, a calcium binding site 
and two heparin binding domains. Extracellular OPN functions through its interaction with multiple 
cell surface receptors. Cells may bind OPN via multiple integrin receptors including the vitronectin 
receptor (αvβ3) as well as various β1 and β5 integrins. Integrin binding may be RGD‐dependent or ‐
independent. OPN does not bind the standard form of CD44 but does bind various isoforms of CD44: 
CD44v3, CD44v6 and CD44v7. These CD44 isoforms bind OPN via multiple sites. OPN may be cleaved 
by thrombin, resulting in the exposure of additional binding sites, like the integrin binding motif 
(SVVYGLR), as well as the production of functional chemotactic fragments (Mazzali et al., 2002). A 
variety of phosphorylation, glycosylation and sulphation can generate different functional forms of 
OPN that have tissue specific and function specific versatility (Fig B.14).  
OPN binding to various integrins and isoforms of CD44 lead to activation of several pathways. 
OPN-associated signaling pathways include PI3K/AKT (Rangaswami, Bulbule, & Kundu, 2006; Urtasun 
et al., 2012; Wei, Wong, & Kwok, 2017), mTOR (Ahmed & Kundu, 2010), as well as IKK-NF-κB (Castello 
et al., 2017; Wei et al., 2017), caspases and Bcl-2, p38/MAPK (Gimba, Brum, & Nestal De Moraes, 
2019).  
3.2 Ostepontin in metabolism and disease 
OPN is a key regulator of many metabolic and inflammatory diseases, like diabetes, 
cardiovascular disease and obesity. OPN was initially identified in osteoblasts as a mineralization-
modulatory matrix protein. It is well stablished that OPN has a role in bone metabolism, 
morphogenesis and remodeling (Morinobu et al., 2003; Standal, Borset, & Sundan, 2004; Uemura et 
al., 2001). Experimental evidence shows a complex cytokine and hormonal crosstalk between bone, 
liver and adipose tissue. Linked to this OPN may play a pivotal role in obesity-associated insulin 
resistance, NAFLD, and osteoporosis. (Musso, Paschetta, Gambino, Cassader, & Molinaro, 2013). 
Metabolically active tissue such as adipose tissue shows an increase in OPN expression under obesity 
(Kahles, Findeisen, & Bruemmer, 2014; Tardelli et al., 2016).  
Regarding lipid metabolism, previous studies have shown that OPN plays a role in cholesterol 
metabolism (Ding et al., 2018; Nunez-Garcia et al., 2017). In liver, OPN regulates the fate of acetyl-
CoA, towards cholesterogenesis, and liver PC concentration is regulated by circulating OPN. In fact, 
high levels of OPN increase liver PC concentration, while PC concentration is low in OPN-KO mice 
(Nunez-Garcia et al., 2017). In addition, during regeneration after partial hepatectomy (PH), 
circulating OPN increases the first 24 hours (h) after PH. OPN-KO mice subjected to PH undergo a 
lipidomic remodeling to cope with the high metabolic demands of regeneration, being thus, involved 




Although non‐manipulated OPN knockout (OPN-KO) mice exhibit a normal phenotype, they 
exhibit markedly abnormal responses to a variety of injurious stimuli (Mazzali et al., 2002), showing 
that OPN plays important biological roles in vivo. 
3.2.1 Metabolic syndrome 
OPN has shown to be involved in a variety of conditions associated with MS. Obesity constitutes 
the major risk factor for the development of insulin resistance, type 2 diabetes and the subsequent 
diabetes-related complications like cardiovascular disease. Chronic low-grade inflammation has 
been described as a fundamental component of adipose tissue expansion in obesity. Some studies 
showed that OPN expression in adipose tissue as well as circulating OPN levels are substantially 
elevated in obese patients compared with lean subjects, and were even more increased in obese 
diabetic or insulin resistant patients (Gómez-Ambrosi et al., 2007). Therefore, OPN could also be 
involved in the pathogenesis of type 2 diabetes. Other studies have also described OPN as a critical 
regulator of adipose tissue inflammation and in insulin resistance. OPN expression in macrophages 
is upregulated by a variety of proinflammatory mediators known to be elevated in type 2 diabetes 
and cardiovascular disease (Kahles et al., 2014). OPN expression has shown to be greatly upregulated 
in adipose tissue from diet-induced and genetically obese mice, and lack of OPN in OPN-KO mice or 
OPN neutralization led to decrease inflammation in adipose tissue and reduced insulin resistance, 
and also improved whole-body glucose tolerance (Kahles et al., 2014; Kiefer et al., 2011b). 
Atherosclerosis and vascular diseases are also related with MS and obesity. OPN is upregulated 
in several animal models of cardiac failure and plays a promoting effect in atherosclerosis (Matsui et 
al., 2003; Rosenberg et al., 2008). 
3.2.2 Non-alcoholic fatty liver disease (NAFLD) 
OPN has been associated with different liver diseases (Nagoshi, 2014; Ramaiah & Rittling, 
2007). Increased OPN expression has been found in hepatocytes and inflammatory cells in liver 
disease (Fig. B.15). Remarkably, OPN is markedly upregulated in the liver in obesity, and 
hepatic OPN levels correlate with liver TG levels (Bertola et al., 2009; Sahai, Malladi, Melin-Aldana, 
Green, & Whitington, 2004). 
Regarding the progression of the disease, several studies in mice models and in humans 
demonstrate the role of OPN in the pathogenesis and progression of NAFLD and in liver fibrosis 
(Coombes et al., 2015; Glass et al., 2018; Syn et al., 2011). Elevated mRNA levels of SPP1 
(osteopontin) are associated with increasing NASH and inflammation (Ryaboshapkina & Hammar, 
2017). 




animal models, hepatic OPN expression is significantly increased in models of bile duct ligation 
(BDL) and carbon tetrachloride (CCl4) (Español–Suñer et al., 2012; Lorena et al., 2006). However, 
the role of OPN in fibrosis is controversial. While some studies show that OPN might have a 
protective role, (I.e. the increase in OPN expression observed during fibrogenesis may play a 
protective role (Lorena et al., 2006)), others show that OPN drives the fibrogenic response and the 
ductular reaction (DR) contributing to scarring and liver fibrosis via TGF-β (X. Wang et al., 2014). 
In general, the fibrogenic role of OPN in liver diseases has been confirmed via significant research 
over the years. However, targeting OPN for resolution of fibrosis still remains controversial due 
to its opposing effects on different pathological conditions (Wen, Jeong, Xia, & Kong, 2016).  
Interestingly, an OPN supplement has been released as a nutritional complement approved by 
the FDA in newborns and infants. In a study that analyzed liver effects of this supplement, milk 
osteopontin supplement diminished ethanol-mediated liver injury in OPN-KO mice. According to the 
authors of this study, milk OPN could be a simple effective nutritional therapeutic strategy to prevent 
alcohol hepatotoxicity due, among others, to gut protective, anti-inflammatory, and anti-steatotic 





Several studies have demonstrated the correlation between elevated OPN secretion and 
various malignancies, such as breast and prostate cancer, squamous cell carcinoma, melanoma, 
osteosarcoma and gliobastoma (Rangaswami et al., 2006). The role of OPN signaling pathways in 
cancer progression and metastasis is becoming increasingly recognized (Bellahcène, Castronovo, 
Ogbureke, Fisher, & Fedarko, 2008)(Weber, 2001). 
Figure B.15 Osteopontin expression is upregulated in many chronic liver diseases. Liver sections from patients 
with non-alcoholic hepatitis (NASH), alcoholic liver disease (ALD) and primary biliary cirrhosis stained for OPN 







Among these malignancies OPN has also been linked to liver cancer. In fact, in hepatocellular 
carcinoma (HCC), OPN has been often regarded as a biomarker. It is markedly elevated in the plasma 
of HCC patients, and has been identified as a diagnostic biomarker, being a good early biomarker 
(Cabiati et al., 2017; Shang et al., 2012; Tsuchiya et al., 2015). In addition, OPN could promote HCC 
metastasis (Dong et al., 2016). Even more, OPN was upregulated in cholangiocarcinoma (CCA) tumor 
cells and the tumor stroma, and serum levels of OPN are elevated in patients with CCA (Loosen et 
al., 2017).  
In tumors, OPN is involved in many processes. OPN regulates tumorigenesis, tumor 
progression and metastasis formation (Zhao et al., 2018a) by activating cell migration, inhibiting 
apoptosis (Huang et al., 2017), stimulating angiogenesis (Wu et al., 2014), controlling energy 
metabolism (Z. Shi, Wang, Chihanga, Kennedy, & Weber, 2014) and modulating the tumor 
microenvironment (Malaponte et al., 2016) and the immune system (Caputo & Bellone, 2018). 
Notably, OPN also promotes cell survival by negatively regulating apoptosis in response to stress 
conditions (Štemberger et al., 2014; H. Zhang et al., 2014).  
Cancer metastasis is a complex process that generally involves the detachment of cancer cells 
from the primary tumor, intravasation, the circulation of cancer cells, adhesion to the blood 
vessel wall, extravasation and the growth of the secondary tumor. Although the role of OPN 
regulating all of these processes is not completely understood, a meta-analysis published recently 
reported that overexpression of OPN is closely associated with the metastasis of colorectal 
cancers, lung cancers and melanomas (Weber, Lett, & Haubein, 2011; Zhao et al., 2018b). The 
epithelial-mesenchymal transition (EMT) has a major role in metastasis. It results in reduced 
epithelial cell intercellular adhesion and causes these cells to acquire fibroblastoid properties, 
thereby improving the ability of cells to migrate. Therefore, the EMT is important for the 
development, invasion and metastasis potential of cancer. Osteopontin acts as a regulator of the 
EM by regulating the EMT-related transcription factors (Jia et al., 2016; Kothari et al., 2016). 
The role of OPN in chemoresistance is currently being investigated, with evidence 
suggesting that OPN is involved in mechanisms inducing chemoresistance (Gimba et al., 2019; Liu 
et al., 2016; Olive et al., 2018). The mechanisms by which OPN induces chemoresistance are 
increased autophagy (Liu et al., 2016) and anti-apoptotic effects of OPN on cancer cells (Yang et al., 
2012). 
3.3 Ostepontin and aging 
OPN plays a role in many diseases in which aging is the primary risk factor such as MS, diabetes, 




OPN as a SASP factor (Flanagan et al., 2017; Pazolli et al., 2009). In addition, there are several studies 
linking OPN and aging. However, the available data does not give conclusive results about the role of 
OPN in the aging process. Nevertheless, its effect seems to be tissue or cell-type dependent.  
In hematopoietic stem cells, OPN is important to maintain the cell function and attenuates aging-
associated phenotypes (Guidi et al., 2017; Li et al., 2018). In muscle, its neutralization improves 
muscle regeneration in old mice (Paliwal, Pishesha, Wijaya, & Conboy, 2012). In cardiac tissue, its 
deficiency protected against age-related cardiac fibrosis, but intriguingly a strong senescence 
induction was found in OPN-KO cardiac fibroblasts (Sawaki et al., 2018). Other studies remark that a 
decreased expression of OPN in old age worsens the response/ remodeling post myocardial 
infarction (Singh, Foster, Dalal, & Singh, 2010). In the liver, OPN deficiency contributes to enhance 
the severity of alcoholic liver disease in old mice (Magdaleno et al., 2018). In the retina, its deficiency 

















































































































































The aging of the population is expected to have a severe socio-economic impact especially in the 
developing countries, which account for over 60% of the older population (World Health 
Organization, 2015). Aging is a complex multifunctional process (López-Otín, Blasco, Partridge, 
Serrano, & Kroemer, 2013). Because the health dynamics of older age are related to increased needs 
for health care, there will be an increased health-care utilization (World Health Organization, 2015). 
Therefore, it is essential to have a better understanding of the mechanisms of the progression of 
organ dysfunction with aging, to be able to find markers, targets and treatments to help to reduce 
or avoid the severity of diseases associated with age and improve as much as possible the health 
span and quality of life of the elderly. Indeed, with aging increases the prevalence of multiple 
diseases, among them diseases in which metabolic dysregulation is key, like metabolic syndrome 
(MS) and non-alcoholic fatty liver disease (NAFLD). In the last decades, there has been a rise in the 
prevalence of NAFLD, paralleling a worldwide increase in diabetes and metabolic syndrome 
(Friedman, Neuschwander-Tetri, Rinella, & Sanyal, 2018). These diseases can boost the development 
of hepatocellular carcinoma (HCC) and cardiovascular diseases. As liver ages, it undergoes several 
changes that can reduce hepatic function and promote liver injury, and aging liver loses its ability to 
respond to stressors (Sheedfar, Biase, Koonen, & Vinciguerra, 2013). In addition, with aging, the 
characteristic ability of the liver to regenerate is reduced (Schmucker & Sanchez, 2011). The 
prevalence of liver disease increases with age. Linked to this, hepatocyte senescence correlates with 
severity of NAFLD (Ogrodnik et al., 2017). Indeed, the accumulation of senescent hepatocytes can 
affect the liver function making the liver more prone to disease progression (Aravinthan et al., 2013).  
Osteopontin (OPN) is a multifunctional glycoprotein that is expressed in many cell types, and it 
is involved in many physiologic and pathological processes. It is involved in the NAFLD pathogenesis 
(Kiefer et al., 2011), and its liver expression is increased in obesity and correlates with steatosis and 
insulin resistance, fibrosis and HCC (Gómez-Ambrosi et al., 2007; Syn et al., 2012; Zhao et al., 2018).  
Previous work in our laboratory have shown that OPN plays a key role modulating liver 
metabolism. OPN modulates the fate of acetyl CoA in liver and regulates the cross-talk between 
phosphatidylcholine (PC) and cholesterol metabolism (Nuñez-Garcia et al., 2017). OPN also 
modulates some nuclear factors related to biliary metabolism, which are altered in NAFLD 
progression. CYP7A1 is the enzyme that catalyzes the rate-limiting step and the major regulator of 
bile acid synthesis, which is the primary mechanism for the removal of cholesterol from the body. 
Thus, CYP7A1 could be involved in the observed metabolic modulation. Hence, we propose that OPN 
might regulate the cross-talk between cholesterol and PC metabolism via CYP7A1 in hepatocytes. 




 In regeneration, deficiency in OPN leads to a remodeling in lipid metabolism allowing the correct 
regeneration after partial hepatectomy (PH) (Nuñez-Garcia et al., 2018). The liver has the capacity 
for regeneration after cellular damage or surgery resection. During regeneration, liver cells need to 
acquire sufficient energy and metabolic precursors. PC, cholesterol and bile acids play an important 
role in liver regeneration. Since OPN can modulate these lipids, we suggest that OPN might have an 
important role orchestrating lipid metabolism in liver regeneration.  
Previous studies have described OPN as a senescent associated secretory phenotype (SASP) 
factor (Flanagan et al., 2017; Pazolli et al., 2009). In addition, there are several studies linking OPN 
and aging, but the available data does not give conclusive results about the role of OPN in the aging 
process. Thus, based on the evidence that OPN is linked with liver disorders and that plays a role in 
liver lipid metabolism; which is dysregulated in aging, we propose that OPN could have a role in the 
susceptibility of the liver to aging-associated NAFLD progression. 
In this background our specific aims were: 
Aim 1. To investigate whether OPN regulates PC and cholesterol metabolism via CYP7A1 in 
hepatocytes, and, if so, to analyze the pathways involved. 
Aim 2. To elucidate which metabolic pathways are involved in OPN-KO mice liver lipid 
remodeling during regeneration after PH. 
Aim 3. To investigate the role of OPN in the metabolic disorders of aging: 
Aim 3.1 To investigate whether OPN is involved in the aging of the liver, and in that case, to 
identify the mechanisms involved. 
Aim 3.2 To find out whether during aging OPN modifies the vulnerability of the liver to the 
development of NAFLD; and if so, to identify the mechanisms involved. 










































































































1.1 Media and buffers 
Media:  
-Krebs-Henseleit (KH) perfusion medium. NaCl 118 mM; NaHCO3 25 mM; KCl 4.7 mM; MgSO4 
1.2 mM; glucose 20 mM; 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (Hepes) 6.5 
mM. 
-Medium for hepatocyte adhesion. Dulbecco's Modified Eagle Medium (DMEM) 1% (w/v); 
NaHCO3 0.2% (w/v) ; glucose 10 mM; fatty acid (FA) free Bovine serum albumin (BSA) 0.2% 
(w/v) supplemented with insulin 84 nM, penicillin 10 U/ml, L-glutamine 2 mM; gentamycin 
50 µg/ml and fetal bovine serum (FBS) 2% (v/v); pH 7.2. 
- Hepatocyte incubation medium. DMEM 1% (w/v); NaHCO3 0.2% (w/v); glucose 10 mM; 
0.2% (w/v) FA free BSA supplemented with insulin 84 nM, penicillin 10 U/ml and L-glutamine 
2 mM;  gentamycin 50 µg/ml; pH 7.2. 
- HepG2 and Hep3B medium: Eagle's Minimum Essential Medium (EMEM) supplemented 




- Sample desnaturalization buffer (5x) for SDS-PAGE. Tris-HCl 300 mM , pH 6.8; glycerol 65% 
(v/v) ; SDS 10% (w/v); 72 mM DTT; bromophenol blue 0.5 (w/v). 
- Electrophoresis buffer. Tris 25 mM; glycine 192 mM, SDS 0.1% (w/v). 
- Homogenization buffer for Western Blot. Sucrose 250 mM ; tris(hidroximetil)aminometan 
hydrochloride (Tris-HCl) 10 mM, pH 7.4; NaF 1 mM; sodium orthovanadate 2 mM; EDTA 0.5 
mM; β- glycerol phosphate 20 mM; protease inhibitor cocktail “Complete EDTA-Free” 1:25 
(tablet/v) from Roche. 
- Homogenization buffer for cellular fractionation: Sucrose 250 mM; Na2EDTA 2 mM; Tris-HCl 





- Homogenization buffer for beta-oxidation: Tris-HCl 25 mM, sucrose 500 nM, EDTA-Na2 1 
mM; pH 7.4 
- Assay buffer for beta-oxidation: Sucrose 100 mM, Tris HCl  10mM, KH2PO4 5 mM, EDTA, 0.2 
mM pH8.0 , KCl 80 Mm, MgCl2 1mM, L-Carnitine 2mM, Malate 0.1 mM, coenzyme A 0.05 mM, 
ATP 2 mM, DTT 1mM, fatty acid (FA) free BSA:palmitate solution 0.7% BSA/500 μM palmitate 
- Loading buffer (6x) for nucleic acid electrophoresis. Sucrose 40% (w/v); bromophenol blue 
0.25% (w/v); xylene cyanol 0.25% (w/v). 
- Transfer buffer for western blotting: Tris-HCl 25 mM (pH 7.6), glycine 192 mM, methanol 
20%.  
 - Physiologic sodium chloride solution: NaCl 0.9% (w/v). 
- Phosphate buffered saline (PBS): Sodium phosphate buffer 10 mM, pH 7.4; NaCl 150 mM. 
- Tris-buffered saline supplemented with Tween 20 0.1% (TBS-T): Tris 20 mM; NaCl 150 mM; 
Tween20 0.1%. 
-TAE buffer: Acetic acid 0.4% (v/v); EDTA 10 mM; Tris 40 mM; pH 8.5. 
- Washing buffer for subcellular fractionation: Tris-HCl 150 mM, pH 8.0; Na2EDTA 2 mM. 
- Stripping buffer: Tris-HCl 62.7mM, pH 6.7, SDS 2%, mercaptoethanol 100mM. 
-Buffers for enzymatic activities: 
- Acid Triglyceride hydrolase (TGH) and cholesteryl ester hydrolase (CEH) assay buffer: 
Acetic acid/acetate 0.1 M, pH 4.6; supplemented with  2-hydroxypropyl-β-cyclodextrin 
(HPBCD) 2.25% (w/v) and BSA 0.05% (w/v) . 
- Extraction salts: Na3BO3/Na2CO3 50 mM.  
- Neutral TGH and CEH assay buffer: Tris-HCl 0.1 M, pH 8; 2- hydroxypropyl-β-
cyclodextrin (HPBCD) 2.25% (w/v). 
- Diglyceride acyltransferase (DGAT) assay buffer: Tris- HCl 20 mM, pH 7.4; NaCl 150 
mM, MgCl2 4 mM, NaF 20 mM, DTT 1 mM and CHAPS 0.1%. 
- Acyl-CoA cholesteryl acyltransferase (ACAT) assay buffer: KH2PO4 0.1 M pH 7.4 
cholesterol 6.25 µM in cyclodextrin 45% (w/v), BSA FA free 80 µM and GSH 2mM. 
‐ Phosphatidylethanolamine N‐methyltransferase (PEMT assay buffer): Tris‐HCl 3.75 
mM, pH 9.2; DTT 150 µM; 12 µl of previously prepared (3.7 mg/ml) 1,2‐dioleoyl‐sn‐
glycero‐3‐phosphoethanolamine‐N‐methyl (PMME) substrate/ 





‐ Stop solution for TGH and CEH activities: chloroform:methanol:n‐heptane:oleic acid 
125:140:100:0.01 (v/v/v/v). 
- Buffers for histochemical staining: 
  - Peroxide blocking: H2O2 3% in PBS 1X. 
  - Sirius red solution: Fast Green 0.01% FCF/Sirius red 0.1% in picric acid (Sigma)                                                                    
- SA-β Galactosidase staining solution:  citric acid 40 mM in Na2HPO4 · 7H2O 0.2 M 
pH 6.0; C6N6FeK3 and K4Fe(CN)6 5 mM, MgCl2 2 mM, NaCl 150 mM and X-Gal 
1mg/mL. 
  - Fixing solution: Neutral buffered formalin (NBF) 10%. 


























 1.2 Equipment 
 
         Blood strips                                                    Arkay Factory, Inc., Shiga, Japan 
 
Centrifuges P selecta, Sorvall RC6 Plus (SM-24 rotor) 
and RT 7 (rotor RTH-750) 
Chamber for electrotransference Bio-Rad Trans-Blot SD 
 
Class II Biological Safety Cabinets Thermo Scientific MSC-Advantage 
Concentrator-evaporator Thermo Scientific Savant SC250EXP 
Densitometer Bio-Rad GS-800 and Molecular Imager FX 
Electrophoresis Power Supply Bio-Rad Power 1000 
Equipment for anesthesia Cibertec, S . A  C A -EAC20, CA-CIS4 and CA-
MRS4m 
Exposure cassette FUJI EC-AWU (18 x 24 cm2) 
Hemocytometer Neubauer depth of 0.100 mm and area of 
0.0025 mm2 
Heater P Selecta Theroven (200 °C) 
Homogenizers Kinematica   Polytron   PT   1200   C   and 
B.Braun Biotech International Potter S 
Horizontal electrophoresis Bio-Rad Sub-Cell GT agarose Gel 
Electrophoresis System 
Incubators of CO2 Jouan EG 120 and Thermo Scientific 
HeraCell 150 
Microcentrifuges Heraeus  Biofuge  primoR,  Biofuge  Fresco 
and Labnet SpectrafugeTM 
Optic microscope Nikon Eclipse 50i and Jenoptik ProgRes® 
CapturePro camera 
pHmeter Crison GLP 21 
 








Spectophotometers Perkin Elmer 550 SE, Nanodrop ND-1000 
Spectophotometer, Spectronic 20 
Genesys and a plate reader Biotek 
Synergy™ HT 
Sterilization Equipment of the sterilization service from 
de Department of Cellular Biology and 
Histology form the UPV/EHU 
Thermocycler Biometra T-Gradient Thermoblock  
 
Thermostatic bath with shaker P-Selecta Unitronic 320 OR 
 
Tube shakers Velp Scientifica 2x3 
 
Ultracentrifuge Beckman Coulter Optima™ L-100 XP 
 
Ultracentrifuge rotors Beckman Coulter 20.4 Ti 
 
Vertical electrophoresis Bio-Rad Mini Protean III 
 






2. Models of study 
2.1 Human samples 
This study included 157 patients; 42 were non-obese and 115 were obese. Individuals were 
considered non-obese when presenting a BMI lower than 30 kg/m2 and obese when the BMI was 
higher than 30 kg/m2. Inclusion criteria for patients with non-alcoholic fatty liver disease  (NAFLD) 
was based on the absence of alcohol intake and the presence of biopsy-proven steatosis without 
necroinflammation and fibrosis along with negative serum tests for hepatitis B virus (HBV), hepatitis 
C virus (HCV) and human immunodeficiency virus (HIV). For obese patients subjected to bariatric 
surgery the liver biopsy was taken during this surgery. For the normal liver (NL) patients with 
asymptomatic cholelithiasis, the liver biopsy was taken during programmed laparoscopic 
cholecystectomy.  All had no evidence of HBV, HCV and HIV infections. In addition, none of 
these individuals consumed >20 g alcohol per day. Neither NAFLD patients nor subjects with NL 
used potentially hepatotoxic drugs. According to Kleiner criteria, (Kleiner et al., 2005) from the obese 
group, 110 individuals had a clinical diagnosis of NAFLD and 5 were obese control individuals with 
NL. From the non-obese group 13 individuals had a clinical diagnosis of NAFLD and 29 control 
individuals had NL. Steatosis w a s  assessed, as outlined by Kleiner et al. (Kleiner et al., 2005), grading 
the percentage of hepatocytes containing lipid droplets in each liver biopsy as follows: grade 0 when 
<5% of steatotic hepatocytes; grade 1 when 5-33% of steatotic hepatocytes; grade 2 when >33-66% 
of steatotic hepatocytes; and grade 3 when  >66% of steatotic hepatocytes. 
Human samples from non-obese patients were provided by Carmelo García-Monzón from the 
Liver Research Unit of the University Hospital Santa Cristina, Instituto de Investigación Sanitaria 
Princesa, Madrid, Spain. The NAFLD and NL obese individuals where patients subjected to a bariatric 
surgery. These samples were obtained in the Hospital Universitario Cruces, Barakaldo, Spain. 
 The study was performed in agreement with the Declaration of Helsinki and with local and 
national laws. The Human Ethics Committee of the University Hospital Santa Cristina and the 
Ethical committee of clinical research of the Basque Country a pproved the study procedures. 
Written informed consent was obtained from all patients before inclusion in the study.  
2.2.1 Clinical and laboratory assessment in human samples 
After a 12 h overnight fast, clinical and anthropometric data as well as venous blood 
samples were obtained from each patient at the time of liver biopsy. Plasma insulin was 
determined by a chemiluminescent microparticle immunoassay (ARCHITECT insulin; Abbot 





2.2 Animals and treatments 
For the study of the effect of osteopontin (OPN) in the modulation of liver lipid metabolism 
and regeneration, 10-12-week-old female OPN deficient (OPN-KO) mice (B6.Cg-Spp1tm1Blh/J) 
and their WT (C57BL/6) littermates were provided by Jackson´s Laboratories. They were 
maintained on a rodent chow diet (Teklad Global 18% Protein Rodent Diet 2018S; Harlan 
Laboratories INC., USA) and water ad libitum. For the study of the effect of OPN in the liver lipid 
metabolism and NAFLD development during aging, 3, 10 and 20 month-old WT and OPN-KO 
female mice were used. They were maintained on a rodent chow diet (Teklad Global 18% Protein 
Rodent Diet 2018S; Harlan Laboratories INC., USA) or a rodent high fat diet (Bioserv S3282, 60% 
Fat) and water ad libitum. For the aging studies, 10-12 week-old male and female WT mice were 
provided by Jackson’s Laboratories, and sacrificed at 3, 6, 10, 14 and 20 months old. Mice were 
maintained on a rodent chow diet (Teklad Global 18% Protein Rodent Diet 2018S; Harlan 
Laboratories INC., USA) and water ad libitum.  
Mice were housed in a temperature-controlled room with a 12 hour (h) - light/dark cycle. 
Animal procedures were approved by the Ethics Committee for Animal Welfare of the Basque 
Country, and were conducted in conformity with the EU Directives for animal experimentation. 
2.2.1 Partial hepatectomy 
Mice were subjected to 2/3 partial hepatectomy (2/3 PH), taking as a reference the methodogy 
used by Mitchell C., et al. (Mitchell & Willenbring, 2008) but with some modifications (Nuñez-
Garcia et al., 2018). The surgery was performed under general anesthesia with inhaled isoflurane 
and they were maintained with O2 inhalation until their recuperation. 
First, the mouse was anesthetized placing into a Plexiglas chamber for induction of anesthesia 
with isofluorane 4% and 0.5-1 l/minute oxygen flow for 2 minutes. After anesthetization, the 
animal was transferred to the place where the surgery was going to be performed and the 
anesthesia was maintained by 1.5% of isoflurane inhalation through a suitable mouthpiece. 
In the midline abdominal skin and muscle an incision was made to expose the xiphoid process. 
The hepatectomized lobes were the left lateral and the median. They were carefully pulled out 
from the abdominal cavity. A 4-0 silk thread was placed on the base of the left lateral lobe, a 
suture was made around the lobe and it was cut above the suture. The thread was again placed 
for the median lobe but in this case the lobe was tied separately performing two knots (Fig 
D.1). They were cut leaving an ischemic stump above the knots and without taking out the 
gallbladder. The peritoneum and the skin were closed. Finally, after the surgery animals were 






2.2.2 High Fat diet treatment 
Part of the animals were fed a rodent high fat diet (HFD) with 60% calories from fat 
(Bioserv S3282). In the case of the aging model, part of the 16 month-old OPN-KO mice (B6.Cg-
Spp1tm1Blh/J) and their WT (C57BL/6) were fed a HFD ad libitum for 16 weeks prior to the sacrifice 
at 20 months-old.  
2.2.3 Recombinant osteopontin (rOPN) treatment 
Recombinant OPN (rOPN) (15 µg/mouse; R&D systems, UK) or vehicle alone (physiologic 
saline solution) was injected to WT mice via the tail vein in two alternate days. 24 h after the last 
injection the mice were sacrificed. 
2.2.4 Atorvastatin treatment 
For atorvastatin treatment, intragastric atorvastatin (100 mg/kg) was provided for 2 weeks 
in alternate days. 24 h after the last dose the mice were subjected to 70% PH and were sacrificed at 
different times (24 h and 48 h).  
2.2.5 Tissue extraction 
The liver and white adipose tissue from each mouse were collected and washed in 
NaCl 0.9%. The liver was weighed and immediately cut into pieces to be formaldehyde-fixed 
or OCT embedded for subsequent histological analysis, or to be frozen in liquid nitrogen and 
kept it at − 80 °C. 
Figure D.1 Schematic drawings of mouse liver anatomy. (A) The thread for the first knot was 
positioned between the caudate and the left lateral lobes at the base of the latter. (B) The 







2.2.6 Serum collection 
The blood was taken from the inferior vena cava or the submandibular vein and it was left 
for 30 minutes at room temperature (RT) to coagulate. To obtain the serum, blood was centrifuged 
at 2,000 xg for 30 minutes at 4 °C and the supernatant was centrifuged again at 10,000 xg for 10 
minutes at 4 °C. After that, the serum was collected, aliquoted and frozen at – 20 °C for subsequent 
analysis. 
2.2.7 Primary hepatocyte isolation and incubation 
Hepatocytes from 3 and 10 month-old OPN-KO and WT mice were isolated. For this, 
perfusion with collagenase type I was used as described previously (Smedsrød & Pertoft, 1985). 
In brief, animals were anesthetized with sodium pentotal (150 mg/kg of body weight) 
intraperitoneal injection, the abdomen was opened and a catheter was inserted into the inferior 
vena cava while the portal vein was cut. Next, liver was washed by perfusion with Krebs-Henseleit 
(KH) perfusion medium equilibrated with fizzed carbogen at 37 °C. After the washing, EGTA 0.05% 
(w/v)  from Sigma-Aldrich (USA) was added to the KH medium and the perfusion was maintained 
for 5 minutes. Finally, an enzymatic digestion was performed perfusing during 10-12 minutes with 
KH perfusion medium supplemented with Ca
2+, 300 µg/ml collagenase from Sigma-Aldrich (USA) 
and 60 µg/ml tripsin inhibitor from Roche (Switzerland). 
After perfusion, the liver was gently disgregated. The viable cells were purified by density 
centrifugation and selective adherence as described before. Isolated pure hepatocytes were 
seeded over collagen and fibronectin-coated culture dishes (60 mm of diameter) at a density of 
1.5 x 10
6 cells per dish in the medium for cell adhesion. Cells were placed at 37 °C in a humidified 
atmosphere of 5% CO2 -95% air. 
After 2 h of attachment, the cell adhesion media was removed and replaced with the cell 
incubation medium supplemented with the treatments. Cultured pure hepatocytes from OPN-
KO were treated with rOPN (1 µg/ml; R&D systems) for 3 h. For metabolic flux studies, pure 
hepatocytes were also incubated with [3H]acetate for 4 h (section 3.5.1), or  [3H]oleate (section 
3.5.2). For inhibition of the FAK-AKT pathway, hepatocytes were pre-incubated for 1 h with FAK 
inhibitor Y15 (30 μM); for inhibition of the PI3K-AKT pathway, downstream FAK, hepatocytes were 
pre-incubated with LY294002 (50 μM) for 1 h and then, hepatocytes were incubated with or 
without rOPN (150 nM) in the presence or absence of the inhibitors for another 3 h. 
2.2.8 Glucose and insulin tolerance tests 
For glucose tolerance test mice were fasted for 4 h, and then were administered a glucose 




administration (time 0) and 15, 30, 60 and 120 minutes post-gavage using blood strips. For insulin 
sensitivity test, mice were injected intraperitoneally 1 U insulin/ kg body weight and glucose levels 
were measured as described above for glucose tolerance test.  
2.3 HepG2 and Hep3B cell lines 
Hepg2 and Hep3B cell lines were obtained from the American Type Culture Collection 
(ATCC). Cells were maintained in EMEM supplemented with fetal bovine serum 10% (v/v), 
Penicillin-Streptomycin 1%, Glutamine and Amphotericin B 1%. Cells were kept at 37 °C within a 
95% humidified atmosphere containing 5% carbon dioxide in an incubator. Depending on the 
experiment, cells were plated in 60 mm culture dishes, 6 well plates or in 24 well culture plates.  
2.3.1 siRNA transfection 
For knocking down experiments, a commercial siRNA was used against osteopontin (gene SPP1) 
or p53 (gene TP53)(Ambion CA, USA). Negative controls were included in each assay by using 
SilencerTM Select Negative Control siRNA (Ambion CA, USA). Lyophilized siRNAs were resuspended 
in nuclease-free sterile water (Ambion, USA) at 50 mM. These stock solutions were stored at -20 °C. 
Work solutions were prepared for immediate use at 1 mM. 
Reverse transfection was performed using RNAiMAX lipofectamine (Invitrogen Life 
Technologies, USA) in OptiMEM media. Briefly, Lipofectamine and siRNA were diluted separately in 
OptiMEM and then dilutions were mixed and incubated for 20 minutes RT. 48 h after transfection, 
transfection media was removed and fresh treatment media was added. Gene silencing efficiency 
was confirmed by RNA expression analysis. 
2.3.2 Palbociclib and palmitic acid treatment  
Senescence inductor palbociclib 2 μM was dissolved in 0.01% DMSO and filtered. 24h after 
transfection cells were exposed to palbociclib or vehicle, which was added to the regular complete 
media. Cells were maintained 4 days with palbocilcib treatment and collected for their study.   
For the palmitic acid treatment, in order to facilitate the in-vitro incorporation, palmitic acid 200 
μM was complexed with fatty acid free BSA 100 μM over-night at 4 °C. Vehicle plates were 
supplemented with fatty acid free BSA 100 μM. Palmitic treatment was added 24 h before collecting 
cells. For cell collection, for western blotting or lipid quantification, plates were washed 3 times with 





2.3.3 Hydrogen peroxide treatment 
Hydrogen peroxide was used for senescence induction. Cells were exposed to hydrogen 
peroxide (H2O2) 700 μM for 1h, then treatment media was removed and fresh media was added. 
Cells were kept in culture for 5 days and collected. For cell collection, for western blotting, plates 
were washed 3 times with cold PBS 1X, and cells were scraped in 1mL PBS 1X and centrifuged at 180 
xg.   
3. Experimental procedures 
3.1 Protein quantification 
For the different analysis, protein quantification was made using a commercial kit based in the 
bicinchoninic acid method, the Pierce BCA Protein Assay Kit. The assays were performed in 96 well 
plates by triplicate. 5 µl of SDS 20% were added to avoid turbidity and 150 µl of the reactives A and 
B in proportion 50:1 were added per well. The plate was incubated for 30 minutes at 37 °C in the 
dark and then absorbance was measured at 562 nm in a microplate reader. The protein 
concentration was calculated by interpolation of the absorbance value in the calibration curve made 
with BSA that was lineal in a range from 0 to 25 µg of protein. 
3.2 Quantification of lipid parameters 
Liver pieces were homogenized using a potter glass homogenizer in 5 or 10 volumes of 
the suitable homogenization buffer for each subsequent assay, by 20 strokes of a Teflon 
pestle at 700 rev./ min at 4 °C. 
3.2.1 Quantification of lipids 
To prepare lipid extracts from liver, the tissue was homogenized as previously described using 
cold PBS 1X and 1-2 mg of protein from liver homogenate. Cells were scraped and resuspended in 
dH2O. Lipids were extracted by the Folch method (Folch, Lees & Sloane Stanley, 1957). For this, 1.5 
ml of dH2O and 8 ml of chloroform:methanol:HCl (2:1:0.0075, v/v)  solution (Scharlau Chemicals, 
Spain) were added to the liver homogenate or cell extract, and tubes were vigorously shaken with a 
vortex for 2 minutes. Tubes were centrifuged at 1,000 xg for 15 minutes at 4 °C to separate the 
aqueous phase from the organic one. The lower organic phase was transferred to another extraction 
tube using a glass pasteur pipette. Lipids from the upper phase were reextracted. For the 
reextraction, 4 ml of chloroform:methanol:HCl (2:1:0.0075, v/v) were added and the tubes were 
vigorously shaken for 2 minutes and were centrifuged at 1,000 xg for 10 minutes at 4 °C. The organic 




chloroform extract was washed with the third part of the total volume of KCl 0.88% solution. Each 
tube was shaken with a vortex for 1 minute and centrifuged for 10 minutes at 1,000 xg and the lower 
phase was transferred to another extraction tube. Finally, the chloroform in extract was evaporated 
in a concentrator- evaporator. Lipids were dissolved in an appropriate volume of toluene and were 
kept in glass vials at -20 °C in N2 atmosphere until they were processed. 
The lipid separation was performed by thin layer chromatography (TLC). It was done by six 
chromatographic developments (Ruiz & Ochoa, 1997). First, the silica-gel plates of 20 x 20 cm (“Pre-
coated TLC-plates SIL-G25”, Macherey-Nagel) were pre-treated with 1 mM EDTA-Na2 (not less than 
4 h). S i l ica-ge l  plates were left drying overnight and washed with chroloform:methanol:dH2O 
(60:40:10, v/v/v) overnight to remove contaminants. The following day, the plates were activated at 
100 °C for 30 minutes; after that, 3 µl of pure lipid mixtures (Avanti Polar Lipids, USA and Sigma-
Aldrich) of known lipid concentrations and 3 or 8 µl of the lipid extracts were applied (per duplicate) 
at 1.5 cm from the lower edge of the plate. Lipid quantities (nmol) for calibration were the following 
ones: Cholesteryl ester (CE) (0.09-1.45), triglycerides (TG) (0.27-17), diglycerides (DG) (0.15-3), free 
cholesterol (FC) (0.36-3.6), cardiolipin (CLn) (0.02-0.3), phosphatidylethanolamine (PE) (0.33-3.91), 
phosphatidylinositol (PI) (0.1-1.72), phosphatidylserine (PS) (0.13-2.22) and phosphatidylcholine (PC) 
(0.63-7.63). 
Six different chromatographic developments were consecutively carried out in solutions of 
decreasing polarity as presented in the Table D.1. After each chromatographic development, 
the plates were dried using hot air. When the chromatographic separations were performed, 
the plate was stained immersing in a CuSO4 solution at 10% (p/v) in H3PO4 at 8% (v/v) for 10 
seconds. After, the plates were dried with hot air until the first dots started to be visible. Then, the 
plates were developed for 3 minutes at 200 °C.  
Table D.1 Mixtures of solvents used in the six chromatographic developments for neutral lipids 
and phospholipids separation by TLC.  
 
The image of the TLC plate was digitalized with the densitometer GS-800 and quantification 
was performed with the Quantity One software. The integrated optic density (IOD) of each lipid 
spot, after subtraction of the background, was interpolated in the IOD values of the calibration 
curves. The results obtained were expressed in µmol per gram of liver or nmol per mg of cellular 
protein. 
Mobile phase composition Proportion (v:v) Distance of the front (cm)
Chloroform:methanol:water 60:40:10 1.8
Chloroform:methanol:water 65:40:05 2.3
Ethyl acetate:ethanol: isopropanol:methanol:chloroform: KCl at 0.25 %(v/v) in H2O 35:20:5:15:22:9 5
Toluene:dietyl eter:ethanol 60:40:03 8





3.2.2 Lipidomic analysis 
Lipid profiles were analyzed in OWL (Bizkaia Science and Technologic Park; Zamudio, 
Spain) as previously described (Barr J., et al, J. Proteome Res., 2012).  Briefly, four UPLC®/time-of-
flight mass spectrometry (TOF-MS) based platforms (Waters) analyzing methanol/dH2O and 
chloroform/methanol liver extracts were combined. Lipids identified in the methanol platform 
included: non-esterified fatty acids (FA), acylcarnitines, BAs, monoacylglycerophospholipids, 
monoetherglycerophospholipids,    and    oxidized    FAs.  For this, methanol was added to the 
frozen liver tissue (30:1, v/w) and the resulting mixture was homogenized with a Precellys 24 
grinder (Precellys, France), followed by protein precipitation. The methanol used for extraction 
was spiked with internal standards not detected in liver tissue using the same method. After brief 
vortex mixing, the samples were incubated overnight at -20 ˚C. Supernatants were collected and 
dried after centrifugation at 16,000 xg for 15 minutes. The dried extracts were resuspended in 
methanol, centrifuged at 16,000 xg for 5 minutes, and finally supernatants were collected and 
transferred to vials for UPLC®-MS analysis. 
Lipid species identified in the chloroform/methanol platform included glycerolipids, CEs, 
sphingolipids, DGs, and acyl-ether-glycerophospholipids profiling. For this, liver tissues were 
homogenized in the Precellys 24 grinder by mixing with chloroform/methanol (2:1, v/v) and 
sodium chloride (50 mM) (overall ratio 1:30:3, w/v/v), followed by protein precipitation. The 
extraction solvent was spiked with internal standards not detected using the same method. After 
brief vortex mixing, the samples were incubated at -20 ˚C for 1 h. After centrifugation at 16,000 xg 
for 15 minutes, the lower organic phase was collected and the solvent removed. The dried extracts 
were then resuspended in acetronitrile/isopropanol (1:1), centrifuged at 16,000 xg for 5 minutes, 
and finally supernatants were transferred to vials for UPLC®-MS analysis. 
3.2.3 Bile acid analysis 
Bile acids (BA) from liver samples were extracted using Silica-based bonded phase cartridges 
(Sep-Pack Plus C18, Waters-Millipore, Madrid, Spain) and analyzed in an HPLC-MS/MS (6410 Triple 
Quad LC/MS, Agilent Technologies, Santa Clara, CA) as previously reported (Nytofte et al., 2011) 
following a modification of the method described (Ye, Liu, Wang, Shao, & Ding, 2007). 
Chromatographic separation was carried out with gradient elution using a Zorbax Eclipse XDB-C18 
column (150 mm x 4.6 mm, 5 μm) at 35 °C and a flow rate of 0.5 ml/min. Mobile phase (pH 4.6) was 
initially 80:20 methanol/water, and it was changed to 97:3 methanol/water over 9 minutes and then 
returned to 80:20 in 1 minute. Both solvents contained 5 mM ammonium acetate and 0.01% formic 
acid. Electrospray ionization (ESI) in negative mode was used, with the following conditions: gas 
temperature 350 °C, gas flow 8 l/minute, nebulizer 10 psi, capillary voltage 2500 V. MS/MS 




transitions: [M-H]- ion to 80.2 for taurine-conjugated bile acids and [M-H]- ion to 74 for glycine-
conjugated bile acids. Unfortunately free BAs did not generate characteristic ion fragments, as 
reported before (Ye et al., 2007) and transition from unfragmented precursor molecular ions 407.1 
to 407.1, 391.3 to 391.3 and 375.3 to 375.3 were selected for trihydroxylated, dihydroxylated and 
monohydroxylated free BAs, respectively. 
 
3.2.4 Malondialdehyde quantification 
Malondialdehyde (MDA) content is generally used as marker for lipid peroxidation. MDA content 
in liver samples was quantified using a commercially available kit from Sigma-Aldrich (St. 
QuentilFallavier, France) following manufacturer’s instructions.  
3.3 Subcellular fractionation of liver tissue 
Lysosomal, microsomal and cytosolic fractions from mouse liver were isolated using a 
serial centrifugation method. 
Pieces of 150-200 mg of liver were homogenized using the homogenization buffer for cellular 
fractionation. For this, liver pieces were homogenized in a potter homogenizer, 20 strokes and 
were centrifuged at 1,000 xg for 20 minutes at 4 °C to remove tissue debris and nuclei. The 
pellet was discarded and the supernatant was collected to be centrifuged at 20,000 xg for 10 
minutes at 4 °C. After the centrifugation, the supernatant was collected and the pellet, with 
most of the mitochondria, was discarded. The supernatant was centrifuged at 22,000 xg for 20 
minutes at 4 °C. After the centrifugation, the pellet and supernatant were separated and 
processed.  
The pellet was used for lysosomal fraction isolation. Thus, the pellet was gently 
resuspended using a glass rod and 1 ml of homogenization buffer. When the pellet was 
properly mixed with the buffer, the last centrifugation was performed at 22,000 xg for 20 minutes. 
Finally, the pellet containing lysosomes was resuspended after addition of 150 µl of 
homogenization buffer. 
The supernatant of the first 22,000 xg centrifugation was used for microsomal fraction and 
cytosol isolation. To perform this isolation 2 ml of homogenization buffer was added to the 
supernatant and was centrifuged at 105,000 xg for 1 h at 4 °C. The supernant was collected 
(cytosolic fraction), including the fat, and it was transferred to another centrifugation tube. The 
pellet (microsomal fraction) was gently homogenized using a glass rod and it was resuspended 
in 2.5 ml of washing buffer. The microsomal and cytosolic fractions were centrifuged again 




supernatant  was  discarded,  the  pellets  were  gently homogenized with the glass rod and 
were resuspended in 200 µl of homogenization buffer. From the cytosol tubes the supernatant 
was collected including the floating fat without removing the pellet. 
3.4  Quantification of enzyme activities 
Cholesteryl ester hydrolase (CEH), triglyceride hydrolase (TGH) diglyceride acyltransferase 
(DGAT), acyl-CoA cholesteryl acyltransferase (ACAT) and phosphatidylethanolamine N-
methyltransferase (PEMT) enzymatic activities were measured. These enzymatic activities were 
quantified using radiometric assays as described by Liza et al. for ACAT (Liza, Romero, Chico, 
Fresnedo, & Ochoa, 1996) ; by Cristobal et al for CEH (Cristobal, Ochoa, & Fresnedo, 1999), Dolinsky 
et al. for TGH (Dolinsky, Douglas, Lehner, & Vance, 2004), by Dolisnky et al. for DGAT (Dolinsky et al., 
2004) and by Ridgway & Vance for PEMT(Ridgway & Vance, 1992). 
3.4.1 Neutral triglyceride and cholesteryl ester hydrolases 
Neutral TGH activity was measured quantifying the released radioactive oleic acid (OA) as a 
result of the split of glycerol tri-[14C]oleate (GE Healthcare, USA) by the sample. This activity was 
measured using 150 µg of protein from microsomal and cytosolic fractions. The substrate was 
prepared as mixed micelles of TG:PC:sodium taurocholate in a molar proportion 10:17:8 and 
glycerol tri-[14C]oleate (56 mCi/mmol; 100 µCi/mL). 
Neutral CEH activity was determined quantifying the released radioactive OA as a result of 
the split of cholesteryl [14C]oleate by the sample. This activity was measured using 60 and 100 
µg of protein from microsomal and cytosolic fractions, respectively. The substrate was prepared 
as mixed micelles of cholesteryl oleate:PC:sodium taurocholate in a molar proportion 10:47:25 
and cholesteryl- [14C]oleate (12 mCi/mmol; 1.25 µCi/mL). In both of the enzymatic assays the 
micelles were prepared following the same protocol. First, the required lipids were added into a 
polypropylene tube (dissolved in toluene or chloroform) containing the radiolabeled triolein (TG) 
for TGH activity or radiolabeled CE for CEH activity, and the organic solvent was evaporated with 
N2. After the evaporation, the assay buffer was added and it was sonicated using a titanium probe 
of 10 mm of diameter in a sonicator at 6 microns of potency in a bath at 50 ˚C. The conditions of 
the sonication were 60 cycles of 30 seconds of sonication and 10 seconds of pause. Finally, the 
micelle preparation was centrifuged at 22,000 xg for 30 minutes to eliminate the metallic 
remnants of the titanium probe. 
The assays were carried out in a final volume of 200 µl of assay buffer with a final 
concentration of TG of 750 µM for TGH and a final concentration of CE of 150 µM for CEH activity. 




started adding each substrate. Thirty minutes later, the reaction was stopped with the addition of 
2.5 ml of stop solution and 500 µl of extraction salts added to make the extraction easier. The 
tubes were vigorously shaken for 90 seconds and were centrifuged at 1,000 xg for 10 minutes at 
4 ˚C for phase separation. Afterwards, 750 µl of the upper aqueous phase, where the free 
radiolabeled oleate is, was transferred to vials containing 4 ml of scintillation liquid “Cocktail 
Biogreen 3” (Scharlau Chemicals, Spain). The radioactivity was determined in the scintillation 
counter. As the blank of the reaction, a mixture of the substrate and the assay buffer without 
enzymatic source (sample) was used. The results were determined as pmol of released FA per mg of 
protein and minute. 
3.4.2 Acid triglyceride and cholesteryl ester hydrolase 
The acid TGH and CEH activities were determined using 30 µg of protein from the lysosomal 
fraction. The substrate was presented as mixed micelles of TG:PC in a molar proportion 10:25 
with a trace of glycerol tri-[14C]oleate (56 mCi/mmol; 100 µCi/mL) for acid TGH and as mixed micelles 
of CHOL:PC in a molar proportion of 1:10 having cholesteryl [14C]oleate (0.25 µCi/incubate) for acid 
CEH (section 3.5.1). Both of the micelle mixtures were dissolved in the assay buffer for acid 
enzymatic activities. The assay was carried out in a final volume of 200 µl of assay buffer and a final 
concentration of TG of 750 µM for acid TGH activity and of CE of 200 µM for acid CEH activity. 
After preincubate the samples shaking for 10 minutes at 37 °C, the reaction was started adding 
the substrate. After 5 minutes, the reaction was stopped with 2.5 ml of stop solution. Finally, 500 
µl of extraction salts were added to help the extraction. All the next steps were followed as 
described for neutral activities determination. 
3.4.3 Acyl-CoA cholesteryl acyltransferase (ACAT)  
ACAT activity was used as a measure of the rate of intracellular CE formation. The ACAT activity 
was determined in the microsomal fraction. The substrate for the activity was prepared by adding 
in a tube 1 µl [14C] oleil-CoA (60 mCi/mmol; 50 µCi/mL) and 120 µM of oleil-CoA to each incubate. 
Tubes were preincubated 10 minutes at 37 °C; and then 50 µl of substrate was added per tube 
and incubated for 6 minutes. The reaction was stopped by adding 5 ml of chloroform: methanol 
(2:1). Then 50 µl of standard [3H] cholesterol oleate (48 Ci/mmol; 1000 µCi/mL) were added. Lipids 
were extracted using the Folch method and the radioactivity incorporated into cellular lipids 





A three chromatographic development separation was performed.  This chromatographic 
method was able to separate the main classes of lipids: CE, TG, FC, DG, FA and PL. These 
developments were performed with 3 different solvents mixture (Table D.2). The plates were 
treated and prepared as explained before (section 3.2.1). The extracted lipids were separated 
using the three chromatographic developments. When the chromatographic plates were dry, 
they were stained with iodine vapors introducing the plates into a chromatographic tank with 
iodine crystals. After the scraping o f  the band corresponding to cholesterol oleate, the silica 
gel was introduced in a vial containing 4 ml of scintillation liquid “Cocktail Biogreen 3” and 
the radioactivity was determined in a scintillation counter. The ACAT activity was determined as 
nmol of oleil-CoA released per mg of protein and per minute.  
3.4.4 Diglyceride acyltransferase (DGAT)  
The DGAT activity was calculated by quantifying the resultant triglyceride from the esterification 
of the diglyceride with the radioactive fatty acid. The substrate was prepared adding 6.2 µl of 
diglyceride 10 mg/ml, 69.2 µl of 14C-Oleil-CoA (58.2 mCi/mmol; 20 µCi/ml) and 10 µl of Oleil-CoA 20 
mg/mL. This solution was evaporated in nitrogen, and then resuspended with 2 ml of assay buffer 
and sonicated for 10 minutes at 37 °C.  
For the assay 200 µg of microsomal sample were used. Tubes were preincubated for 5 minutes 
at 37 °C, and then 100 µl of substrate were added. Samples were incubated for 10 minutes. Then, 
reaction was stopped by adding 5 ml of chloroform/ methanol (2:1) and 1.25 ml of the extraction 
salts (KCl 0.88%) was added. 50 µl of a standard of 3H-CE were added to each tube to normalize the 
extraction. Lipids were extracted and separated as explained before (section 3.4.3). The bands of TG 
and CE were scraped off to vials with scintillation liquid. The radioactivity of the vials was quantified 
with a scintillation counter. The DGAT activity was calculated as pmol of recovered triglyceride/ mg 
of protein/ minute.  
3.4.5 Phosphatidylethanolamine N-methyltransferase (PEMT)  
PEMT activity was measured quantifying the incorporation of radioactive methyl groups from S‐
adenosyl‐L‐(methyl‐3H) methionine ([3H]SAMe)(10 µCi/mmol; 550 µCi/mL) (Perkin Elmer, USA) into 
PE to give PC. This activity was measured using 50 µg of protein from liver homogenate. 
Table D.2 Mixture of solvents used for three chromatographic separation of lipids classes in TLC 
plates. 
 Mobile phase composition Proportion (v:v) Distance of the front (cm)
Chloroform:methanol:water 60:40:10 1.8





First, 1,2-dioleoyl-sn‐glycero-3‐phosphoethanolamine‐N‐methyl (PMME) substrate (Avanti Polar 
Lipids, USA) was prepared from a PMME stock, which was dissolved in chroloform:metanol 1:2 (v/v). 
The PMME stock needed to have a final concentration of 3.7 mg/ml of PMME substrate was 
evaporated with nitrogen. EDTA buffer together with Triton X-100 0.0004% was added, mixed 
properly with the vortex and finally sonicated with 3 cycles of 30 seconds at no more than 6 microns 
using a sonicator. 
The assay was carried out in a final volume of 150 µl of assay buffer with a final concentration of 
SAMe 1 mM (Sigma-Aldrich, USA).  The substrate contained 0.66 µCi/incubate of [3H]SAMe. Samples 
were preincubated for 15 minutes at 37 ˚C and [3H]SAMe/SAMe. After 30 minutes at 37 ˚C, the 
reaction was stopped with 2 mL of stop solution. 2 mL of NaCl 0.5% were added and the samples 
were vigorously shaken for 90 seconds and finally centrifuged at 1,000 xg for 10 minutes at 4 ˚C to 
separate the aqueous phase from the organic one. The aqueous phase was removed and the organic 
one was washed 3 times with 0.5% (w/v) NaCl:metanol:chloroform 50:50:4 (v:v:v) and after the last 
wash all the upper phase was removed. Finally, 200 µl of the lower organic phase was transferred to 
vials with 4 mL of scintillation liquid “Cocktail Biogreen 3”. The radioactivity was determined in the 
scintillation counter. As the blank of the reaction, a mixture of the substrate with the assay buffer 
without sample was used. The activity was expressed as total pmol of released CHs per mg of protein 
and minute. 
3.5 Metabolic fluxes 
To quantify metabolic fluxes, radioisotope incorporation experiments were performed by 
primary incubation of isolated hepatocytes from mice liver as described previously.  
3.5.1 [3H]Acetate incorporation 
For de novo lipogenesis analysis, primary hepatocytes (1.5 x 10
6 cells/plate) were incubated 
with sodium [3H]acetate (20 µCi/ml; 20 µM). At different times, 120 and 240 minutes, cells and 
mediums were collected and cells were washed 5 times with PBS. To quantify the radioactivity 
incorporated from [3H]acetate into lipids, lipids (TG, DG, CE, FC, phospholipids (PL) and FA) were 
extracted and separated as explained before (section 3.4.3). After the scraping of the 
corresponding bands, the silica gel was introduced in a vial containing 4 ml of scintillation 





3.5.2 [3H]Oleate incorporation 
For fatty acid esterification analysis, primary hepatocytes (1.5 x 106  cells/plate) were incubated with 
[3H]oleate (54 Ci/mmol; 2 µCi/ml; 20 µM). At different times, 120 and 240 minutes, cells and 
mediums were separated and cells were washed 5 times with PBS. Lipids were extracted using the 
Folch method and the radioactivity incorporated into cellular lipids were determined after TLC 
separation. A 6 chromatographic development separation was performed to quantify the 
radioactivity incorporated from [3H]oleate into lipids. CE, TG, FC, DG, FA, PC and PE were separated 
as previously described. Radioactivity incorporated to each lipid was quantified as explained above 
in 3.4.3 section.  
3.5.3 Palmitate beta oxidation rate 
Beta-oxidation was assessed as described before (Gao et al., 2015; Hirschey & Verdin, 2010). 
Fresh liver pieces were homogenated in a Potter homogenizer (5 strokes) in cold homogenization 
buffer and sonicated for 10 seconds. Then, the homogenates were centrifuged at 500 xg for 10 
minutes at 4 °C. Approximately 500 µg of protein from the homogenates supernatant was used for 
the assay in a volume of 200 µl. The reaction started by adding 400 µl assay buffer containing 14C-
palmitate (56 mCi; 0.4 μCi/mL; 500 μM) to the samples and was incubated for 1 h at 37 °C in 
eppendorf tubes with a whatman paper circle in the cap. The reaction was stopped by carefully 
adding 300 µl of perchloric acid 3 M and NaOH 1 M was added to impregnate the whatman cap. 
After 2 h the Whatman caps were removed and the radioactivity associated was measured 
in a scillation counter. The eppendorf tubes were centrifuged at 21,000 xg 10 minutes at 4 °C. 400 µl 
from the supernatant were collected and the radioactivity was counted in a scintillation counter. The 
supernatant contained the acid soluble metabolites (ASM)(incomplete palmitic oxidation) and the 
whatman caps captured the released CO2 (complete palmitic oxidation). 
3.6 Western blotting 
Electrophoresis SDS-PAGE. Liver samples were homogenated in lysis buffer and protein was 
quantified. Samples mixed with denaturing buffer were denaturalized for 5 minutes at 95 °C. 
Electrophoresis was made in polyacrylamide gels of different percentage depending on the protein 
of interest, using a vertical Mini Protean II electrophoresis equipment (Bio-rad, USA). 20 ug of sample 
were loaded in each well, and a commercial mixture of protein marker was added (PageRuler 
Prestained Protein Ladder Plus, Thermo). Electrophoresis at 150 V for an h in electrophoresis buffer. 
 Transfer: After running the electrophoresis, wet transfer was performed. Either 




Wet transfer: PVDF membranes were activated by keeping them 1 minute in methanol, then 
2 minutes in distilled water and 5 minutes in transfer buffer with methanol 20%. Nitrocellulose 
membranes were directly moisten in transfer buffer. Then, the gel and membrane were sandwiched 
between a sponge and the whatman paper (sponge/3 Whatman paper/gel/membrane/3 whatman 
paper/sponge) and all were clamped tightly. The sandwich was submerged in transfer buffer, keeping 
it cold with an ice plate. Then, a voltage of 100 V was applied for 2 h. 
To check the efficacy of the transference the gels were washed in distilled water and stained 
with Gel Code from Pierce at RT for 1h and the nitrocellulose membranes were stained with Ponceau 
S staining. 
 Blocking: Membranes were incubated in TBST with a blocking agent depending on the 
protein of interest, BSA or milk, for 1 h under agitation at RT.  
 Incubation and inmunodetection: After blocking, the membranes were incubated with the 
primary antibody (table D.3) over night (o.n) at 4 °C with gentle agitation. The primary antibodies 
used and their concentrations are represented in table 4. After this incubation, membranes were 
washed with TBST 3 times for 10 minutes at RT with agitation. Then, membranes were incubated 
with the appropriate secondary antibody. All the incubations were done at RT for 1 h. Another 3 
washes with TBST were made as previously described. Chemiluminiscent detection was performed 
by an ECL Western blotting detection kit from Amersham Biosciences, and membranes were exposed 
to an X-ray film (Fujifilm). 








3.7 Liver histochemistry 
The histological analysis were carried out in the laboratory of Dr. Mª Luz Martínez Chantar, 
CIC Biogune (Derio). Paraffin-embedded sections (5 μm thick) of formalin-fixed liver samples or OCT 
embedded samples were used. Paraffin-embedded sections were initially deparaffinized in xylene or 
xylene-substitute and rehydrated through graded alcohol solutions. Once hydrated, sections were 
subjected to the following stainings: 
Hematoxylin and eosin:  After the deparaffinization and rehydration process, sections were subjected 
to conventional hematoxylin and eosin staining. Briefly, sections were submerged for 5 minutes in 
Harris hematoxylin, and then sections were washed in water for 5 minutes and then stained in eosin 
Table D.3 Primary antibodies used for Western Blotting 
 
Target Ab Manufacturer Blocking solution Antibody dilution
ACC CST Milk 5% TBST  1:1000
p-ACC CST Milk 5% TBST  1:1000
AKT CST Milk 5% TBST  1:1000
p-AKT CST Milk 5% TBST  1:1000
AMPKα CST Milk 5% TBST  1:1000
p-AMPKα CST Milk 5% TBST  1:1000
Caspase 12 CST Milk 5% TBST 0,736111111
CYP7A1 Santa Cruz Milk 5% TBST  1:1000
EIF2α CST Milk 5% TBST  1:1000
p-EIF2α CST Milk 5% TBST  1:1000
ERK CST Milk 5% TBST  1:1000
p-ERK CST Milk 5% TBST  1:1000
FAK CST Milk 5% TBST  1:1000
p-FAK CST Milk 5% TBST  1:1000
GAPDH Abcam Milk 5% TBST  1:20000
GRP78 ENZO Milk 5% TBST  1:1000
gamma H2A.X Abcam Milk 5% TBST  1:1000
Ire1a CST Milk 5% TBST  1:1000
p-Ire1a CST Milk 5% TBST  1:1000
JNK CST Milk 5% TBST  1:1000
p-JNK CST Milk 5% TBST  1:1000
mTOR CST Milk 5% TBST  1:1000
p-mTOR CST Milk 5% TBST  1:1000
OPN Santa Cruz Milk 5% TBST  1:1000
p21 Santa Cruz Milk 5% TBST  1:1000
S6 CST Milk 5% TBST  1:1000
p-S6 CST Milk 5% TBST  1:1000
ppRB CST Milk 5% TBST  1:1000




for 15 minutes. After this, samples were washed in water for 3 minutes and then dehydrated and 
cleared with Histoclear and mounted with DPX (Sigma Aldrich).  
Sirius Red: Rehydrated sections were stained with Sirius red solution (0.01% Fast Green FCF/0.1% 
Sirius red in picric acid, Sigma Aldrich) for 30 minutes. Sections were then dehydrated directly in 
100% alcohol and mounted in DPX mounting media. 
SA-β Galactosidase: 10 μm thick frozen tissue sections were fixed with 4% NBF/0.5 % Glutaraldehyde 
solution. For the staining solution, a citric acid 40 mM was prepared in sodium phosphate 
heptahydrate 0.2 M pH 6.0. Potassium ferricyanide and potassium ferrocyanide was added to this 
solution, final concentration 5mM, MgCl2 2 mM and NaCl 150 mM. Staining solution was heated at 
37 °C and 1mg/mL X-Gal was added. Samples were incubated overnight in a humid chamber. Finally, 
samples were counterstained with 1% Fast Red for 2 minutes, dehydrated and mounted with DPX. 
For the analysis, five pictures were taken and analyzed with CellProfiler.  
DHE: Samples were sectioned in a cryostat (8 μm), and incubated with MnTBAP 150 μM at RT for 1 
h. The samples were then incubated with DHE 5 μM for 30 minutes at 37 °C. Sections were mounted 
with mounting media containing DAPI. 
Sudan Red: Cut liver cryostat section of 8 μm were incubated with freshly-prepared Sudan III stain 
(Sigma-Aldrich) and counterstained with Mayers hematoxylin. Stained area percentage of each 
sample were calculated using FRIDA software (Framework for Image Dataset Analysis). 
 
Immunohistochemistry: 5 μm thick OCT embedded sections were made with the 
cryomicrotome for F4/80 staining. Sections were unmasked according to the primary antibody to be 
used and subjected to peroxide blocking, 3% H2O2 in PBS, 10 minutes RT. For stainings with mouse-
hosted antibodies in mouse tissues, samples were blocked with goat anti-mouse FAB fragment 
(Jackson Immunoresearch, USA) (1:10, 1h RT) and then blocked with 5% goat serum (30 minutes, 
RT). Then, sections were incubated in a humid chamber with the primary antibody in DAKO antibody 
diluent (DAKO) followed by Envision anti-rabbit or anti-mouse (DAKO) HRP conjugated secondary 
antibody incubation (30 minutes, RT). Colorimetric detections was confirmed with vector VIP 
chromogen (Vector) and sections were counterstained with hematoxylin. Samples were mounted 
using DPX mounting medium. For the analysis, images were taken with an upright light microscope.   
The histopathological study of the 20 month-old mice liver was performed by an expert 
pathologist from the Animal Medicine and Surgery department in the Veterinary Faculty of the 




3.8 Serum analysis 
3.8.1 Serum transaminases, lipids and ketone bodies quantification. 
 Serum transaminase alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
were determined using commercially available kits (Spinreact, Spain). For the quantitative serum ALT 
and AST 10 µl of mouse serum were mixed with 200 µl of reagent and were incubated for 1 minute 
at 37 °C. Absorbance was measured at 340 nm in 1 minute intervals for 30 minutes. The standard 
range used for the calibration curve was from 129 to 1548 µU. 
Serum total cholesterol (CHOL), TG and free fatty acids (FFA) were also measured using 
commercially available kits (Menarini, Italy and Wako, Germany). All the measurements were made 
using the plate reader spectrophotometer. For serum CHOL measurement, 5 µl of mouse serum were 
used and 200 µl of the reagent ready to use were added, mixed and incubated for 5 minutes at 37 °C 
protected from direct light. Absorbance at 510 nm was measured. The standard range used for the 
calibration curve was from 1.4 to 27.8 µg. For serum TG 5 µl of mouse serum were used and 200 µl 
of the reagent ready-to-use were added, mixed and incubated for 10 minutes at 37 °C. Serum FFA 
were measured using 5 µl of serum. Sample was mixed with 160 µl of R1 for 3 minutes at 37 °C. Then 
80 µl of R2 were added and after 8 minutes absorbance was measured at 546 nm. The calibration 
range was 0.5 to 12 µM. 
Serum ketone bodies (KB) were determined using a commercially available kit (Wako, 
Germany). Serum KB were measured using 5 µl of serum. Sample was mixed with 180 µl of R1 and 
incubated for 5 minutes at 37 °C. Then, 60 µl of R2 were added and after 10 minutes incubation 
absorbance was measured at 405 nm. The calibration range was 0.5 to 12 µM. 
3.8.2 Osteopontin quantification by ELISA 
Serum OPN in mice was quantified using commercially available mouse OPN ELISA Kit 
(R&D Systems, UK) following the manufacturer’s instructions. The standard range used for the 
calibration curve was from 39 to 2500 pg/ml. For human serum  OPN  determination another specific 
OPN ELISA Kit (R&D Systems, UK) was used following the manufacturer’s instructions. The standard 
curve used for the calibration curve development was from 0.312 to 200 ng/ml. 
3.9 White adipose tissue lipolysis 
Fresh white adipose tissue (WAT) pads of 20 mg were extracted from gonadal white adipose 
tissue. These WAT pads were incubated in DMEM supplemented with fatty acid free BSA 4 % and 




incubated in DMEM with fatty acid free BSA 4 % for the basal condition. After incubating the tissue 
for 4 h, culture medium was collected and the released glycerol and FAs were measured using 
commercially available kits. 
3.10 Analysis of gene expression 
3.10.1 RNA extraction 
Total RNA from mouse liver tissue was extracted using Trizol Reagent (Invitrogen Life 
Technologies, USA) and following the commercial protocol steps. All the material was treated with 
RNaseZap®, an RNase decontamination solution (Thermo Fisher Scientific, USA). An additional 
treatment with DNase (Invitrogen Live Technologies, USA) was included in the process. The quality 
of the RNA was assessed by electrophoresis in an agarose gel of 1% (w/v) dissolved in TAE buffer 
and Sybr safe™ DNA gel stain at 1:25 (v/v) dilution from Molecular probes (Thermo Scientific, USA) 
using a horizontal electrophoresis equipment (Bio-rad, USA). 
3.10.2 cDNA  synthesis  and  real  time-quantitative  polymerase  chain reaction (rt-qPCR) 
The retrotranscription was performed using 1.8 µg of DNAse I pre-treated RNA extract and 
using the commercially available kit “SuperScript III First-Strand Synthesis System for RT-PCR” 
(Invitrogen Live Technologies, USA). Manufacturer instructions were followed to obtain the cDNA. 
A final treatment with RNAse H was performed. cDNA samples were diluted 1/10 before real time-
qPCR assessment. 
For real time qPCR quantification, the fluorescence dye SYBR® Green (Applied Biosystems) was 
used. All samples were assayed in triplicated and 40 cycles with a melting temperature of 60 °C for 1 
minute and 95 °C for 15 seconds were performed. The equipment for the qPCR was the AbiPrism 7000 
“Sequence Detection System” from Applied Biosystems. 
Ct (cycle threshold) values were determined for each sample and extrapolated to a standard curve. 
The standard curve was constructed with serial dilutions of a mixture of cDNA. The expression levels 
are showed as arbitrary units. Expression levels were normalized using geNorm software, taking in 
consideration the values of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cyclophilin and 
TATA-box-binding protein (TBP). Primers were synthesized by Invitrogen Life Technologies. Melting 
curve was tested to ensure specificity of the PCR products.  
3.11 Statistical analysis 
The results were expressed as the arithmetical mean ± SEM (Standard error of the mean). 




groups the Student t-test was performed. For the comparison of more than two groups, a two way 
variance (ANOVA) analysis was used. For human samples comparison a correlation analysis between 
serum OPN and the age was performed. To evaluate significance of the correlation analysis a 
Pearson Correlation test was performed in NL, non-obese NL, NAFLD and non-obese NAFLD patients. 
These statistical analyses were performed using the “GraphPad Prism” software. Differences 
were considered significant when the probability of the null hypothesis (p) was <0.05. The statistical 
significant differences are stated with different symbols as explained in each figure. The ANOVA p 

























































1. Osteopontin controls bile acid metabolism by regulating CYP7A1 
levels in liver and hepatocytes 
 
Nuñez-Garcia, M., Gomez-Santos B. et al. (2017) Osteopontin regulates the cross-talk between phosphatidylcholine 
and cholesterol metabolism in mouse liver. J. Lipid Res. 58, 1903-1915. 
 
Osteopontin (OPN) is involved in different diseases in which metabolic dysruption is a 
hallmark. On previous work, we found that OPN regulates the glycerolipid metabolism and the liver 
cross-talk between phosphatidylcholine PC and cholesterol (Chol) metabolism in mouse liver. High 
levels of OPN increase liver PC concentration, while PC concentration is low in OPN deficient (OPN-
KO) mice. We showed that in non-obese non-alcoholic fatty liver disease (NAFLD) patients, in which 
serum OPN is increased, serum OPN positively correlates with liver PC, phosphatidylethanolamine 
(PE) and CHOL concentration. We also found that when mice were treated with recombinant 
osteopontin (rOPN) PC, phosphatidylethanolamine (PE) and Chol levels were increased in liver. In 
addition, OPN deficiency resulted in an increased cholesterogenesis and reduced de novo lipogenesis 
of several lipids such as triglycerides (TG) and phospholipids (PL) in hepatocytes. This shows that OPN 
regulates the fate of acetyl-CoA in liver. In addition, in vivo inhibition of cholesterogenesis normalized 
PC content in OPN-KO mice. This demonstrates that OPN regulates the PC and Chol metabolism 
interplay (Nuñez-Garcia et al., 2017). Both PC and Chol are highly interconnected, both being bile 
lipids synthesized in the liver. On previous work, we found that several factors involved in biliary PC 
secretion and nuclear factors that regulate cholesterol 7α-hydroxylase (CYP7A1) expression were 
upregulated in OPN-KO mice, and downregulated in rOPN treated mice.  CYP7A1 is the enzyme that 
catalyzes the initial and rate-limiting step in cholesterol catabolism and bile acid synthesis. Thus, we 
wanted to explore whether OPN could modulate liver metabolism by regulating CYP7A1 
1.1 Osteopontin regulates CYP7A1 in hepatocytes 
We wanted to elucidate whether OPN could directly modulate CYP7A1, which is the enzyme 
that is in charge of the conversion of Chol into bile acids (BA), in hepatocytes and to identify the 
mechanism involved. In order to analyze whether OPN could directly modulate CYP7A1 activity in 
hepatocytes, we treated hepatocytes with recombinant OPN (rOPN) for 3 hours (h). We observed 
that the rOPN treated hepatocytes showed reduced CYP7A1 levels together with a trend toward 
decreased 7a-hydroxi-4-cholesteren-3-one (C4) levels. This compound is an indirect biomarker of 





1.2 Osteopontin regulates FAK activation and cholesterol levels in mice liver 
OPN interacts with integrins and/or CD44 at the cell surface of hepatocytes, among other 
cell types, thus, inducing a signaling cascade through phosphorylation/activation of FAK and AKT. To 
determine the mechanism by which OPN downregulates CYP7A1.  We took into account that several 
reports have involved AKT (Li, Ma, & Chiang, 2008) and/or ERK and JNK (Henkel, Anderson, Dewey, 
Kavesh, & Green, 2011; Li, Jahan, & Chiang, 2006), in regulation of CYP7A1 transcription. Thus, the 
activation of these pathways was investigated in liver and in primary culture of hepatocytes. In WT 
mice treated with rOPN, phosphorylation and activation of FAK was increased, while in OPN-KO 
animals FAK phosphorylation was reduced (Fig E.2A). In rOPN treated WT mice, together with the 
increased FAK phosphorylation there was an increased free cholesterol (FC) concentration (Fig E.2B). 
This supports the hypotesis that rOPN downregulates CYP7A1 levels, which in turn decreases the 
conversion of Chol into BA, increasing the Chol levels in liver. 
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Figure E.1 OPN regulates CYP7A1 in hepatocytes. Primary hepatocytes from WT mice were incubated with  
recombinant OPN (rOPN) (150nM) for 3h. CYP7A1 levels in hepatocytes were assessed and transferrin was 
used as loading control. Analysis of 7a-hydroxi-4-cholesteren-3-one (C4) levels in hepatocytes were 
assessed. Values are the mean ± SEM of 4 plates per group. Significant differences between Ctrl and rOPN 





1.3 Recombinant OPN decreases CYP7A1 by activation of the FAK-AKT 
pathway 
We wanted to know if the liver response to rOPN observed in vivo was mainly due to the 
hepatocyte response. Thus, we performed different assays on isolated hepatocytes. The FAK-AKT 
signaling pathway was induced after treatment with rOPN, as shown by the increased 
phosphorylation of FAK and AKT (Fig E.3A). However, the ERK and JNK phosphorylation was not 
affected (Fig E.3A). In order to assure the involvement of the FAK-AKT pathway in regulation of 
CYP7A1 expression we used the PI3K and FAK inhibitors LY294002 and Y15, respectively. When 
inhibiting the FAK-AKT signaling pathway, CYP7A1 levels increased in rOPN treated hepatocytes (Fig 
E.3B). Thus, demonstrating a mechanism by which rOPN decreases CYP7A1 levels in hepatocytes. 
Taking all together, we propose that OPN will induce, through activation of the FAK-AKT signaling, 
the downregulation of CYP7A1 protein levels, and thus will decrease the conversion of Chol into BA. 
OPN will decrease the synthesis and secretion of BA. This decreased secretion will also decrease PC 
secretion, which will contribute to the higher liver concentration of PC. 
 
Figure E.2 OPN regulates FAK activation and free cholesterol (FC) levels in mice liver. (A) Recombinant OPN 
(rOPN) (15 µg/mouse) (WT+ rOPN) or vehicle treated wild-type mice (WT+ vehicle), and osteopontin 
knockout (OPN-KO) and their control mice (WT) were used. Liver Tyr-397 phosphorylated focal adhesion 
kinase (FAK) and total focal adhesion kinase (FAK) levels were assessed by immunoblotting using transferrin 
as the loading control. (B) Lipids were extracted from liver homogenate and free cholesterol (FC) was 
separated and quantified.Values are means ± SEM of 5 animals per group. Significant differences between 
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Figure E.3 Recombinant 
OPN (rOPN) decreases 
CYP7A1 by activation of 
FAK-AKT pathway. (A) 
Primary hepatocytes from 
WT mice were incubated 
with rOPN (150 nM) during 
3 h and the FAK-AKT 
signaling pathway was 
analyzed. Transferrin was 
used as a loading control. 
(B) Primary hepatocytes 
from WT mice were 
incubated with rOPN (150 
nM) during 3 h in the 
presence or absence of the 
FAK and PI3K inhibitors, Y15 
(30 µM) or LY294002 (50 
µM). Values are means ± 
SEM of 4 plates per group. 
Significant differences 
between control (Ctr) and 
rOPN-treated hepatocytes, 
rOPN and rOPN+LY294002 
are denoted by *P < 0.05, 
**P < 0.01, and ***P < 
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2. Rewiring of lipid metabolism modulates liver regeneration after 
partial hepatectomy in OPN-KO mice 
 
Nuñez-Garcia, M., Gomez-Santos B. et al.,(2018) Atorvastatin provides a new lipidome improving early regeneration 
after partial hepatectomy in osteopontin deficient mice. Sci Rep.;8(1):14626. 
 
The liver has the capacity for regeneration after cellular damage or surgery resection. During 
regeneration, liver cells need to acquire sufficient energy and metabolic precursors to support the 
metabolic demands for rapid proliferation. Thus, a variety of metabolic pathways is switched on. 
Regarding phospholipid metabolism, the synthesis of PC, the mayor phospholipid in cellular 
membranes, is coordinated with the activation of the cell cycle and it is an essential step in cell 
proliferation. Changes in the hepatic PC/PE molar ratio have been linked to impaired liver 
regeneration (van der Veen et al., 2005). Concerning TG metabolism, hepatic TG content is widely 
variable and increases during liver regeneration. However, alterations in lipid metabolic pathways, 
has demonstrated to promote or diminish hepatic lipid content influencing hepatocyte proliferation 
(Newberry et al., 2008). Chol is also essential for the correct regeneration since it is a critical 
structural component of biological membranes that influences properties such as permeability and 
fluidity, while also contributing to the modulation of the membrane proteins, protein trafficking, and 
transmembrane signaling (Delgado‐Coello, Briones‐Orta, Macías‐Silva, & Mas‐Oliva, 2011). Related 
to liver Chol metabolism, the BA metabolism has also demonstrated to play a role in liver 
regeneration. In fact, the relative BA overload after partial liver resection causes activation of BA 
receptors in non-parenchymal and parenchymal cells in the liver, thus, providing signals to the 
regenerative process (van de Laarschot, Liyanne FM, Jansen, Schaap, & Damink, 2016). Therefore, 
modulation of lipid metabolism is required to ensure an adequate regeneration after partial 
hepatectomy (PH). The technique of PH is widely used to model liver regeneration and cell cycle 
dynamics in vivo, avoiding the massive necrosis observed in other regeneration models (Mitchell & 
Willenbring, 2008). 
On previous work, we found that circulating OPN levels increases in the levels of circulating 
OPN during the first 24 h after PH. The OPN increase occurs at a time when hepatocytes accumulate 
a significant amount of lipids (mainly TGs), in the widely recognized transient regeneration-
associated liver steatosis. Although deficiency in OPN does not result in changes in liver regeneration, 
OPN deficiency leads to remodeling of liver lipidome. OPN deficient mice exhibit changes in the 
enrichment of several species of TG and PC in the quiescent livers. These differences observed 




PC and TG species, primarily during the first 24 h after PH. The fluctuations in several TG species 
along regeneration are not associated with changes in concentration of liver TG, while those of PC 
species are linked to decrease of PC concentration in quiescent and regenerative liver. The different 
liver lipidome is not associated with changes in the lipid cargo of serum lipoproteins. The inhibition 
of Chol synthesis restores PC levels in liver and improves liver regeneration (Nuñez-Garcia et al., 
2017). The atorvastatin treatment causes an early liver regeneration in OPN-KO mice as reflected by 
the increased in liver to body weight ratio, percentage of ki67 positive hepatocytes and the 
expression of the proliferating cell nuclear antigen (Nuñez-Garcia et al., 2018).  
2.1 Dietary fatty acid contribution to the liver triglycerides in OPN-KO mice 
Taking into account all the previous data, we wanted to address several unsolved questions 
regarding lipid modulation in the OPN-KO mice livers. First, considering that PC and TG de novo 
synthesis are reduced in OPN-KO mice hepatocytes while TG concentration remains unaltered and 
PC is decreased, we wanted to analyze the contribution of dietary fatty acids (FA). For this, we 
evaluated if TG and PC species containing the essential linoleic acid (18:2) were altered. The linoleic 
acid cannot be synthesized by the cell and must be acquired from the diet. We observed that most 
of the TG species that were increased in OPN-KO livers were enriched in linoleic acid. We also 
observed that PC species containing the linoleic acid were reduced in the quiescent OPN-KO liver 
compared to the WT. This suggests that the decreased de novo TG synthesis observed in the OPN-
KO mice liver is compensated by increased dietary FA uptake. However, this compensation does not 
occur with PC loss (Figure E.4A). Since the big changes in liver lipid content during regeneration occur 
mainly 24h after PH, we also analyzed whether the increased TG storage was associated with the 
increase in linoleic acid. The results showed that increase in linoleic acid-containing TG species was 
significantly more marked in WT than in OPN-KO mice liver (Fig. E.4B). However, changes in linoleic-
acid containing PC species were less consistent, since some linoleic acid containing PC species 









Figure E.4 Liver triglyceride is enriched in the dietary linoleic acid (18:2) in OPN-KO mice. (A) Osteopontin 
knockout (OPN-KO) mice and their controls (WT) were subjected to partial hepatectomy (PH), and liver was 
collected before and 24 h post-PH. Triglycerides (TG) and phosphatidylcholine (PC) species containing the 
essential linoleic acid (18:2) were analyzed comparing differences in the quiescent liver species between both 
genotypes. (B) Differences during the first 24 h of liver regeneration in each genotype. The results are represented 
as log2 of the fold-change. Values are mean of the fold change from 5 animals per group and significant differences 





2.2 Liver lipid oxidation rate is increased in OPN-KO mice 24 h post partial 
hepatectomy 
Transient liver TG accumulation during PH has been correlated with changes in lipid 
oxidation (Newberry et al., 2008; Schofield, Sugden, Corstorphine, & Zammit, 1987). Herein, we 
assessed liver lipid oxidation rate by measuring the rate of conversion of 14C- palmitate into acid-
soluble metabolites (ASM) or CO2 (Fig. E.5A). 24 h post PH, incomplete (ASM) and complete (CO2) 
lipid oxidation was increased in OPN-KO mice when compared to WT mice (Fig. E.5A). By contrast, 
no differences were observed in the quiescent liver or in the regenerating liver 48 h post PH. For 
mitochondrial lipid oxidation to occur, FAs need to be converted into acylcarnitines by CPT-1 before 
being transported from the cytosol. Importantly, altered acylcarnitines content has been associated 
with changes in lipid oxidation. In this study, we observed that acylcarnitine levels were increased in 
livers of OPN-KO mice under basal (quiescent) conditions when compared to WT mice. However, 
although acylcarnitine levels were increased in both OPN-KO and WT mice 24 h after PH, the increase 
was more marked in WT mice (Fig. E.5B), in which beta oxidation was not increased (Fig. E.5A). 48 h 
post PH, acylcarnitines were even higher in WT mice while decreased in the KO mice (Fig.E.5B) 
suggesting an increased consume in beta oxidation. 
Next, we found that 24 h post PH, the increased lipid oxidation in the OPN-KO was associated 
with increased dihydroethidium (DHE) in liver slices (Fig. E.5C), which have been used extensively to 
evaluate reactive oxygen species (ROS) production while no differences were observed in 
malondialdehyde (MDA) (Fig. E.5D), which is a natural bi-product of lipid peroxidation, or in oxidated 
fatty acids (FA) (Fig. E.5D). Thus, this shows that despite the increased fatty acid oxidation and 
increased levels of ROS production, lipid peroxidation levels remained unaltered in OPN-KO mice 

















Figure E.5 Lipid oxidation is higher in OPN-KO mice than in WT mice 24 h after partial hepatectomy. Osteopontin 
knockout (OPN-KO) mice and their controls (WT) were subjected to partial hepatectomy (PH), and livers were 
collected before and 24 h and 48 h post-PH. (A) Fatty acid oxidation assay was performed and the released 
radioactive acid soluble metabolites (ASM) and CO2 were quantified. (B) Total acylcarnitine content was measured. 
(C) Representative liver sections of DHE staining and quantification. (D) Malondialdehyde (MD) levels in liver 
samples represented in nmol/gram of tissue (left) and the content of oxidized fatty acids (FA) (right). Values are 
mean ± SEM from 4-5 animals per group. Significant differences between OPN-KO and the corresponding WTs are 
denoted by *p <0.05 (Student’s t test); Significant differences along regeneration are indicated by †p <0.05, ††p 
















































































































































2.3 Atorvastatin induces changes in the lipidome 24 h after PH only in the 
OPN-KO mice 
As previously reported, the greatest increase in serum OPN levels occurred during the first 
24 h after PH since no changes were observed between 24 and 48 h. This increase in serum OPN was 
linked with the peak of body weight loss (Nuñez-Garcia et al., 2018). We demonstrated that in vivo 
inhibition of cholesterogenesis with atorvastatin restores PC content in OPN-KO mice (Nuñez-Garcia 
et al., 2017). As reported, OPN modulates liver lipid metabolism (and liver lipidome) during 
regeneration after PH (Nuñez-Garcia et al., 2018). To provide more information to elucidate how 
atorvastatin improves liver regeneration in OPN-KO mice. Here we evaluated the effect of 
atorvastatin in the liver lipid concentration of OPN-KO mice and their WT. We found that in OPN-KO 
mice, treatment with atorvastatin resulted in greater body weight loss 24 h after PH, while this effect 
was not observed in WT mice (Fig. E.6A). Atorvastatin treatment did not alter liver FC levels in WT or 
KO mice (Fig. E.6B). However, 24 h after PH liver levels of cholesteryl ester (CE) (a form of Chol 
storage) were lower in OPN-KO than in WT mice treated with atorvastatin (Fig. E.6B). Atorvastatin 
also increased liver diglycerides (DG) and PC content 24 h after PH in OPN-KO mice inducing no effect 
in WT mice (Fig. E.6C), as we had previously observed in the quiescent livers.  
Atorvastatin treatment did not induce changes in the accumulation of lipid droplets or in the 
liver TG content 24 h after PH in the OPN-KO or WT mice (Fig E.7A). Atorvastatin decreased liver DG 
content in OPN-KO mice 48 h after PH (Fig. E.7C) while it did not induce changes in body weight loss 
or concentration in other lipids (Fig. E.7A, B and C). Since we observed that in OPN-KO mice the 
increased lipid oxidation was associated with increased DHE, here we wanted to know if this increase 
maintained after atorvastatin treatment, that restores the lipidome. The results showed that 
differences between WT and OPN-KO in DHE disappeared after atorvastatin treatment (Fig. E.7B). 
Taken together, these results show that, the decrease in the PC liver concentration and de 
novo synthesis is not compensated with the dietary essential FA linoleic, unlike what happens with 
TGs. The increased dietary-lipid uptake in OPN-KO mice provides the metabolic precursors required 
for regeneration 24 h and 48 h after PH. Atorvastatin induces changes in the liver lipidome in 






                                                                                                                                                 
 
Figure E.6 In OPN-KO mice atorvastatin treatment induces changes in liver lipidome 24 h after partial hepatectomy. 
Osteopontin knockout (OPN-KO) mice, OPN-KO mice treated with atorvastatin (100 mg/kg), and their respective 
controls treated or untreated with atorvastatin (WT) were subjected to partial hepatectomy (PH) and livers were 
collected  0 h (quiescent), 24 h and 48 h post-hepatectomy. (A) Percentage of body weight loss. (B) Liver free 
cholesterol (FC), cholesteryl ester (CE). (C) Diglycerides (DG) and phosphatidylcholine (PC) content are represented in 
nmol/gram of liver. Values are mean ± SEM of 4-8 animals per group. Statistical differences between treated or 
untreated mice within one genotype are denoted by *p <0.05 (Student’s t test) and differences along regeneration 











Figure E.7 Atorvastatin treatment modulation of liver TG 24 h after partial hepatectomy. (A) Representative liver 
sections stained with Sudan III (left) and liver triglycerides (TG) content (right) is represented in nmol/gram of liver. 
(B) Representative liver sections stained with DHE (left) and quantification (right). Values are mean ± SEM of 4-8 
animals per group. Statistical differences between treated or untreated mice within one genotype are denoted by *p 
<0.05 (Student’s t test) and differences along regeneration and between genotype are indicated by †p <0.05, ††p <0.01 





3. Osteopontin plays a role in the age-associated NAFLD progression 
 3.1 Osteopontin and aging 
OPN is expressed in many organs and tissues such as the liver, brain, bone, lungs and kidney, 
among others. It can also be found in blood and urine. This protein is involved in many physiological 
and pathological processes and its expression is increased in many diseases in which aging in the 
primary risk factor. OPN has been linked to aging in several studies. However, the available data does 
not give conclusive results about the role of OPN in the aging process, but its effect seems to be 
tissue or cell-type dependent. 
During aging, the liver undergoes a series of changes and loses its ability to respond correctly to 
damage. With aging, body fat undergoes redistribution, from adipose tissue to other tissues, 
including the liver. This results in an increased liver lipid accumulation in the liver. In addition, the 
prevalence of non-alcoholic fatty liver disease (NALFD) increases with age, and with aging the 
number of biochemical and histological alterations increases. Besides, cirrhosis has a higher 
prevalence among older people. Therefore, vulnerability to the development and progression of liver 
disease increases with age. In order to elucidate if during aging OPN is involved in the increased 
vulnerability of the liver to NAFLD, we analyzed if serum OPN levels increased with age in different 
models. 
3.1.1 The positive correlation between age and serum OPN levels is lost in NAFLD patients 
We analyzed circulating OPN concentration in a human cohort with normal liver (NL) (n=34) 
(Table E.1) and observed a positive correlation between serum OPN concentration and age (Fig E.8A). 
Aging is the primary risk factor for a number of diseases in which the metabolic component is key, 
such as cardiovascular diseases, cancer and metabolic syndrome. In fact, NAFLD has been considered 
the hepatic manifestation of the metabolic syndrome. We previously reported a role for OPN 
controlling liver lipid metabolism. Besides, we observed that circulating OPN levels were increased 
in NAFLD patients (Nuñez-Garcia et al., 2018; Nunez-Garcia et al., 2017). Thus, to analyze whether 
the positive correlation between OPN and age observed in NL individuals maintains in NAFLD 
patients, we analyzed a cohort of NAFLD patients (n=129) (Table E.1). We measured OPN serum 
concentration and observed that the correlation between circulating OPN concentration and age was 
lost in NAFLD patients, in which OPN levels were already high (Fig E.8A). The result indicates that 
variations on OPN levels might play a role in the pathogenesis of age-associated NAFLD. As 
mentioned earlier, NAFLD is often associated to metabolic syndrome and obesity. Since OPN levels 
can be altered in obesity, we wanted to discard the obesity as the cause for the observed lack of 




obese patients (Table E.1). We observed that the correlation age-serum OPN concentration 
maintained in non-obese NL, and was lost in the non-obese NAFLD group, assuring the possible role 






Table E.1 Demographic, metabolic, biochemical and histological characteristics of individuals with normal 
liver (NL), non-alcoholic fatty liver disease (NAFLD), non-obese NL and non-obese NAFLD. Obese patients 
where considered when the BMI was ≥ 30. 
 
Data are the mean or percentage (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHOL, 
cholesterol; BMI, Body mass index; HDL, high-density lipoprotein; TG, triglyceride. Values are means of n=34 for 
NL, n=129 for NAFLD, n=29 for non-obese NL individuals and n=13 for non-obese NAFLD patients. Significant 
differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing NL vs NAFLD, and when 
comparing non-obese NL vs non-obese NAFLD (Student’s t test).  
 
NL NAFLD non-obese NL non-obese NAFLD 
BMI (kg/m2) 28,1 41,18*** 25,71 25,96
Age(Years) 48,3 49,5 48,27 52,92307692
Male gender % 32,4 31,7 34,62 46
Female gender % 67,6 68,3 65,38 54
TG (mg/dL) 104,3 145,87*** 89,31 128,1*
Glucose (mg/dL) 95,4 91,3 95,38 104
CHOL (mg/dL) 188,4 166,3 188,38 201,154
CHOL-HDL (mg/dL) 49,9 38,6 49,88 53,154
ALT (IU/l) 19,2 36,53** 19,15 34,62**
AST (IU/l) 18,1 27,86** 18,13 25,69**
Insulin (mU/mL) 6,6 11,9 6,63 6,9
Steatosis %
Grade 0 100 34,8 100 0
Grade 1 37,8 84,6
Grade 2 17,8 15,4





3.1.2 OPN levels increase in serum and liver during aging in mice 
To ascertain whether the observed positive correlation between OPN and age in humans with NL 
was also observed in mice, we analyzed OPN in serum, for this we used a natural model of aging: 
male and female wild type (WT) mice ranging from 3 to 20 months-old (m). We measured serum 
OPN levels and, as observed in humans, we found a positive correlation between age and OPN levels 
(Fig E.9A). Given the lack of studies performed in female mice, particularly in age-related studies, we 
analyzed if OPN was increased in serum and liver of natural aged female mice. In this model, 3 m 
mice represent young mice, 10 m mice represent intermediate-age mice and 20 m mice represent 
aged mice. We observed that in female mice there was an increase in serum OPN concentration from 
3 to 10 m, and that this increase maintained in 20 m mice (Fig E.9B). We also analyzed liver OPN 
protein expression, and observed a similar result, in which OPN was increased in 10 m mice and levels 
maintained high at 20 m (Fig E.9C).  
Figure E.8 Serum OPN in NL, NAFLD and non-obese NL and NAFLD patients. (A) Serum samples from normal 
liver (NL) individuals (n=34), non-alcoholic fatty liver disease (NAFLD) patients (n=129), (B) non-obese NL (n=29) 
and non-obese NAFLD patients (n=13) were quantified by ELISA to asses circulating OPN levels. Correlation 




Taking all together, we suggest that serum OPN increased with age as a consequence of increased 
liver secretion. However, if this secretion of OPN is a protective mechanism or makes the liver more 
vulnerable to liver disease is something we do not know yet. 
3.1.3 Osteopontin expression increases when senescence is induced in the HepG2 cell line 
OPN is a cytokine known to be part of the senescence-associated secretory phenotype (SASP). 
Senescence is one of the hallmarks of aging, and it is primarily a protective mechanism in order to 
preserve the functionality of the tissue by avoiding the proliferation of damaged cells. Although 
cellular senesce is part of the aging process, aging is a more complex process. Since the number of 
senescent cells increases with aging, it has been widely assumed that senescence contributes to 
aging. In addition, other of the deleterious effects of senescence is that it can paradoxically promote 
tumorogenesis and cancer, which prevalence is increased with aging. 
Given that OPN serum levels show a correlation with age in NL individuals, and 10 and 20 m mice 
show increased serum and liver OPN levels, we wanted to know if the senescence induction could 
Figure E.9 Circulating and liver OPN levels during aging in a mouse model of aging. (A) Serum OPN levels 
of 3, 6 10, 14 and 20 month-old (m) wild type (WT) mice was quantified by ELISA. (B) Serum OPN levels of 
3, 10 and 20 m female WT mice was quantified by ELISA. Immunoblot analysis of OPN from liver extract was 
assessed using transferrin as loading control. Values are means ± SEM of n= 3-8. Significant differences are 





induce OPN  expression and secretion in HepG2 cells. We induced senescence using two different 
methods: treating cells with hydrogen peroxide (H2O2) and with palbociclib. We checked the 
induction of senescence using the SA-β-Galactosidase staining, which was positive in both cases. In 
addition, with both treatments, OPN protein levels and secretion of OPN was induced (Fig E.10), 
suggesting that OPN might mediate , at least in part, cellular senescence. Besides, the results showed 
that the senescence induction by palbociclib, which inhibits the cyclin kinase 4/6 (CDK4/6) and thus 
the Rb protein (pRB) phosphorylation, was reduced  when cells were treated with rOPN (Fig E.11). 
Thus, the effect of palbociclib was reduced when cells were treated with rOPN. This suggest that OPN 
might be a factor expressed to avoid or restrain senescence. 
 
 
Figure E.10 Senescence induction and OPN protein levels in an in-vitro model. HepG2 cells were treated with 
hydrogen peroxide (H2O2)(700 µM) and Palbociclib (Palbo) (2 µM) or vehicle (Veh). Senescence induction was 
assessed with the SA-βGalactosidase staining. OPN protein levels from HepG2 cells were measured by 
immunoblotting using glyceraldehyde -3-phosphate dehydrogenase (GAPDH) as loading control. Secreted OPN 
in the media was measured by ELISA. Values are means ±SEM of n=4. Significant differences are denoted by 







3.2 OPN is plays a role in age-associated hepatosteatosis 
3.2.1 Increased liver lipid accumulation is observed in OPN-KO mice during aging 
The previous results show that osteopontin is involved in aging, and suggest that it might play 
a role in the age-associated liver vulnerability to NAFLD progression. Thus, we wanted analyzed if the 
increased OPN expression during aging is protective or detrimental for the age-associated 
hepatosteatosis development. 
In order to study the role of OPN in the pathogenesis of NAFLD during aging, female WT and OPN-
KO mice of 3, 10 and 20 m were used. In these animals, the increase in body weight with aging was 
similar between genotypes, with a slight increase in body weight in 10 m OPN-KO mice compared to 
their age-matched WTs (Table E.2). The liver weight increase with age was higher in the 10 m OPN-
KO mice compared to their WTs (Table E.2). Serum alanine aminotransferase (ALT) increased as mice 
aged, but there were no differences between genotypes. Regarding serum lipids, levels of 
triglycerides (TG) were increased in 10 and 20 m OPN-KO mice compared to their age-matched 
controls while fatty acids (FA) just increased in 10 m OPN-KO animals. Finally, no changes in serum 
Chol were found (Table E.2).  
 
Figure E.11 Recombinant osteopontin (rOPN) reduces palbociclib senescent effect in HegG2 cells. rOPN 
treated cells (rOPN) and vehicle cells (Veh) were treated with Palbociclib (Palbo) (2µM) to induce 
senescence or vehicle (Veh). Phosphorylated Rb protein (ppRB) levels were measured by immunoblotting 
to study palbociclib effect using glyceraldehyde -3-phosphate dehydrogenase (GAPDH) as loading control. 
Values are means ±SEM of n=4. Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 






Regarding liver lipid concentration, changes along aging were different in WT and OPN-KO mice; 
while the peak of concentration for all lipids was at 20 m in WT mice, being the concentration similar 
at 3 and 10 m, in the OPN-KO mice the peak was at 10 m and kept elevated at 20 m. This rise in 
storage lipid concentration was also observed when analyzing H&E staining (Fig E.12A). The analysis 
showed a premature increase in TG, CE, FA, DG, PC and FC concentration in 10 m OPN-KO mice 
compared to their age-matched WTs (Fig E.12B).   
 
Table E.2. Body and serum parameters of WT and OPN-KO female mice. 
Body weight, liver weight (LW), serum alanine aminotransferase (ALT), serum Triglycerides (TG), non-esterified 
fatty acids (NEFA) and cholesterol (Chol) are represented. Values are means ±SEM of n=4-8. Significant 
differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing genotypes of the same age 
group, and #p<0.05, ##p<0.01 and ###p<0.001 when comparing with previous age group in the same genotype 
(Student’s t test). 
 
WT KO WT KO WT KO
Weight (g) 21,43 21,08 24,665### 26,5 * ### 29,1325### 30,59###
LW (g) 0,77 0,74 0,98## 1,12*  ### 1,2## 1,14
ALT (U/L) 17,30** 14,12 18,41 23,61 49,5 ### 46,91 ###
Serum TG (mg/dL) 73,620 78,140 43,87# 72,65* 56,611 84,25*
Serum NEFA (mg/dL) 14,69 11,98 11,24 18,52*# 15,44 15,53
Serum Cho (mg/dL) 92,68 98,14 93,21 78,7
#
75,63 82,04





Figure E.12 Liver lipid concentration in OPN-KO and WT mice during aging. (A) H&E staining was performed to 
study the histology of the liver. Lipids were extracted from liver homogenates and triglycerides (TG), cholesteryl 
ester (CE), diglycerides (DG), fatty acids (FA), free cholesterol (FC), phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinosiltol (PI) were separated and 
quantified. Values are means ±SEM of n=4-8. Significant differences are denoted by *p<0.05, **p<0.01 and 
***p<0.001 when comparing genotypes of the same age group, and #p<0.05, ##p<0.01 and ###p<0.001 when 





3.2.2 20 month-old OPN-KO mice show increased fibrosis 
Next, we analyzed if together with the lipid accumulation there were other markers of NAFLD 
progression such as fibrosis or inflammation. The Sirius red staining showed that fibrosis was 
increased in 20 m OPN-KO mice when compared to their age-matched WT or with 10 m OPN-KO mice 
(Fig E.13A). In contrast, the F4/80, a marker of macrophages and Kupffer cells, showed no changes 
between WT and OPN-KO mice (Fig E.13B). Taken together, these results show that OPN might be 





Figure E.13 Liver fibrosis and F4/80 histochemical analysis in OPN-KO and WT mice during aging. (A) Sirius Red 
and (B) F4/80 stainings were performed to assess fibrosis and inflammation. Values are means ±SEM of n=4-8. 
Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing genotypes of the 
same age group, and #p<0.05, ##p<0.01 and ###p<0.001 when comparing with previous age group in the same 





3.3 Osteopontin deficiency results in several metabolic changes involved in 
the early disease progression during aging 
Metabolic dysregulation is a hallmark for NAFLD development and progression. When the 
capacity of the liver to handle the excessive energy uptake from metabolic substrates is 
compromised, the liver starts accumulating lipids and other toxic metabolites. This will induce stress 
that drives liver damage, fibrogenesis and other harmful effects. Here, we have observed that OPN 
is required to slow down the development of age-associated hepatosteatosis. We wanted to 
understand the mechanism involved. For this, 10 m mice were used since it was the age in which 
deficiency of OPN induced increased lipid accumulation. 
3.3.1 Metabolic pathways associated with the liver lipid accumulation in the OPN-KO mice 
3.3.1.1 Increased de novo lipogenesis in hepatocytes is associated with the lipid storage in the 
OPN-KO mice liver 
Taking into account that an increased lipogenesis might explain the increased lipid 
concentration in the liver, we analyzed the de novo lipogenesis (DNL) from acetate in purified 
hepatocytes from 10 m WT and OPN-KO mice. TG, DG, CE and PL de novo synthesis was increased in 
10 m OPN-KO mice hepatocytes (Fig E.14A). In concordance with this, protein levels of the fatty acid 
synthase (FAS), the enzyme that catalyzes the fatty acid synthesis, was augmented, while no changes 







3.3.1.2 Incorporation of oleate into triglyceride and phospholipids is increased in OPN-KO mice 
During esterification FAs are added to glycerol 3-phosphate to finally synthesize TG or PLs; 
or to Chol for the formation of CE. Thus, the esterification of fatty acids into TG, CE and PLs was 
studied in purified hepatocytes of 10 m OPN-KO and WT mice. In addition, activity of key enzymes 
that control esterification and hydrolysis of lipids was analyzed. First, we analyzed the esterification 
flux in TG and synthetic and hydrolytic enzymes activity. Esterification of oleate into TG was increased 
in OPN-KO mice (Fig E.15A) even though diglyceride acyltransferase (DGAT) activity, which catalyzes 
the formation of triglycerides from diglycerides and acyl-CoA, was not changed (Fig E.15B). Regarding 
hydrolytic enzymes, the only activity that changed was the cytosolic triglyceride hydrolase (TGH), 
which was increased in 10 m OPN-KO mice (Fig E.15C). However, the microsomal and lysosomal TGH 
activity maintained unaltered (Fig E.15C). The esterification of oleate into CE remained unchanged 
Figure E.14 De novo lipogenesis (DNL) is increased in 10 month-old (m) OPN-KO mice. (A) Hepatocytes isolated 
from both 10 m  WT and OPN-KO mice were cultured in medium with [3H]acetate for 2 and 4 h. Lipids were 
extracted and radioactivity incorporated into triglycerides (TG), diglycerides (DG), cholesteryl ester (CE), 
diglycerides (DG), fatty acids (FA), free colesterol (FC), phospholipids (PL) was assesed by liquid scintillation. (B) 
Fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACCt) and its phosphorylated form (pACC) protein levels 
were assesed by inmunoblotting using transferrin as loading control. Values are means ±SEM of n=6-8. Significant 
differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing 10 m WT and OPN-KO mice 





(Fig E.16A), as well as the synthetic and hydrolytic enzyme activities involved in CE metabolism (Fig 
E.16B, C). Phospholipid metabolism was analyzed too. The oleate esterification was increased for 
both, PC and PE (Fig E.17A). However, the phosphatidylethanolamine N-methyltransferase (PEMT) 
activity, in charge  of converting phosphatidylethanolamine (PE) to phosphatidylcholine (PC) in the 
liver, did not change (Fig E.17B).  
 
 
Figure E.15 Oleate esterification and liver enzyme activities in 10 month-old (m) WT and OPN-KO 
hepatocytes. (A) Oleate esterification in triglyceride (TG), (B) diglyceride acyltransferase (DGAT) and (C) 
cytosolic, neutral and acid triglyceride lipase (TGH) enzyme activities were determined using radiometric 
assays. Values are means ±SEM of n=6-8. Significant differences are denoted by *p<0.05, **p<0.01 and 






Figure E.16 Oleate esterification and liver enzyme activities in 10 month-old (m) WT and OPN-KO 
hepatocytes. (A) Oleate esterification in cholesteryl ester (CE), (B) acyl-CoA cholesteryl acyltransferase 
(ACAT) and (C) cytosolic, neutral and acid cholesteryl ester hydrolase (CEH) activities were determined using 
radiometric assays. Values are means ±SEM of n=6-8. Significant differences are denoted by *p<0.05, 
**p<0.01 and ***p<0.001 when comparing 10 m WT and OPN-KO mice (Student’s t test). 
 
Figure E.17 Oleate esterification and liver enzyme activities in 10 month-old (m) WT and OPN-KO 
hepatocytes. (A) Oleate esterification in phosphatidylcholine (PC) and in phosphatidylethanolamine (PE) and 
(B) Phosphatidylethanolamine N-methyltransferase (PEMT) activity was determined using radiometric assays. 
Values are means ±SEM of n=6-8. Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 





3.3.1.3 Fatty acid beta oxidation rate is not altered in 10 month-old OPN-KO mice 
The increased cytosolic TGH activity (shown in 3.3.1.2) will provide more FA, that among 
others, could be catabolized through beta oxidation (β-oxidation). Thus, palmitate β-oxidation was 
assessed in 10 m mice livers. We analyzed the liver palmitate β-oxidation rate together with the 
serum ketone bodies (KB), which are a product of β-oxidation and are produced in the mitochondria 
of liver cells. β-oxidation was not altered, since no changes were found in the acid soluble 
metabolites (ASM), the CO2 production (Fig E.18A), or in circulating KB concentration (Fig E.18B). The 
AMP-activated protein kinase (AMPK) is a sensor of cellular energy status and acts as a metabolic 
master switch, that when activated, promotes fatty acid oxidation. There were no changes in AMPK 
phosphorylation (Fig E.18C) as in fatty acid oxidation. Thus, alteration of the β-oxidation was 
discarded as one of the driving mechanisms for the observed phenotype.    
 
 
3.3.1.4 Several bile acid species and CYP7A1 levels are increased in 10 month-old OPN-KO mice.  
We have shown how OPN directly regulates CYP7A1 in hepatocytes via the FAK/AKT signaling 
pathway, thus, regulating the Chol and BA metabolism. In order to analyze whether this process was 
altered, we analyzed the liver bile acid composition, and observed in OPN-KO mice an increase of the 
liver free BA concentration, and a trend towards increase in the total BA concentration (Fig E.19A) 
Figure E.18 Beta oxidation is not altered in 10 month-old (m) OPN-KO mice. (A) Fatty acid oxidation assay 
was performed and the released radioactive acid soluble metabolites (ASM) and CO2 were quantified. (B) 
Serum ketone bodies (KB) concentration was quantified. Values are means ±SEM of n= 6. (C) Inmunoblot 
analysis of phospho/total AMPK phospho/total protein from liver extract were assesed using transferrin as 
loading control. Values are means ±SEM of n=6-8.  Significant differences are denoted by *p<0.05, **p<0.01 








(Table E.3). In concordance with the increased synthesis of BA and our previous results, we also 
observed an increase of the protein levels of CYP7A1 in the OPN-KO mice (Fig E.19B). This enzyme is 
in charge of the conversion of Chol into BA and could be regulating Chol concentration in the OPN-
KO mice (Nunez-Garcia et al., 2017). As shown earlier, unlike most liver lipids, which are increased in 
the OPN-KO mice, FC concentration is not increased in 10 m OPN-KO mice when compared to WT 
mice. Thus, CYP7A1 might be regulating Chol levels by diverting it towards BA synthesis in the OPN-
KO mice. In young OPN-KO mice, the FAK/AKT pathway was regulating CYP7A1 levels. Thus, in order 
to determine whether the implicated signaling pathway for the increased CYP7A1 levels in 10 m mice 
was indeed FAK/AKT, we analyzed AKT phosphorylation and observed that it was decreased and thus, 
could be the cause for increased CYP7A1 levels, as observed in younger mice (Fig E.19C). 
 
 
Figure E.19 Liver bile acid concentration and CYP7A1 levels in 10 month-old WT and OPN-KO mice. (A) Total 
bile acids were quantified. (B) Cholesterol 7 alpha-hydroxylase (CYP7A1) protein levels were assessed by 
inmunoblotting using GAPDH as loading control (C) Phosphorylated and total AKT protein levels were assessed 
by inmunoblotting using transferrin as loading control . Values are means ±SEM of n= 4-6. Significant differences 








3.3.2 Altered mechanisms related to aging in OPN-KO mice. 
3.3.2.1 Lipid accumulation in the OPN-KO mice during aging is associated to increased markers of 
senescence. 
Cellular senescence is a state of irreversible cell-cycle arrest combined with the secretion of 
proinflammatory cytokines and mitochondrial dysfunction. Senescent cells contribute to age-related 
tissue degeneration and their accumulation promotes hepatic fat accumulation and steatosis 
(Ogrodnik et al., 2017).  We have shown that OPN might have a role in senescence, and since OPN-
KO mice show an early lipid accumulation profile compared to WT mice, we wanted to know whether 
the OPN-KO mice accumulated more senescent cells. For this, we analyzed the senescence markers 
p21 and senescence associated β-Galactosidase (SA- β-Galactosidase) in 10 m WT and OPN-KO mice. 
We observed that both markers were increased in OPN deficient mice (Fig E.20). Because the 
accumulation of senescent cells promotes steatosis, the increase of senescent cells in the OPN-KO 
liver could be linked with the observed lipid accumulation. 
Table E.3 Liver bile acid concentration in OPN-KO and WT mice. 
 
 
Values are means ± SEM in nmol/gram of liver from 4 animals per group. Significant differences 
between OPN- KO and WT mice are denoted by *p <0.05. CA, cholic acid; CDCA, 
chenodeoxycholic acid; DCA, deoxycholic acid; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; 
UDCA, ursodeoxycholic acid; αMCA, alpha-muricholic acid; βMCA, beta-muricholic acid. All the 







3.3.2.2 ER stress is associated to the early senescence and lipid accumulation in OPN-KO mice liver. 
Loss of proteostasis is a hallmark of aging. The endoplasmic reticulum (ER) is an important 
organelle for regulating calcium homeostasis, lipid homeostasis, protein synthesis, and post-
translational modifications and trafficking. Many insults can disturb ER homeostasis, which leads to 
ER stress. This stress and the unfolded protein response (UPR) pathways are involved in lipid 
metabolism and lipotoxocity. In fact, it can modulate expression levels of key enzymes involved in 
lipid synthesis or modification (Han & Kaufman, 2016). It is well stablished that lipid accumulation 
can disturb the endoplasmic reticulum function generating ER stress. If this stress is defective or 
chronic, there can be an increased transcription of lipogenic genes, and a decrease of fatty acid 
oxidation genes. Thus, ER stress can increase the accumulation of lipids in hepatocytes, which in turn 
exacerbates the ER stress increasing the lipid accumulation, generating a vicious cycle. ER stress 
response has been proposed to play a crucial role in both the development of steatosis and 
progression to nonalcoholic steatohepatitis (NASH).  
We wanted to analyze whether OPN deficiency during aging was linked to ER stress development. 
When we analyzed ER stress markers in 10 m mice we found that phosphorylation of eIF2a (peIF2a) 
was increased in OPN-KO mice and the chaperone GRP78 levels were decreased, which can 
contribute to a worse response to ER stress (Fig E.21A). Several studies have demonstrated that the 
decrease in chaperone number diminishes the efficacy to deal with unfolded proteins. In addition, 
the decrease in the number of chaperones is associated with aging, which can be one of the causes 
of the increase in ER stress with aging. Some studies have shown that forced expression of GRP78 
Figure E.20 Senescence markers in 10 month-old (m) mice. Liver SA β-Galactosidase positive area 
percentage was quantified. Immunoblot analysis of p21 protein from liver extract was assessed using 
transferrin as loading control. Values are means ±SEM of n=6. Significant differences are denoted by 





attenuates steatosis by inhibiting sterol regulatory element-binding protein (SREBP-1c) (Kammoun 
et al., 2009). Thus, the reduced GRP78 levels could increase the steatosis by activation of SREBP-1c, 
and thus, lipogenic genes. In concordance with this, we showed earlier increased DNL and FAS 
protein levels, which are regulated by SREBP-1c. Besides, a chronically active ER stress can lead to 
apoptosis. Thus, in order to know whether the observed ER stress could be causing apoptosis, we 
analyzed caspase 12 cleavage, which remained unchanged when comparing genotypes. Besides, we 
analyzed if the ER stress observed at the intermediate age in the OPN-KO mice was also observed in 
the younger mice, in order to identify if the ER stress was prior to the steatosis and thus, a cause of 









Figure E.21 ER stress markers proteins. (A) Immunoblot analysis of GRP78, total and phosphorylated peIF2a 
and IRe1a and cleaved caspase 12 protein from liver extract was assessed using transferrin or 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control in 10 month-old (m) and (B) 3 m 
WT and OPN-KO mice. Values are means ±SEM of n=6-8. Significant differences are denoted by *p<0.05, 





3.3.2.3 Nutrient sensing is dysregulated in 10 month-old OPN-KO mice. 
An altered nutrient sensing is other of the metabolic distinctives of aging. AMPK and mTOR are 
key metabolic switches. mTOR is part of the TORC1 and 2 complexes which activation is linked to 
lipogenesis activation. When analyzing this pathway, we observed that not only was not active, but 
markedly decreased in the 10 m OPN-KO mice (Fig E.22). Therefore, we discarded the activation of 
this pathway as an explanation for the increased lipogenesis. However, the observed decrease in S6K 
phosphorylation (Fig E.22) supports the hypothesis that the 10 m OPN-KO mice are dealing with ER 
stress. Usually under ER stress conditions, the unfolded protein response (UPR) lowers the protein 
synthesis as a coping mechanism.  
Taking together all these results, at 10 m, OPN-KO mice livers exhibit ER stress linked to decreased 
chaperone levels. This situation could aggravate the pro-lipogenic environment worsening the 
progression of the liver disease. Therefore, deficiency of OPN induces early lipid accumulation via 
increased DNL and ER stress; thus, OPN might be necessary to cope with the insults that the organism 






Figure E.22 There is a dysregulated nutrient sensing in the 10 month-old (m) OPN-KO mice. Inmunoblot 
analysis of total and phosphorylated mTOR and S6 protein from liver extract were assessed using transferrin 
as loading control. Values are means ±SEM of n=6-8. Significant differences are denoted by *p<0.05, 





3.4 Osteopontin knockdown in HepG2 cells increases cell vulnerability to 
senescence by downregulating the ER stress response.   
In order to analyze the effect of OPN deficiency in ER stress generation and chaperone levels upon 
senescence; OPN (SPP1 gene) was silenced in HepG2 cells, which were treated with palbociclib to 
analyze the effect in senescent cells. In order to simulate a lipid rich environment we treated a group 
of cells with palmitic acid 200 µM. Knockdown of OPN did not change the levels of GRP78 chaperone 
(Fig E.23A). However, when treating cells with palbociclib, GRP78 chaperone level decreased in OPN 
silenced cells (Fig E.23B). Moreover, when OPN was silenced, the decrease in chaperone levels was 
even greater when senescent cells where challenged with palmitic acid. In this situation, the decrease 
in the chaperone was 5 times greater when compared with control-silenced cells. In addition, we did 
not observe the activation of eIF2a pathway in any of these situations, showing that the decrease in 
the chaperone levels is prior to the activation of this UPR branch (Fig E.23C).  
Thus, while the siCtrl group is able in both conditions to deal with the lipid rich environment 
without fluctuations in their chaperone capacity, the OPN silenced cells are more susceptible to the 
chaperone decrease and thus to ER stress. Therefore, senescence induction in absence of OPN 


















Figure E.23 OPN deficiency in senescent cells decreases GRP78 expression. (A) In HepG2 cells GRP78, 
phosphorylated eIF2a (peIF2a), and eIF2a protein levels were measured by immunoblotting using glyceraldehyde 
-3-phosphate dehydrogenase (GAPDH) as loading control were measured in siCtrl and siOPN HepG2 cells, (B) in 
siCtrl and siOPN HepG2 cells treated with palbociclib (Palbo) for inducing senescence and (C) in siCtrl and siOPN 
HepG2 cells treated with Palbo and palmitic acid. Values are means ±SEM of n=4. Significant differences are 





3.5 In old mice, high fat diet aggravates the NAFLD progression when OPN is 
absent. 
We have shown that OPN deficiency at 10 m is associated with increased lipid storage, de novo 
lipogenesis and decreased GRP78 levels, also decreased in vitro when silencing OPN and inducing 
senescence to HepG2 cells. Next, we wanted to analyze the consequences of this phenotype in old 
mice. 
3.5.1 Feeding a high fat diet (HFD) induces an advanced progression of liver disease in 20 month-
old OPN-KO mice. 
 We generated a group of WT aged mice fed a high fat diet (HFD) for 16 weeks prior to the sacrifice 
at 20 m. We observed that when feeding a HFD the circulating concentration of OPN in 20 m mice 
was higher than in those fed a chow diet (CD) (Fig E.24). Thus, in order to ascertain if OPN deficiency 
increased the vulnerability to age-associated NAFLD development, we generated other group of 
OPN-KO aged mice fed a high fat diet (HFD). We analyzed body parameters and found that the body 
weight gain in response to the HFD was similar in both genotypes. Serum ALT increased in mice fed 
a HFD when compared to the CD fed mice in both genotypes but there were no differences between 
OPN-KO and WT mice (Table E.4). By contrast, serum AST was increased in HFD fed OPN-KO mice 
compared to their WTs. Serum lipid analysis showed an increase of TG in OPN-KO mice in HFD 
condition compared to their WTs, which also happened in 10 and 20 m mice (Table E.4).  
 
 
Figure E.24 HFD induces increased circulating OPN levels in 20 month-old (m) mice. Serum OPN of 
chow diet (CD) and high fat diet (HFD) fed 20 m wild type (WT) mice was quantified by ELISA. Values 
are means ±SEM of n=4-6. Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 









Table E.4 Body and serum parameters of HFD 20 month-old (m) WT and OPN-KO mice 
Body weight, liver weight (LW), serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), serum TG, NEFA and Cho are represented. Values are means ±SEM of 
n=4-6. Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when 
comparing 20 m HFD fed WT and OPN-KO mice (Student’s t test). 
 
Figure E.25 HFD induces metabolic dysregulation in 20 month-old (m) OPN-KO mice. (A) Glucose (GTT) and insulin 
tolerance test (ITT) were performed in HFD fed 20 m WT and OPN-KO mice. (B) Lipolysis was measured as the 
release of glycerol and FFA from WAT pads. Values are means ±SEM of n=4-6. Significant differences are denoted 
by *p<0.05, **p<0.01 and ***p<0.001 when comparing genotypes (Student’s t test). Significant differences in GTT 
and ITT are denoted by ANOVA test. 
 
WT OPN-KO
Weight (g) 46,33 44,71
LW (g) 1,67 1,38
ALT (U/L) 144,40 165,90
AST (U/L) 55,03 95,14*
Serum TG (mg/dL) 69,516 92,20*
Serum NEFA (mg/dL) 15,93 18,03





While serum FA concentration did not change, serum Chol increased in both genotypes when fed 
a HFD, but no differences were found between genotypes (Table E.4). ITT analysis in 20 m OPN-KO 
mice fed a HFD showed that the response to insulin was lower than in WT mice, while the GTT 
maintained unaltered (Fig E.25A). When stimulating lipolysis in white adipose tissue (WAT), released 
glycerol was increased in OPN-KO mice, while no changes were found in released FA (Fig E.25B).  
When liver was analyzed, both HFD fed WT and OPN-KO mice showed the expected increase in 
hepatic TG (Fig E.26A), while young OPN-KO mice are resistant to hepatosteatosis when fed a HFD 
(Kiefer et al., 2011; Lancha et al., 2014), in old age this resistance is lost. The evaluation of the liver 
by an expert histopathologist confirmed the increase in steatosis score in both genotypes when fed 
a HFD (Fig E.26B). Sirius red staining and the fibrosis score after the trichrome staining (Fig E.26B) 
showed increased fibrosis in OPN-KO mice compared to their WTs. In terms of inflammation, OPN-
KO mice had increased inflammation score compared to their controls (Fig E.26B). In addition, F4/80, 
a macrophage/ Kupffer marker was higher in HFD fed OPN-KO mice. All together, these results show 








Figure E.26 HFD induces an advanced progression of the disease in 20 month-old (m) OPN-KO mice. (A) H&E, 
triglycerides (TG) were extracted from liver homogenates and quantified; Sirius Red and F4/80 stainings were 
performed to assess tissue morphology, fibrosis and inflammation. Values are means ±SEM of n=4-6. Significant 
differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing genotypes of the same diet 
group and #p<0.05, ##p<0.01 and ###p<0.001 when comparing CD and HFD groups of the same genotype 
(Student’s t test). (B) Histopathological study was performed by an expert pathologist. Steatosis, fibrosis and 







Given the observed phenotype, we analyzed the liver lipid profile of 20 m mice. We previously 
showed (Fig E.27) the liver TG levels, which were increased in HFD fed mice compared with the CD 
group. CE levels were also increased in HFD fed mice compared to their CD group (Fig E.27). On the 
Figure E.27 Liver lipid concentration in 20 month-old (m) mice liver. (A) Lipids were extracted from liver 
homogenates and free cholesterol (FC), cholesteryl ester (CE), diglycerides (DG), phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI) and fatty acids 
(FA) were separated and quantified. Values are means ±SEM of n=4-6. Significant differences are 
denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing genotypes of the same diet group and 
#p<0.05, ##p<0.01 and ###p<0.001 when comparing CD and HFD groups of the same genotype 





contrary, FC levels did not change in liver. Regarding phospholipids, PC, the most abundant 
phospholipid was decreased in both CD and HFD OPN-KO mice, whereas the other phospholipids 
show different profiles. Particularly interesting is the sharp increase in phosphatidylserine (PS) in HFD 
fed OPN-KO mice.   
PS if often related to apoptosis process, and taking into account that 10 m OPN-KO mice show ER 
stress symptoms and the worsened progression observed at 20 m, we wanted to know if this could 
lead to liver damage and apoptosis. First, we analyzed protein levels of GRP78 (Fig E.28), which 
recovered in both CD and HFD OPN-KO mice. Despite this chaperone recovery, gamma-H2AX levels 
were increased in both CD and HFD OPN-KO mice. In addition, in 20 m HFD fed OPN-KO mice, cleaved 
caspase 12 was increased compared to the HFD fed WTs. This shows that apoptosis processes and 
hepatocyte damage are more active in OPN-KO mice than in WT mice. Thus, this reinforces the 
worsened progression observed in 20 m OPN-KO mice, particularly in the HFD fed group. 
Altogether, the results show a worsened progression of the liver disease with aging when OPN is 
deficient, showing thus, a protective role for OPN in the aging liver. It delays the onset of metabolic 






Figure E.28 Damage markers in CD and HFD fed 20 month-old (m) mice liver. Immunoblot analysis of 
GRP78, Caspase 12 and γH2Ax protein levels from liver extract were assessed using transferrin as loading 
control in chow diet (CD) and high fat diet (HFD) fed 20 month-old (20 m) mice. Values are means ±SEM of 
n=4-5. Significant differences are denoted by *p<0.05, **p<0.01 and ***p<0.001 when comparing WT and 




3.6 p53 regulates osteopontin expression in liver 
3.6.1 Differential hepatic cell line expression of OPN and p53 
p53 controls cellular functions and modulates cellular adaptations to stress and is one of the 
most important tumor suppressor genes. In addition, p53 and other p53 family member, including 
p63 and p73, controls many metabolic pathways (Napoli & Flores, 2017). Some studies have linked 
p53 to OPN regulation in fibroblasts (Morimoto, Sasaki, Ishida, Imai, & Tokino, 2002) and in 
endometrium carcinoma cells (Franco et al., 2017). It has been reported that p53 null mice fed a HFD 
show increased liver fat content and ER stress markers, and its overexpression improves steatosis 
and ER stress (Porteiro et al., 2017). 
We wanted to analyze whether p53 could regulate OPN expression in liver, for this we 
analyzed in the Cancer Cell Line Encyclopedia (The Broad Institute of MIT & Harvard) database the 
mRNA expression of the OPN gene (SPP1) and TP53 gene in several liver cell lines. We observed that 
the cell line with lower expression of SPP1 was also the cell line with lower expression of TP53 (Fig 
E.29). While the cell lines that show more expression of p53 have also increased SPP1 expression. 









Figure E.29 Differential mRNA expression (RNAseq) of SPP1 and TP53 genes in liver cell lines in liver. SPP1 







3.6.2 Silencing p53 decreases OPN levels intra and extracellularly 
In order to elucidate whether p53 could be regulating OPN, we silenced p53 with a siRNA in 
HepG2 cells, and observed that OPN levels, both intracellular and secreted were decreased when 
silencing p53 (Fig E.30A). Interestingly, treating p53-silenced cells with palbocilcib lead to a lower 
increase of OPN (Fig E.30B) than the increase induced in HepG2 cells (Fig E.30C), showing that p53 
might be necessary for the senescence-induced OPN expression. To confirm that p53 could be 
regulating OPN, we treated Hep3B, that do not express p53, with palbociclib. 
 
 
Figure E.30 OPN expression in p53 silenced HepG2 cells. (A) Protein levels of p53 and OPN in siCtrl and sip53 
cells were measured by immunoblotting using glyceraldehyde -3-phosphate dehydrogenase (GAPDH) as loading 
control. Extracellular OPN was measured using an ELISA. (B) Protein levels of OPN were measured in sip53 vehicle 
(sip53 Veh) and sip53 Palbociclib (sip53 Palbo) treated cells, (C) and in siControl (siCtrl) and sip53 palbocilcib 
(sip53 Palbo) treated cells. Values are means ±SEM of n=4. Significant differences are denoted by *p<0.05, 




3.6.3 Palbociclib and H2O2 treatment induces the increase in OPN expression and secretion in 
HepG2 cells, but not in Hep3B cells 
We have shown earlier that senescence treatment increases OPN levels in HepG2 cells intra 
and extracellularly. Hep3B cells, that are p53-null, did not show an increased OPN levels when 
treated with palbocilcib or H2O2 (Fig E.31A). Next, we wanted to analyze whether senescence 
induction could increase the OPN secretion, because an increased OPN secretion could be one of the 
causes for the low intracellular OPN expression in Hep3B cells. We observed that HepG2 cells 
increased OPN secretion to the media when treated with palbociclib or H2O2. In contrast, Hep3B cells 
did not show an increased OPN secretion (Fig E.31B). In fact, OPN secretion levels, even in the vehicle 
condition were much lower in Hep3B than in HepG2 cells. This result shows that p53 is required for 
OPN expression under senescent stimuli. 
Figure E.31 HepG2, but not Hep3B cells increase OPN protein levels and secretion after palbociclib or H2O2 
treatment. (A) OPN protein levels from Hep3B cells were measured by immunoblotting using 
glyceraldehyde -3-phosphate dehydrogenase (GAPDH) as loading control. Values are means ±SEM of n=4. 
(B) OPN media levels from Hep3B cells treated with either Vehicle (Veh) or Palbociclib (Palbo) or hydrogen 
peroxide (H2O2) were measured by ELISA. Values are means ±SEM of n=4. Significant differences between 





3.6.4 HFD does not induce OPN expression in p53-KO mice 
In order to elucidate if p53 is required for OPN expression in vivo we used p53-KO mice and 
their WT controls. Both groups were fed a CD or a HFD for 4 weeks. Feeding a HFD increased OPN 
levels in WT mice, as it has been reported before (Bertola et al., 2009); however, p53-KO mice did 
not show any increase of the OPN liver levels, being the OPN levels low in both CD and HFD (Fig E.32). 







Figure E.32 p53-KO mice do not increase OPN expression when fed a HFD. OPN protein levels from liver 
homogenates were measured by immunoblotting using glyceraldehyde -3-phosphate dehydrogenase 
(GAPDH) as loading control. Values are means ±SEM of n=4-6 Significant differences are denoted by 






















































1. Osteopontin controls biliary metabolism by regulating CYP7A1 
levels in liver and hepatocytes. 
The liver is the largest and most important metabolic organ in the human body. It has many 
different functions, including metabolism regulation, detoxification processes and digestion. There 
has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD is an umbrella 
term that comprises a spectrum of conditions, ranging from hepatic steatosis, to nonalcoholic 
steatohepatitis (NASH) to fibrosis. NAFLD has a very important metabolic component, it is strongly 
associated with obesity, insulin resistance, hypertension and dyslipidemia and it has been considered 
the hepatic manifestation of the metabolic syndrome.  
OPN is a multifunctional cytokine that expresses during inflammation and cancer in different 
tissues (Ramaiah & Rittling, 2007; Zeyda et al., 2011). It plays a role in liver fibrogenesis (Glass et al., 
2018) (Syn et al., 2012) and in obesity-related hepatosteatosis (Bertola et al., 2009). 
In this work, we provide evidence of a mechanism by which OPN regulates lipid metabolism 
and conversion of Chol into BA in hepatocytes and liver. As previously mentioned (Nuñez-Garcia el 
al., 2017), OPN regulates the fate of acetyl-CoA towards cholesterogenesis, and regulates liver PC 
and FC metabolic cross-talk in mouse liver. These lipids are highly interconnected, both being bile 
lipids synthesized in the liver. Indeed, PC constitutes 90-95% of bile glycerophospholipids (GPL). 
Experimental and clinical evidence have linked altered hepatic Chol homeostasis to liver disease 
(Arguello, Balboa, Arrese, & Zanlungo, 2015). Besides, some BA species are increased in liver of 
patients with NASH. Thus, the role of extracellular OPN regulating hepatocyte lipid metabolism is of 
high relevance for liver disease. 
On previous work, we found that OPN deficiency led to increased mRNA levels of enzymes 
involved in the CDP-choline pathway, and to decreased PC content in liver. Here, we propose a 
mechanism through which extracellular OPN directly modulates biliary metabolism. We previously 
reported that several factors involved in biliary PC secretion (Abcb4) and nuclear factors that regulate 
cholesterol 7α-hydroxylase (CYP7A1) expression were upregulated in OPN-KO mice and 
downregulated in rOPN treated mice. Here we show that protein levels of CYP7A1, in charge of the 
conversion of FC into BA, were higher in OPN-KO mice than in WT mice, while decreased when WT 
mice were treated with recombinant OPN (rOPN). We previously found that liver levels of CYP7A1 
were slightly decreased in non-obese patients with NAFLD, in whom serum OPN correlates with liver 
Chol, suggesting that OPN might participate in this regulation of CYP7A1 that could be in charge of 




It has been demonstrated previously in HCV-infected hepatocytes that the secreted OPN 
interacts with integrins and/or CD44 at the cell surface of hepatocytes, among other cell types, thus, 
inducing a signaling cascade through phosphorylation/activation of FAK and AKT (Iqbal et al., 2014). 
In addition, several reports have involved AKT (Li, Ma, & Chiang, 2008), in CYP7A1 transcription. Here, 
we show that OPN, through regulation of the FAK-AKT signaling pathway, modulates CYP7A1 levels 
in hepatocytes. The specific mechanism involved is still not fully understood and remains to be 
studied. However, different combinations of integrins that bind to OPN are expressed by hepatocytes 
(Couvelard et al., 1998; Yokosaki, Tanaka, Higashikawa, Yamashita, & Eboshida, 2005); therefore, we 
believe that the OPN-integrin interaction leads to the activation of FAK-AKT signaling in mouse 
hepatocytes, regulating CYP7A1 (Fig F.1), which is the main axis in the cross-talk between PC and 















2. Rewiring of lipid metabolism modulates liver regeneration 
after partial hepatectomy in OPN-KO mice. 
The liver has the capacity for regeneration after cellular damage or surgery resection. During 
regeneration, liver cells need to acquire sufficient energy and metabolic precursors to support the 
metabolic demands for rapid proliferation. Thus, a variety of metabolic pathways is switched on. The 
synthesis of PC, the mayor phospholipid in cellular membranes, is coordinated with the activation of 
the cell cycle and is an essential step in cell proliferation. Changes in the hepatic PC/PE molar ratio 
have been linked to impaired liver regeneration (van der Veen, Jelske N et al., 2017). Although 
hepatic TG content is widely variable and increases during liver regeneration, alterations in either 
exogenous or endogenous lipid metabolic pathways, demonstrated to promote or diminish hepatic 
steatosis and influence hepatocyte proliferation (Newberry et al., 2008). Chol is also essential to 
perform an adequate regeneration, since it is a critical structural component of biological 
membranes that influences properties such as permeability and fluidity, while also contributing to 
the modulation of the membrane proteins, protein trafficking, and transmembrane signaling 
(Delgado‐Coello, Briones‐Orta, Macías‐Silva, & Mas‐Oliva, 2011). A growing body of evidence has 
demonstrated that BAs are important for liver regeneration. The relative BA overload after partial 
liver resection causes activation of BA receptors in non-parenchymal and parenchymal  cells in the 
liver, thus, providing signals to the regenerative process (van de Laarschot, Liyanne FM, Jansen, 
Schaap, & Damink, 2016). It is therefore clear, that modulation of lipid metabolism is required to 
ensure an adequate regeneration after partial hepatectomy (PH). The technique of partial 
hepatectomy (PH) is widely used to model liver regeneration and cell cycle dynamics in vivo, avoiding 
the massive necrosis observed in other regeneration models. 
We previously showed that OPN regulates the de novo lipogenesis in hepatocytes by regulating 
the fate of acetyl-CoA and modulates glycerolipid and cholesterol metabolism cross-talk (Nunez-
Garcia et al., 2017). Therefore, there is a need to understand how OPN affects lipid metabolism 
during regeneration. On previous studies, we show that there is a substantial increase in the levels 
of circulating OPN during the first 24 h after PH, occurring at a time when hepatocytes accumulate a 
significant amount of lipids (mainly TGs), in droplets, in the widely recognized transient regeneration-
associated liver steatosis (Tijburg, Nyathi, Meijer, & Geelen, 1991). Evidences suggest that the 
transient steatosis is likely related to the increased lipogenic activity and the altered lipid fluxes into 
and out of the hepatocyte (Miyamura et al., 2011). We previously reported that OPN-KO mice are 
able to regenerate properly, but they show a lipid remodeling when undergoing regeneration 
(Nuñez-Garcia et al., 2018). Hence, we wanted to analyze which metabolic processes underlie this 




Previously, we demonstrated that de novo TG synthesis is decreased while the liver TG content 
maintains unaltered in OPN-KO hepatocytes (Nunez-Garcia et al., 2017). Thus, OPN-KO mice must 
get TG in another way different from de novo synthesis. Here, we demonstrate that OPN-KO mice 
show enrichment of liver TGs in the most abundant dietary essential FA, the linoleic acid (18:2). 
Altogether, these results show that the decreased de novo TG synthesis is compensated with dietary 
FA in OPN-KO mice livers.  
During the first 24 h period after PH, the enrichment of TGs in linoleic acid was higher in the WT 
than in OPN-KO mice, in which beta-oxidation was increased. Altogether, suggesting an increased 
consumption of dietary fatty acids in the OPN-KO mice. Our findings demonstrated that in OPN-KO 
mice liver, in which the source of TGs is different, regeneration was not impaired 24 or 48 h after PH. 
It has also been described that during the first hours (h) of the G1 phase there is an increase in the 
TG hydrolysis that releases FAs for mitochondrial beta-oxidation (Brasaemle, 2006). Here we 
observed that in OPN-KO mice there is an increase in beta-oxidation 24 h after PH, which prevents 
the accumulation of acylcarnitines observed in quiescent livers, and will induce the decrease in 
acylcarnitines 48 h after PH. This increase in beta-oxidation is coupled with the increase in positive 
cells for DHE, a marker of ROS. It has been described that the hypoglycaemia that follows PH induces 
systemic lipolysis which supplies the required FA (Gazit et al., 2010). The loss of body weight that 
follows the PH is less marked in OPN-KO mice than in WT mice, suggesting that lipolysis of adipose 
tissue is not the source of FA for the increased beta oxidation. These results are in concordance with 
the fact that in mice, OPN deletion prevents the development of obesity and hepatosteatosis via 
impaired adipose tissue functionality (Lancha et al., 2014). Our results suggest that dietary FA will 
provide the required TG and FA for lipid accumulation and beta-oxidation in OPN-KO mice, allowing 
a correct regeneration. 
The synthesis of PC, the major phospholipid in cellular membranes, is coordinated with the cell 
cycle activation (Jackowski, 1994). Our results show that liver regeneration is not impaired in OPN-
KO mice even when PC content is decreased 24 h post PH. We also found that the decreased de novo 
PC synthesis previously observed is associated reduced liver PC content, but unlike TGs, PC content 
is not compensated with the dietary essential FA linoleic. Importantly, treatment with atorvastatin, 
which inhibits cholesterogenesis, induces a new lipidome where PC and DG content increases 24 h 
after PH. This new metabolic rewiring was associated with improved liver regeneration 24 h after PH, 
and is consistent with our previous reports of increased de novo cholesterogenesis in OPN-KO mice. 
This study reinforces the role of OPN as a metabolic driver during liver regeneration. However, in this 
mice model, non-obese with healthy liver, the lack of OPN results in a metabolic remodeling ensuring 
the success in regeneration 24 and 48 h after partial hepatectomy. OPN is increased in liver diseases 




study we are not able to know if the lack of OPN will alter liver regeneration in a model of obesity 
with NAFLD. Liver transplants are increasing due to metabolic disease. Thus, this should be 
investigated in the future. 
In conclusion, the results here support the role of OPN as a liver metabolic driver. OPN regulates 
multiple metabolic pathways involved in liver regeneration. Treatment with atorvastatin, an inhibitor 
of de novo cholesterogenesis, provides a new metabolic scenario linked to improvement of early 

















3. Osteopontin plays a role in the age-associated NAFLD 
progression 
Osteopontin (OPN) plays a role in the liver lipid metabolism (Nunez-Garcia et al., 2017) (Nuñez-
Garcia et al., 2018). Because some of the substantial changes that liver undergoes as it ages are 
metabolic modifications and liver regeneration decline, we investigated if OPN might regulate liver 
lipid metabolism during aging. Epidemiological studies have demonstrated that NAFLD is common 
among the elderly (Bertolotti et al., 2014; Fierbinteanu-Braticevici et al., 2017). Aging is a complex 
multifunctional process, in which metabolism plays an important role (López-Otín, Blasco, Partridge, 
Serrano, & Kroemer, 2013; López-Otín, Galluzzi, Freije, Madeo, & Kroemer, 2016). Many aging 
related diseases, such as diabetes, NAFLD, cardiovascular disease among others, have a metabolic 
component. In addition, several studies link OPN and aging. However, the available data does not 
give conclusive results about the role of OPN in the aging process, but its effect seems to be tissue 
or cell-type dependent. On this study, we show for the first time the involvement of OPN in 
modulation of liver lipid metabolism during aging. 
Here, we show that there is a positive correlation between circulating OPN levels and aging in 
individuals with normal liver but not in NAFLD patients. In addition, this positive correlation was also 
observed in WT mice. Thus, showing a possible link between OPN and the liver aging process and 
disease development. In vitro results showed that OPN expression increased both intra and 
extracellularly when senescence was induced, which reinforces its role as a senescence associated 
secretory phenotype (SASP) factor and thus, its involvement in aging related senescence.  
It is known that aging affects differently to females and males (Austad & Fischer, 2016). Since 
most of the studies are performed in male mice, and given that there is a higher complexity in 
metabolic regulation of females, we focused this study in females. In addition, we decided to use a 
natural model of aging. It is tempting to study aging using mice with accelerated aging and/or 
reduced lifespan. However, data obtained from these models should be interpreted carefully. 
Progeroid mice models might show typical features of aging, but they often exhibit features not seen 
in normal old mice (Kõks et al., 2016). Consequently, the available mouse models of accelerated 
aging do not fully represent normal aging in mice. Because of this, and despite the fact that aging 
research on mice is expensive and time-consuming, we decided to use a natural model of aging in 
order to obtain reliable data of the aging process. 
To elucidate whether the increase of OPN observed during aging was protective or deleterious, 
we studied the aging process in OPN deficient mice. We observed that mice lacking OPN show a 
premature lipid accumulation in the liver and increased serum levels of TGs. Interestingly, linked with 




was increased in both obese and non-obese NAFLD patients, compared to their healthy controls. 
Aging is associated with progressive changes in total and regional fat redistribution, from adipose 
tissue to other tissues such as the liver, hearth, skeletal muscle and others. These changes have 
negative health consequences. Indeed, this redistribution increases risk for insulin resistance and 
cardiovascular disease, and changes in body composition can occur independent of changes in total 
adiposity, body weight or waist circumference, and represent a phenotype closely associated with 
increased morbidity and mortality risk (Kuk, Saunders, Davidson, & Ross, 2009). Together with this 
premature lipid accumulation, old OPN-KO mice show increased liver fibrosis and inflammation (Fig 
F.2). Surprisingly, OPN is known to be a pro fibrogenic factor and several studies claim that its 
deficiency avoids fibrosis (Coombes et al., 2015) but there is no previous information of the OPN 
involvement in fibrosis in old livers. Certainly, aging is the most common cause for the progression 
of NAFLD. Linked to this, induction of fibrosis by senescent hepatocytes is a way of limiting tissue 
injury as part of wound healing process. However, accumulation of senescent hepatocytes leads to 
continuous activation of stellate cells and thereby fibrosis progression (A. Aravinthan et al., 2013; A. 
D. Aravinthan & Alexander, 2016). The worsened progression observed in old OPN-KO mice, was 
even more marked when old mice were fed a high fat diet (HFD), since OPN-KO mice fed a HFD mice 
show more fibrosis together with inflammation, cell damage and apoptosis markers. In addition, they 
also exhibit higher levels of AST and a mild insulin resistance.  
 Overall, OPN-KO mice show a worsened progression when compared to their WTs. The early 
hepatosteatosis observed in 10 m OPN-KO mice leads to a fibrotic and inflammation scenario at 20 
m. Thus, we propose that OPN plays a protective role in the aging-associated NAFLD progression, 
and its deficiency could be detrimental. Supporting the protective role of OPN, other studies have 
shown a protective role of OPN in alcoholic hepatitis (Lazaro et al., 2015). In addition, it has been 
reproted that OPN deletion caused greater liver injury and lipid peroxidation, contributing to the 
pathogenesis and enhancement of alcoholic liver disease in old mice (Magdaleno et al., 2018). 
Besides, OPN is typically considered an anti-apoptotic factor, and its deficiency could facilitate the 













Since the previously mentioned premature liver lipid accumulation occurs at 10 m, we took this 
age point to study the altered underlying mechanism that leads to the observed steatosis and 
worsened liver disease progression. We show that the de novo lipogenesis (DNL) is increased in the 
OPN-KO mice hepatocytes. Supporting the increased DNL, there is increased esterification of FA to 
TGs. Several authors have shown that liver DNL increase with aging (Cohen, Horton, & Hobbs, 2011; 
Sheedfar, Biase, Koonen, & Vinciguerra, 2013). Under physiological conditions, DNL contributes to 
no more than 5-10% of the hepatic TG content, whereas the contribution increases to more than 
25% in NAFLD patients, showing that DNL may be a major determinant for NAFLD development in 
humans. Age- associated changes in DNL appear to be primarily through changes in systemic 
mediators such as insulin resistance and changes in GH/IGF axis. Other metabolic alteration linked 
to aging is the decrease in the FA beta-oxidation, being the mitochondrial dysfunction one of the 
possible causes (López-Otín et al., 2016). However, in the OPN deficient mice, beta-oxidation remains 
unaltered. Thus, we determined that increased DNL is one of the causes for the increased lipid 
storage, and the stored lipid is not consumed in oxidation processes.  
Several studies have addressed age-related bile composition alterations (B. Y. Lee et al., 2006; 
G. Lee, Lee, Hong, Lee, & Jung, 2016). Aging is associated with a reduced bile acid synthesis, possibly 
related to decreased hepatic expression of hepatocyte nuclear factor-4 and consequently of CYP7A1 
(Bertolotti et al., 2007). OPN can decrease CYP7A1 levels (Nunez-Garcia et al., 2017), thus the OPN 
increase with aging is linked with its decrease. Consequently, 10 m OPN-KO mice show increased 
expression of CYP7A1 and some increased BA species. The increase in CYP7A1 could be linked to 
decreased AKT pathway activation. Hepatic degradation to bile acids is the most relevant metabolic 






pathway whereby the organism can dispose of excess Chol. Linked to this, liver free cholesterol 
concentration does not increase when compared to WTs, as happens with other lipids, probably as 
a consequence of increased flux of Chol to BA. In addition, it has been reported that the ratio 12α-
hydroxylated BA/ non-12α-hydroxylated BA increases in NAFLD patients and is associated with lower 
insulin sensitivity and higher plasma TG (Haeusler, Astiarraga, Camastra, Accili & Ferrannini, 2013). 
Our BA analysis shows that in 10 m OPN-KO mice this ratio is increased, this is consistent with the 
high levels of TG observed in this group and also supports the observed worsened progression in the 
OPN-KO. 
Regarding senescence, 10 m OPN-KO mice showed increased percentage of beta galactosidase 
positive hepatocytes and p21 levels. These markers are known to be increased in hepatocytes upon 
senescence. The accumulation of senescent hepatocytes can affect the liver function making the liver 
more prone to disease progression (A. Aravinthan et al., 2013). Linked with this, hepatocyte 
senescence correlates with severity of NAFLD (Ogrodnik et al., 2017). Interestingly, it has been 
reported that FAS levels, which are increased in 10 m OPN-KO mice contributing to hepatosteatosis, 
are upregulated during senescence, and FAS inhibition stops cellular senescence induction (Fafián-
Labora et al., 2019). We found that together with the increased senescence markers FAS protein 
levels were also increased together with de novo lipogenesis. Other hallmark of aging is the 
dysregulated nutrient sensing (López-Otín et al., 2016). We observed that the mTOR signaling 
pathway was markedly decreased in mice lacking OPN. Paradoxically, downregulation of mTOR has 
been associated to longevity in caloric restriction models (DiLoreto & Murphy, 2015; DiLoreto & 
Murphy,2015; Johnson, Rabinovitch, & Kaeberlein, 2013). Indeed, downregulation of translation 
upon reduced nutrient availability extend lifespan in many organisms via mTOR signaling in caloric 
restriction models. However, in our model, the downregulation of this pathway seems to be linked 
to the attenuation of translation in response to loss of proteostasis, which is another feature of aging. 
The endoplasmic reticulum (ER) is an important organelle for regulating calcium homeostasis, lipid 
homeostasis, protein synthesis, and post-translational modifications and trafficking. Many insults 
can disturb ER homeostasis, which leads to ER stress. The buffering capacity of the proteostasis 
network decreases with aging. Indeed, aging is directly associated with specific alterations in distinct 
components of the proteostasis network. Such alterations disrupt the healthy functioning of the cell 
and may contribute to the emergence of disease (Martínez, Duran‐Aniotz, Cabral‐Miranda, Vivar, & 
Hetz, 2017). ER stress can modulate expression levels of key enzymes involved in lipid synthesis or 
modification (Han & Kaufman, 2016). It is well stablished that lipid accumulation can disturb the ER 
function generating ER stress. In this work, we show that OPN-KO mice show activation of the PERK 
branch of the unfolded protein response, which activates when there is ER stress. We also found the 
decreased chaperone capacity, which is probably involved in this activation. Supporting this, we 




to cope with ER stress when PERK branch of the UPR is activated (Han & Kaufman, 2016). Thus, the 
decrease in phosphorylation of mTOR and S6K might be a response trying to attenuate ER stress. 
Interestingly, some studies have shown that OPN can induce s6K and mTOR phosphorylation in 
breast cancer cells, and therefore might have a role on its activation (Ahmed & Kundu, 2010). Several 
studies have demonstrated that the decrease in chaperone number diminishes the efficacy to deal 
with unfolded proteins. In addition, the decrease in the number of chaperones is associated with 
aging (A. S. Lee et al., 2017) which can be one of the causes of the increased ER stress with aging. 
Some studies have shown that forced expression of GRP78 attenuates steatosis by inhibiting sterol 
regulatory element-binding protein (SREBP-1c) (Kammoun et al., 2009). Thus, the reduced GRP78 
levels could increase the steatosis by increased activation of SREBP-1c, and thus, lipogenic genes like 
FAS, which is increased in 10 m OPN-KO mice together with increased lipid accumulation. Severe or 
prolonged ER stress is associated with the development of degenerative and fibrotic responses in 
many organs (Kropski & Blackwell, 2018). Thus, in old OPN-KO mice, the prolonged exposure to ER 
stress could be cause of the observed fibrosis and apoptosis at old age. Paradoxically, at 20 m we did 
not observe the decreased GRP78 chaperone, but this could be as a consequence of an adaptive 
response to apoptosis, indeed, GRP78 is known for preventing ER stress-induced cell death by 
blocking caspase-7 and 12. In the in-vitro model, we observed how silencing OPN with a siRNA 
decreased GRP78 levels when senescence was induced in HepG2 cells. Some previous studies have 
suggested the association between OPN with GRP78 in renal tissue in rats (Bhardwaj et al., 2017). In 
addition, OPN has been linked with other chaperones; e.g. OPN-induced signal transduction involves 
activation of Hsp90-dependent pathways (Mutrie, Chambers, & Tuck, 2011). Hence, here we 
observed for the first time, how lack of OPN is associated with reduced GRP78 levels in senescent 
hepatic cells. We observe that senescence leads to decreased chaperone levels when OPN is 
deficient. Senescent cells lose the capacity to activate the transcriptional pathways leading to 
chaperone synthesis, which generates lower levels of chaperone. These low levels in senescent cells 
is one of the causes for damage accumulation (Ogrodnik, Salmonowicz, & Gladyshev, 2018).  
Taking together the mechanisms that are altered in 10 m OPN-KO mice (increased DNL, 
increased senescence and increased ER stress with low GRP78 levels) apart from being involved in 
aging, will lead to and increased transcription of lipogenic genes, causing thus, the increased lipid 
accumulation that with time will progress to further stages of the disease. We propose that OPN is a 
protein required to properly respond to stressors, and thus upon aging its deficiency makes cells 
more vulnerable to insults and senescence. 
Senescence is one of the key hallmarks of aging. It is a permanent state of cell-cycle arrest 
in response to different stresses, being thus, a cellular defense mechanism. Senescence happens in 




is one of the causative processes of aging and it is responsible of many aging-related disorders, 
senescent cells can also play a positive role in other processes. For example, it is required for tissue 
repair and it is an important mechanism for preventing tumorigenesis (Calcinotto et al., 2019). 
Regarding liver disease, senescence of hepatocytes and other liver cell types is a key feature of 
chronic liver disease independent of etiology, and plays an important role in the progression of 
chronic liver disease (A. D. Aravinthan & Alexander, 2016). In our in vitro study, we show that OPN 
expression increases when treating with senescence-inducing agents and treating cells with rOPN 
made cells more resistant to senescence. Previous work have described OPN as a SASP factor 
(Flanagan et al., 2017; Pazolli et al., 2009). Interestingly, integrin beta 3, one of the integrins to which 
OPN binds, has been found to be a marker and regulator of senescence (Rapisarda et al., 2017). 
Although senescence-associated cell-cycle exit likely evolved as an anti-tumor mechanism, the SASP 
contains both anti- and pro-tumorigenic potential (Lau & David, 2019). Thus, identification and 
characterization of the SASP factors that are pro and those that are anti-tumorigenic depending on 
the contexts and tissue is crucial. In response to senescence stresses, cells initially trigger survival 
pathways that prevent damage and promote recovery; however, if the damage persists and becomes 
unsustainable, cells undergo senescence and senescent cells can accumulate, disrupting the 
physiological integrity of the tissue. Thus, OPN might be a factor expressed in response to senescent 
stimuli to prevent cells from becoming senescent. While preventing senescence can be a desirable 
process in normal aging, in other scenarios can be detrimental. 
Indeed, one of the most important features of senescence is that acts as a potent tumor 
suppressive. Current research indicates that many chemotherapeutic drugs and radiation induce 
senescence in cancer cells. Senescence-inducing treatments have the advantage of enhancing the 
efficacy and decreasing the side effects of anticancer therapy. The role of OPN in chemoresistance is 
currently under investigation, with pre-clinical evidence suggesting that OPN is involved in inducing 
chemoresistance (Ding et al., 2015; Zhao et al., 2018). As mentioned above, increasing concentration 
of OPN in the media makes cells more resistant to senescence-inducing agent palbociclib, therefore 
reinforcing its role in senescence, as an anti-senescent agent. In addition, neutralizing OPN makes 
cells more vulnerable to senescence inducing agents by impairing ER response to stress. As we 
explained above, GRP78 levels could be linked to OPN expression, although the mechanism remains 
to be elucidated. In this context of chemoresistance it has been described that elevated expression 
of GRP78, has shown to induce chemoresistance and serves as an indicator of poor prognosis in 
patients (Gifford & Hill, 2018). Thus, in cancer treatment context, OPN could be targeted to improve 
drug treatment. However, this needs to be further investigated.  
In this work we also propose a mechanism by which OPN expression increase in both aging 
and senescence. p53 is one of the most important tumor suppressor genes.  p53 family members 




KO mice show increased hepatic fat content, and hepatic overexpression of p53 ameliorates hepatic 
steatosis (Porteiro et al., 2017). Some previous work have shown that OPN is a p53 target in 
fibroblasts (Morimoto, Sasaki, Ishida, Imai, & Tokino, 2002) and in endometrium carcinoma cells 
(Franco et al., 2017). Here, we wanted to analyze whether p53 could regulate OPN expression when 
senescence is induced in cells and in models of HFD induced NAFLD. When analyzing the gene 
expression of OPN (SPP1 gene) and p53 (TP53) of several hepatic cell lines, we observed that the cell 
line with the least TP53 expression had also the lower SPP1 expression, implying that there might be 
a relation between these two proteins. Our results show that silencing p53 with a siRNA diminished 
OPN protein levels, intra and extracellularly. In the senescence context, p53 expression has shown 
to be upregulated when inducing senescence to hepatocytes (A. Aravinthan et al., 2014). In vitro, 
when we treated cells with senescent inducing agents, HepG2 cells increased their OPN levels, both 
intracellular and secreted, while Hep3B cells, that are p53 null, do not show this increase. Thus, 
showing that p53 might be necessary for OPN expression under senescent stimuli. In the in-vivo 
model, it has been reported that p53 null mice fed a HFD show increased liver fat content and ER 
stress markers, and its overexpression improves steatosis and ER stress (Porteiro et al., 2017). HFD 
induces OPN expression in liver of WT mice, however, we observed that feeding a HFD to p53-KO 
mice did not induce the expected increase in OPN, reinforcing the link between p53 and OPN in 
hepatosteatosis. Altogether, the results show how p53 induces OPN expression in liver when facing 
senescence and HFD, and suggest that p53-induced OPN might be important for preventing the lipid 
dysregulation associated to these processes. 
With all these evidences, we propose that OPN is involved and has a protective role in liver 
disease development during aging. Its expression in liver seems to be protective, since its deficiency 
in aging results in premature senescence, increased lipid accumulation and a worsened ER stress 
response that leads to a worse progression of the age-associated liver disease. The results suggest 
that p53 might induce OPN expression in liver and it might mediate a link between cellular 



























1. Osteopontin (OPN) regulates the cross-talk between cholesterol and PC metabolism 
through modulation of CYP7A1 levels in hepatocytes. The FAK-AKT signaling pathway is 
involved in the regulation of CYP7A1 by OPN in liver.  
 
2. OPN modulates metabolic pathways involved in TG and cholesterol metabolism during liver 
regeneration. 
2.1 OPN deficient (OPN-KO) mice show increased fatty acid catabolism when facing 
regeneration. The increased metabolic demands and the decreased de novo synthesis of TG 
are compensated with dietary fatty acids.  
2.2 Inhibition of cholesterogenesis using atorvastatin provides a new metabolic scenario 
linked to improvement of early regeneration in OPN-KO mice. 
 
3. OPN is required to maintain the whole body metabolic homeostasis during aging. 
3.1 OPN is involved in liver aging. Serum OPN positively correlates with age in individuals 
and animal models with normal liver. In the animal model, the increased OPN levels in 
serum are linked to increased levels in liver. The induction of senescence in HepG2 cells, 
through modulation of p53, increases cellular OPN levels and its secretion. 
3.2  OPN is regulated to maintain the liver lipid metabolism balance during aging. OPN 
deficiency in mice makes the liver more vulnerable to age-associated hepatosteatosis, 
being the underlying mechanism the increased de novo lipogenesis linked with induced 
senescence and an impaired ER stress response due to the GRP78 decreased levels.  
3.3 In old HFD-fed mice, deficiency in OPN does not induce body weight changes. However, 
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